<SEC-DOCUMENT>0001193125-25-179482.txt : 20250813
<SEC-HEADER>0001193125-25-179482.hdr.sgml : 20250813
<ACCEPTANCE-DATETIME>20250813085132
ACCESSION NUMBER:		0001193125-25-179482
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20250813
DATE AS OF CHANGE:		20250813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CARDINAL HEALTH INC
		CENTRAL INDEX KEY:			0000721371
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		ORGANIZATION NAME:           	07 Trade & Services
		EIN:				310958666
		STATE OF INCORPORATION:			OH
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-289513
		FILM NUMBER:		251209126

	BUSINESS ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017
		BUSINESS PHONE:		6147573033

	MAIL ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CARDINAL DISTRIBUTION INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d42072d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) <BR>Registration No. 333-289513 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P><DIV STYLE="position:relative; overflow:visible; width:651pt; height:30pt; transform-origin:bottom left; transform: rotate(-90deg) translate(-100%, 100%) translateX(30pt);">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and
the accompanying base prospectus are not an offer to sell these securities, and are not soliciting an offer to buy these securities in any jurisdiction where the offer and sale are not permitted.
</B></FONT></P></DIV><DIV STYLE="position:relative; overflow:visible; margin-left:48pt; margin-right:48pt; transform: translateY(-30pt);"> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>Subject to Completion, Dated August 13, 2025 </B></FONT></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B><U>PRELIMINARY PROSPECTUS SUPPLEMENT</U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>&#8195;&#8195;&#8195;&#8195;, 2025 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>(To Prospectus dated
August&nbsp;12, 2025) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>$&#8195;&#8195;&#8195;&#8195; </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42072g68d84.jpg" ALT="LOGO" STYLE="width:2.98917in;height:1.17041in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Cardinal Health, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>$&#8195;% Notes due 20&#8195; </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>$&#8195;% Notes due 20&#8195; </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">The&#8195;&#8195;% notes will mature on&#8195;&#8195;&#8195;&#8195;, 20&#8195; (the &#8220;20&#8195; notes&#8221;) and the&#8195;&#8195;% notes will mature
on&#8195;&#8195;&#8195;&#8195;, 20&#8195; (the &#8220;20&#8195; notes&#8221; and together with the 20&#8195; notes, the &#8220;notes&#8221;). Interest on the notes will accrue from&#8195;&#8195;&#8195;, 2025. Interest on the notes will be payable
semi-annually in arrears on&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;of each year, commencing&#8195;&#8195;&#8195;&#8195;, 2026. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">At our
option, we may redeem the notes of either series offered hereby, in whole or in part at any time and from time to time, before their maturity at the applicable redemption prices described herein under &#8220;Description of the Notes&#8212;Optional
Redemption.&#8221; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If a change of control repurchase event occurs, we will be required to offer to purchase the notes from holders at a purchase price of
101% of the principal amount of the notes. See &#8220;Description of the Notes&#8212;Repurchase at the Option of Holders Upon a Change of Control.&#8221; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">We intend to use the net proceeds from the sale of the notes offered hereby to fund a portion of the consideration payable in connection with our proposed
acquisition of Solaris Health (&#8220;Solaris&#8221;) (the &#8220;Acquisition&#8221;) and the fees and expenses in connection therewith . Pending application of the proceeds to fund the consideration payable in connection with the Acquisition, we
may temporarily use such funds for general corporate purposes. The sale of the notes is not conditioned upon the consummation of the Acquisition, which, if completed, will occur subsequent to the closing of the sale of the notes. See &#8220;Use of
Proceeds.&#8221; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If (i)&nbsp;the Acquisition is not consummated on or before the later of (x)&nbsp;August 12, 2026 (the &#8220;End Date&#8221;) and
(y)&nbsp;the date that is five business days after any later date to which the End Date may be extended in the Acquisition Agreement (as defined herein) (such later date, the &#8220;Special Mandatory Redemption End Date&#8221;) or (ii)&nbsp;we
notify the trustee under the indenture that we will not pursue the consummation of the Acquisition, then we will be required to redeem the notes (the &#8220;Special Mandatory Redemption&#8221;), in whole, at a special mandatory redemption price
equal to 101% of the aggregate principal amount of the notes being redeemed, plus accrued and unpaid interest, if any, to, but excluding, the Special Mandatory Redemption Date (as defined herein). The proceeds from the sale of the notes will not be
deposited into an escrow account pending completion of the Acquisition or any Special Mandatory Redemption, nor will we be required to grant any security interest or other lien on those proceeds to secure any redemption of the notes. See
&#8220;Description of Notes&#8212;Special Mandatory Redemption.&#8221; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">The notes will be our senior unsecured obligations and will rank equally in right of
payment with our other senior indebtedness outstanding from time to time. The notes will also be effectively junior to any secured debt of Cardinal Health to the extent of the value of the assets securing such indebtedness. The notes will be
structurally subordinated to the liabilities of Cardinal Health&#8217;s subsidiaries, including trade payables. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>Investing in the notes involves risk.
See &#8220;<A HREF="#supptoc42072_5">Risk&nbsp;Factors</A>&#8221; beginning on page <FONT STYLE="white-space:nowrap">S-13,</FONT> as well as the risks set forth in our other filings with the Securities and Exchange Commission (the
&#8220;SEC&#8221;), which are incorporated by reference in this prospectus supplement and the accompanying prospectus, for a discussion of certain risks that you should consider in connection with an investment in the notes. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Neither the SEC nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this
prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per</B><br><B>20&#8195;&nbsp;note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>20&#8195;<BR>notes&nbsp;Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>20&#8195;&nbsp;note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>20&#8195;<BR>notes&nbsp;Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Price to Public<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Underwriting Discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds to Us Before Expenses<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Plus accrued interest, if any, from and including &#8195;&#8195;&#8195;&#8195;, 2025. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Currently, there are no public markets for the notes. We do not intend to apply for the listing of either series of notes on a securities exchange or for the
inclusion of either series of notes on an automated dealer quotation system. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">We expect that delivery of the notes will be made to investors in book-entry
form only through The Depository Trust Company for the accounts of its participants, including Euroclear Bank SA/NV and Clearstream Banking, S.A., on or about&#8195;&#8195;&#8195;&#8195;, 2025. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Joint Book-Running Managers </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Goldman Sachs&nbsp;&amp; Co. LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>BofA Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>Wells Fargo Securities</B></TD></TR>
</TABLE> </DIV> <p STYLE="clear:both; font-size:1pt; height:0">&nbsp;</p>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc42072_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc42072_2">WHERE YOU CAN FIND MORE INFORMATION AND INCORPORATION OF CERTAIN DOCUMENTS
 BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc42072_3">INFORMATION CONCERNING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc42072_4">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc42072_5">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc42072_6">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-16</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc42072_7">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-17</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc42072_8">DESCRIPTION OF THE NOTES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-18</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc42072_9">U.S. FEDERAL INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-34</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc42072_10">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-38</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc42072_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-44</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc42072_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-44</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_2">WHERE YOU CAN FIND MORE INFORMATION AND INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_4">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_5">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_7">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_8">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_9">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_10">VALIDITY OF THE SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_12">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc42072_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated or unless the context requires otherwise, all references in this prospectus supplement to &#8220;we,&#8221; &#8220;us,&#8221;
&#8220;our&#8221; or the &#8220;Company&#8221; mean Cardinal Health, Inc., an Ohio corporation, and its consolidated subsidiaries, and references to &#8220;Cardinal Health&#8221; refer to Cardinal Health, Inc., excluding its consolidated
subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of the notes we are
offering and other matters relating to us. The second part is the accompanying prospectus, which gives more general information about securities we may offer from time to time, some of which does not apply to the notes we are offering. If
information contained or incorporated by reference in the prospectus supplement differs from information in the accompanying prospectus, you should rely on the information contained or incorporated by reference in this prospectus supplement. Before
investing in the notes, you should read carefully both this prospectus supplement and the accompanying prospectus, together with additional information described under the heading &#8220;Where You Can Find More Information and Incorporation of
Certain Documents by Reference&#8221; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not, and the underwriters and their affiliates do not, take any responsibility for, and can provide no
assurance as to the reliability of, any information that others may provide to you. You should not assume that the information contained or incorporated by reference in this prospectus supplement or in the accompanying prospectus is accurate as of
any date other than the date of this prospectus supplement or the date of the document in which the incorporated information appears, unless otherwise noted in such documents. Our business, financial condition, results of operations and prospects
may have changed since those dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The distribution of this prospectus supplement and the accompanying prospectus and the offering of the notes in
certain jurisdictions may be restricted by law. We are not making an offer of the notes in any jurisdiction where the offer is not permitted. Persons who come into possession of this prospectus supplement and the accompanying prospectus should
inform themselves about and observe any such restrictions. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer or solicitation by anyone in any jurisdiction in which such
offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to any person to whom it is unlawful to make such offer or solicitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should not consider any information in this prospectus supplement or the accompanying prospectus to be investment, legal or tax advice. You should consult
your own counsel, accountant and other advisors for legal, tax, business, financial and related advice regarding the purchase of the notes. We are not making any representation to you regarding the legality of an investment in the notes by you under
applicable investment or similar laws. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc42072_2"></A>WHERE YOU CAN FIND MORE INFORMATION AND INCORPORATION OF CERTAIN
DOCUMENTS BY REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC allows us to
incorporate by reference the information we file with it, which means that we can disclose important business and financial information to you that is not included in or delivered with this prospectus supplement and the accompanying prospectus by
referring you to publicly filed documents that contain the omitted information. Our SEC filings are available on the SEC&#8217;s website at <I>http://www.sec.gov</I>. Such filings may also be available on our website at <I>http://
www.ir.cardinalhealth.com</I>. All references to our website in this prospectus supplement and the accompanying prospectus are inactive textual references only and the information contained on our website is not incorporated by reference into this
prospectus supplement and the accompanying prospectus. You may also request a copy of these filings, at no cost, by writing or telephoning us as follows: Cardinal Health, Inc., 7000 Cardinal Place, Dublin, Ohio 43017, (614) <FONT
STYLE="white-space:nowrap">757-5035</FONT> Attention: Investor Relations. Exhibits to the filings will not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be sent unless those exhibits have been specifically incorporated by reference in this prospectus supplement or the accompanying prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC an &#8220;automatic shelf&#8221; registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;), as a &#8220;well-known seasoned issuer&#8221; (as defined in Rule 405 under the Securities Act) covering the securities described in this prospectus supplement and the accompanying
prospectus. This prospectus supplement and the accompanying prospectus do not contain all of the information included in the registration statement, some of which is contained in exhibits included with or incorporated by reference into the
registration statement. The registration statement, including the exhibits contained or incorporated by reference therein, can be read at the SEC&#8217;s website. Any statement made in this prospectus supplement or the accompanying prospectus
concerning the contents of any contract, agreement or other document is only a summary of the actual contract, agreement or other document. If we have filed or incorporated by reference any contract, agreement or other document as an exhibit to the
registration statement, you should read the exhibit for a more complete understanding of the document or matter involved. Each statement regarding a contract, agreement or other document is qualified in its entirety by reference to the actual
document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incorporate by reference the following documents filed with the SEC by us and any future filings we make with the SEC after the date of this
prospectus supplement under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), until we complete our offering of the securities offered by this prospectus supplement and the
accompanying prospectus. We are not incorporating by reference any documents or portions thereof, whether specifically listed below or filed in the future, that are not deemed &#8220;filed&#8221; with the SEC (including the Current Reports on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> listed below), unless otherwise specified. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="63%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">SEC Filings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Period/Date</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/721371/000072137125000079/cah-20250630.htm">Form <FONT STYLE="white-space:nowrap">10-K</FONT> </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fiscal Year ended June&nbsp;30, 2025, filed with the SEC on August&nbsp;12, 2025.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Portions of the Company&#8217;s <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/721371/000072137124000103/cah-20240913.htm">Proxy Statement</A> on Schedule 14A for our 2024 Annual Meeting of
Shareholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Incorporated by reference into the Company&#8217;s Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the Fiscal Year ended June&nbsp;30, 2024, filed with the SEC on September<U></U>&nbsp;16, 2024 (with
respect to the &#8220;Letter to Cardinal Health Shareholders,&#8221; &#8220;Notice of Annual Meeting of Shareholders,&#8221; &#8220;Proxy Summary,&#8221; &#8220;Corporate Governance,&#8221; &#8220;Executive Compensation,&#8221; &#8220;Audit
Committee Maters,&#8221; &#8220;Share Ownership Information,&#8221; and &#8220;Other Matters&#8221; only).</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any statement contained or incorporated by reference in this prospectus supplement and the accompanying prospectus shall be
deemed to be modified or superseded for purposes of this prospectus supplement and the accompanying prospectus to the extent that a statement contained herein or therein, or in any subsequently filed document which also is incorporated by reference
herein or therein, modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement and the accompanying prospectus.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc42072_3"></A>INFORMATION CONCERNING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus, our filings with the SEC, including our Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended June&nbsp;30, 2025 (the &#8220;2025 Form <FONT STYLE="white-space:nowrap">10-K&#8221;),</FONT> our Annual Report to Shareholders, any of our Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> and any of our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (together with any exhibits to such reports as well as any amendments to such reports), our news releases, or any other written
or oral statements made by or on behalf of us, may include, directly or by incorporation by reference, forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act intended to be
covered by the safe harbor provided for under these sections that reflect our current view (as of the date such forward-looking statement is first made) about future events, prospects, projections or financial performance. The matters discussed in
these forward-looking statements are subject to certain risks and uncertainties and other factors that could cause actual results to differ materially from those projected, anticipated or implied in or by such statements. These risks and
uncertainties include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitive pressures in the markets in which we operate, including pricing pressures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties relating to the pricing of and demand for generic pharmaceuticals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significantly increased costs for commodities and other materials used in the Global Medical Products and
Distribution segment manufacturing, including various components, compounds, raw materials or energy such as <FONT STYLE="white-space:nowrap">oil-based</FONT> resins, pulp, cotton, latex and other commodities and the possibility that we may not
successfully offset or mitigate these increases; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties relating to the timing, frequency and profitability of generic pharmaceutical launches or other
components of our pharmaceutical generics program; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the timing or frequency of the introduction of branded pharmaceuticals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">material reductions in purchases, pricing changes, <FONT STYLE="white-space:nowrap">non-renewal,</FONT> early
termination, or delinquencies or defaults under contracts with key customers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with the nonrenewal of a large Pharmaceutical and Specialty Solutions segment customer at the
end of fiscal year 2025, including the adverse impact of unwinding the negative net working capital associated with this customer and the risk that we may not be successful in mitigating the negative impact to segment profit; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs or claims resulting from quality issues, or other potential or alleged errors or defects in our
manufacturing or sourcing of medical devices or other products or in our compounding, repackaging, information systems or pharmacy management services that may injure persons or damage property or operations, including costs from recalls,
remediation efforts, and related product liability claims and lawsuits, including class action lawsuits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any compromise of our information systems or of those of a third-party service provider, including unauthorized
access to or use or disclosure of company or customer information, disruption of access and ancillary risks associated with our ability to effectively manage any issues arising from any such compromise or disruption; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continuing risks associated with the resolution and defense of the lawsuits and investigations in which we have
been or will be named relating to the distribution of prescription opioid pain medication, including the investigations by the U.S. Department of Justice which concerns our anti-diversion program, our anti-diversion policies and procedures and our
distribution of certain controlled substances; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with the national opioid settlement agreement, including the risk that the maintenance of the
required changes to distributors&#8217; controlled substance anti-diversion programs may result in unforeseen costs or operational challenges and the risk that if we fail to or are alleged to have failed to comply with the terms of the settlement
agreement, we could incur monetary or other penalties or result in additional lawsuits being filed against us; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties related to Cardinal Health Brand products, including our ability to manage cost and infrastructure,
retain margin, increase volume and improve performance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks arising from acquisitions, including possible liabilities relating to the operations or activities of such
businesses prior to their acquisition, and uncertainties relating to our ability to achieve the anticipated results from acquisitions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with the tax benefit from our self-insurance loss claims, including, certain state courts&#8217;
interpretation of laws and insurance policies in ways that may impact our self-insurance loss, which could negatively impact our financial position; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruption, damage or lack of access to, or failure of, our or our third-party service providers&#8217;
information systems, our critical facilities, including our national logistics center, or our distribution networks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with our Corporate Integrity Agreement with the Office of Inspector General of the Department of
Health and Human Services, including the risk that failure to comply with the requirements set forth therein could result in monetary or other penalties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our high sales concentration with certain key customers, including CVS Health Corporation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain the benefits of our generic pharmaceutical sourcing venture with CVS Health Corporation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement
Administration, certain agencies within the U.S. Department of Health and Human Services (including the U.S. Food and Drug Administration, Centers for Medicare and Medicaid Services, the Office of Inspector General and the Office for Civil Rights),
the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance authorities, state health departments, state insurance departments, state
Medicaid departments or comparable regulatory bodies or governmental authorities or foreign equivalents that, in each case, could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning
letters, recalls, seizures, injunctions or monetary sanctions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shortages in commodities, components, compounds, raw materials or energy used by our businesses, including supply
disruptions of radioisotopes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily
available; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties with respect to certain business process initiatives, including IT infrastructure activities and
outsourcing relationships, including the ability to achieve the expected benefits from such initiatives, the risk that we could incur unexpected charges, and the risk that we may fail to retain key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties or delays in the development, production, manufacturing, sourcing and marketing of new or existing
products and services, including difficulties or delays associated with obtaining or maintaining requisite regulatory consents, whether our own or third parties&#8217;, or approvals associated with those activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing disruptions, whether due to regulatory action, including regulatory action to reduce ethylene oxide
(&#8220;EtO&#8221;), production quality deviations, safety issues or raw material shortages or defects, or because a key product is manufactured at a single manufacturing facility with limited alternate facilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with industry reliance on EtO to sterilize certain medical products that we manufacture or
distribute, including the possibility that regulatory actions to reduce EtO emissions could become </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">more widespread, which may result in increased costs or supply shortages; and risks that the lawsuits against us
alleging personal injury resulting from EtO exposure could become more widespread; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions,
including the possibility that the corporate tax rate in the U.S. could be increased; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks arising from possible violations of healthcare fraud and abuse laws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks arising from possible violations of the U.S. Foreign Corrupt Practices Act and other similar
anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks arising from our collecting, handling and maintaining patient-identifiable health information and other
sensitive personal and financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks arising from certain of our businesses being Medicare-certified suppliers or participating in other federal
and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program, which businesses are subject to accreditation and quality standards and other rules and regulations, including applicable reporting, billing,
payment and record-keeping requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks arising from pharmaceutical manufacturers&#8217; restriction of sales under the 340B drug pricing program
to contract pharmacies, which may adversely impact our customers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks arising from certain of our businesses manufacturing pharmaceutical and medical products or repackaging
pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs, which businesses are subject to federal and state laws that establish eligibility for reimbursement by such programs and
other applicable standards and regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in laws or changes in the interpretation or application of laws or regulations, as well as possible
failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier
relationships, or changes in customer mix; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and
payments to settle these challenges, which may adversely affect our effective tax rate or tax payments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties due to possible government healthcare reform, including proposals related to Medicare drug rebate
arrangements, possible repeal or replacement of major parts of the Patient Protection and Affordable Care Act, proposals related to prescription drug pricing transparency and the possible adoption of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Medicare-For-All;</FONT></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reductions or limitations on governmental funding at the state or federal level or efforts by healthcare
insurance companies to limit payments for products and services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in manufacturers&#8217; pricing, selling, inventory, distribution or supply policies or practices;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in legislation or regulations governing prescription drug pricing, healthcare services or mandated
benefits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties arising as a result of the Supreme Court decision on Dobbs vs. Jackson, including uncertainties
associated with states&#8217; proposed and adopted laws which may impact our ability to distribute or store certain pharmaceutical products and the risk that we could incur unforeseen costs to comply with these new laws in various jurisdictions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in hospital buying groups or hospital buying practices; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in distribution or sourcing models for pharmaceutical and medical and surgical products, including an
increase in direct and limited distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to the prescription drug reimbursement formula and related reporting requirements for generic
pharmaceuticals under Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continuing consolidation in the healthcare industry, which could give the resulting enterprises greater
bargaining power and may increase pressure on prices for our products and services or result in the loss of customers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks to our business and information and controls systems in the event that business process improvements,
infrastructure modernization or initiatives to use third-party service providers for key systems and processes are not effectively implemented; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that we may not effectively implement and maintain data governance structures across businesses to allow
us to access and interpret our data, which could put us at a competitive disadvantage relative to our peers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results, costs, effects or timing of any commercial disputes, government contract compliance matters, patent
infringement claims, qui tam actions, government investigations, shareholder lawsuits or other legal proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that our business performance or internal control over financial reporting may be adversely
impacted if we are not successful at attracting, retaining and developing talent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">losses relating to product liability lawsuits and claims regarding products for which we cannot obtain product
liability insurance or for which such insurance may not be adequate to cover our losses, including the product liability lawsuits we are currently defending relating to alleged personal injuries associated with the use of Cordis inferior vena cava
filter products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with the importation of products or source materials used in products that we manufacture or
distribute, including risks associated with our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-of-origin</FONT></FONT> determinations and the possibility that we could experience additional supply disruptions as a result
of the Uyghur Forced Labor Prevention Act or other similar regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain adequate intellectual property protections; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to manage and complete divestitures or other strategic business combination transactions, including
our ability to find buyers or other strategic exit opportunities and risks associated with the possibility that we could experience greater <FONT STYLE="white-space:nowrap">dis-synergies</FONT> than anticipated or otherwise fail to achieve our
strategic objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">bankruptcy, insolvency or other credit failure of a customer or supplier that owes us a substantial amount;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with global operations, including the effect of local economic environments, inflation,
recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their
impact on our ability to source products or materials that we need to conduct our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with our use of and reliance on the global capital and credit markets, including our ability to
access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to introduce and market new products and our ability to keep pace with advances in technology;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enter new lines of business and execute our strategy; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant charges to earnings if goodwill or intangible assets become impaired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties relating to general political, business, industry, regulatory and market conditions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failing to complete the Acquisition or successfully integrate Solaris to achieve the expected benefits of
Acquisition; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other factors described in the &#8220;Risk Factors&#8221; section of the 2025 Form
<FONT STYLE="white-space:nowrap">10-K.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As and when made, we believe that our forward-looking statements are reasonable. However,
as a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. You should not place undue reliance on these
forward-looking statements. The words &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221;
&#8220;project,&#8221; &#8220;continue,&#8221; &#8220;likely,&#8221; and similar expressions generally identify &#8220;forward-looking statements,&#8221; which speak only as of the date the statements were made, and also include statements
reflecting future results or guidance, statements of outlook and expense accruals. We undertake no obligation to update or revise any forward-looking statements or to update the reasons actual results could differ materially from those anticipated,
to reflect circumstances or events that occur after the statements are made, except to the extent required by applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc42072_4"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following summary highlights selected information contained elsewhere in this prospectus supplement, the accompanying prospectus and in the documents
incorporated by reference in this prospectus supplement and does not contain all the information you will need in making your investment decision. You should read carefully this entire prospectus supplement, the accompanying prospectus and the
documents incorporated by reference in this prospectus supplement. See &#8220;Where You Can Find More Information and Incorporation of Certain Documents by Reference&#8221; in this prospectus supplement. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cardinal Health, Inc., an
Ohio corporation formed in 1979, is a global healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in
the home. We provide pharmaceuticals and medical products and cost-effective solutions that enhance the healthcare system and supply chain efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care
coordination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The mailing address of our executive offices is 7000 Cardinal Place, Dublin, Ohio 43017, and our telephone number is (614) <FONT
STYLE="white-space:nowrap">757-5000.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information concerning our business and affairs and descriptions of certain laws and
regulations to which we may be subject, please refer to the information in the documents incorporated by reference in this prospectus supplement and the accompanying prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Developments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Solaris Acquisition
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;12, 2025, we announced that we, through GI Alliance (&#8220;GIA&#8221;), our majority owned subsidiary, entered into a definitive
agreement to acquire Solaris for a purchase price of approximately $1.9&nbsp;billion in cash, subject to certain adjustments. In connection with the closing of the Acquisition, we will issue common units in GIA to certain Solaris physicians and
management which are estimated to have a grant date fair value of approximately $500&nbsp;million, a portion of which will be recognized as post-combination expense. Following the closing of the Acquisition, we will own approximately 75% of GIA,
which we have rebranded to be The Specialty Alliance. The Acquisition is expected to close by the end of calendar year 2025, subject to customary closing conditions, including receipt of required physician and regulatory approvals. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Solaris is a leading national urology management services organization (&#8220;MSO&#8221;). Solaris&#8217;s MSO platform includes over 750 physicians across
more than 250 practice locations in 14 states, with extensive reach into the local communities they serve. Solaris is committed to enhancing access to specialty healthcare and continually improving patient outcomes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to use the net proceeds from the sale of the notes to fund a portion of the consideration payable in connection with the Acquisition and the fees and
expenses in connection therewith. We intend to fund the balance of the consideration payable in connection with the Acquisition with cash on hand. The sale of the notes is not conditioned upon the consummation of the Acquisition, which, if
completed, will occur subsequent to the closing of the sale of the notes. See &#8220;Use of Proceeds.&#8221; </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If (i)&nbsp;the Acquisition is not consummated on or before the Special Mandatory Redemption End Date or
(ii)&nbsp;we notify the trustee under the indenture that we will not pursue the consummation of the Acquisition, then we will be required to redeem the notes in whole, at a special mandatory redemption price equal to 101% of the aggregate principal
amount of the notes being redeemed, plus accrued and unpaid interest, if any, to, but excluding, the Special Mandatory Redemption Date. See &#8220;Description of Notes&#8212;Special Mandatory Redemption.&#8221; The proceeds from this offering of the
notes will not be deposited into an escrow account pending completion of the Acquisition or any Special Mandatory Redemption, nor will we be required to grant any security interest or other lien on those proceeds to secure any redemption of the
notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will be able to consummate the Acquisition and the related transactions on a timely basis, on the terms
described herein, or at all. See &#8220;Risk Factors.&#8221; </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following summary is provided solely for your convenience. The summary is not intended to be complete. You should read the full text and more specific
details contained elsewhere in this prospectus supplement. For a more detailed description of the notes, see &#8220;Description of the Notes.&#8221; </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Issuer </P></TD>
<TD>Cardinal Health, Inc. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Notes Offered </P></TD>
<TD>$&#8195;&#8195;&#8195;&#8195; aggregate principal amount of notes consisting of: </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">$&#8195;&#8195;&#8195;&#8195;
aggregate principal amount of &#8195;&#8195;% notes due 20&#8195;; and </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:38%; font-size:10pt; font-family:Times New Roman">$&#8195;&#8195;&#8195;&#8195; aggregate principal amount of
&#8195;&#8195;% notes due 20&#8195;. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Interest </P></TD>
<TD>&#8195;&#8195;% per year for the 20&#8195; notes; and <br>&#8195;&#8195;% per year for the 20&#8195; notes; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Maturity </P></TD>
<TD>&#8195;&#8195;, 20&#8195; for the 20&#8195; notes; and </TD></TR></TABLE> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#8195;&#8195;, 20&#8195; for the 20&#8195; notes; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Interest Payment Dates </P></TD>
<TD>&#8195;&#8195; and&#8195;&#8195;&#8195;&#8195;of each year, commencing&#8195;&#8195;&#8195;&#8195;, 2026. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Record Dates </P></TD>
<TD>&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Optional Redemption </P></TD>
<TD>We may, at our option, redeem the notes of either series in whole at any time, or in part from time to time, as described under &#8220;Description of the Notes&#8212;Optional Redemption.&#8221; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Special Mandatory Redemption </P></TD>
<TD>If (i)&nbsp;the Acquisition is not consummated on or before the Special Mandatory Redemption End Date or (ii)&nbsp;we notify the trustee under the indenture that we will not pursue the consummation of the Acquisition, then we will be required to
redeem the notes in whole, at a special mandatory redemption price equal to 101% of the aggregate principal amount of the notes being redeemed, plus accrued and unpaid interest, if any, to, but excluding, the Special Mandatory Redemption Date. See
&#8220;Description of Notes&#8212;Special Mandatory Redemption.&#8221; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The proceeds from this offering of the notes will not be deposited into an escrow account pending completion of the Acquisition or any Special Mandatory Redemption, nor will we be required to grant any security interest
or other lien on those proceeds to secure any redemption of the notes. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Change of Control Repurchase Event </P></TD>
<TD>Upon the occurrence of a change of control repurchase event, we will be required to make an offer to purchase the notes at a price equal to 101% of the principal amount of the notes, plus accrued and unpaid interest, if any, to, but excluding,
the date of repurchase. See &#8220;Description of the Notes&#8212;Repurchase at the Option of Holders Upon a Change of Control.&#8221; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Priority </P></TD>
<TD> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The notes will be senior unsecured debt obligations of Cardinal Health. The notes will rank equally in right of payment with all of
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Cardinal Health&#8217;s existing and future senior debt; and senior to all of Cardinal Health&#8217;s existing and future subordinated debt. As of June&nbsp;30, 2025, Cardinal Health had
outstanding approximately $8.5&nbsp;billion of indebtedness and guarantees of subsidiary indebtedness for borrowed money with which the notes would rank equally in right of payment. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The notes will be structurally subordinated to the liabilities of Cardinal Health&#8217;s subsidiaries, including trade payables. As of June&nbsp;30, 2025, Cardinal Health&#8217;s subsidiaries had approximately
$124.0&nbsp;million of indebtedness for borrowed money (which is guaranteed by Cardinal Health) and Cardinal Health&#8217;s subsidiaries had an aggregate of approximately $34.7&nbsp;billion of trade payables, to which the notes would be structurally
subordinated. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The notes will be effectively junior to any secured debt of Cardinal Health to the extent of the value of the assets securing such indebtedness. Cardinal Health currently has no secured debt. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Form of Notes </P></TD>
<TD>The notes of both series will initially be represented by one or more global notes, registered in the name of Cede&nbsp;&amp; Co., the nominee of The Depository Trust Company (&#8220;DTC&#8221;). The notes of both series will be issued in
denominations of $2,000 and integral multiples of $1,000 in excess thereof. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </P></TD>
<TD>We estimate that the net proceeds from the sale of the notes, after deducting the underwriting discount and estimated unreimbursed offering expenses, will be approximately $&#8195;&#8195;&#8195;&#8195;. We intend to use the net proceeds from the
sale of the notes offered hereby to fund a portion of the consideration payable in connection with the Acquisition and the fees and expenses in connection therewith. Pending application of the proceeds to fund the consideration payable in connection
with the Acquisition, we may temporarily use such funds for general corporate purposes. The sale of the notes is not conditioned upon the consummation of the Acquisition, which, if completed, will occur subsequent to the closing of the sale of the
notes. See &#8220;Use of Proceeds.&#8221; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Further Issuances </P></TD>
<TD>We may from time to time, without the notice to or consent of the holders of the notes, create and issue additional notes of either series offered by this prospectus supplement which will rank equally and ratably in all respects with the notes
of the applicable series so offered, have the same terms and conditions (other than the issue date, the price to public, and if applicable, the first interest payment date) as such series, so that such additional notes will be consolidated and form
a single series with the 20&#8195; notes or the 20&#8195; notes, as applicable. See &#8220;Description of the Notes.&#8221; </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </P></TD>
<TD>See &#8220;Risk Factors&#8221; beginning on <FONT STYLE="white-space:nowrap">page&nbsp;S-13,</FONT> as well as the risks set forth in our other filings with the SEC, which are incorporated by reference in this prospectus supplement and the
accompanying prospectus, for a discussion of factors you should carefully consider before deciding to invest in the notes. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Trustee </P></TD>
<TD>The Bank of New York Mellon Trust Company, N.A. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Governing Law </P></TD>
<TD>The notes will be, and the indenture pursuant to which we will issue the notes is, governed by the laws of the State of New York. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc42072_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our notes involves various risks. There are a number of factors, including those described below and in our 2025 <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> which is incorporated by reference in this prospectus supplement, as they may be amended, updated or modified periodically in our reports filed with the SEC, that could materially and adversely
affect our results of operations, financial condition, liquidity and cash flows. You should carefully consider the risks and uncertainties described below and the other information in this prospectus supplement and the accompanying prospectus and in
the documents incorporated by reference before deciding whether to purchase Cardinal Health&#8217;s notes. These risks are not the only risks that we face. Our business operations could also be affected by additional factors that are not presently
known to us or that we currently consider to be immaterial to our operations. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to the Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The notes will be structurally subordinated to all existing and future liabilities of Cardinal Health&#8217;s subsidiaries. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cardinal Health conducts nearly all of its operations through subsidiaries and it expects that it will continue to do so. Cardinal Health&#8217;s subsidiaries
are separate and distinct legal entities. None of Cardinal Health&#8217;s subsidiaries will have an obligation to pay any amounts due on the notes, subject to existing or future contractual obligations between Cardinal Health and its subsidiaries,
to provide Cardinal Health with funds for its payment obligations, whether by dividends, distributions, loans or other payments. As a result, the right of Cardinal Health to participate as a shareholder in any distribution of assets of any
subsidiary upon such subsidiary&#8217;s liquidation or reorganization or otherwise and the ability of holders of the notes to benefit as creditors of Cardinal Health from any such distribution are subject to the prior claims of creditors of the
subsidiary, except to the extent that Cardinal Health is a creditor of the subsidiary and its claims are recognized. In addition, any payment of dividends, distributions, loans or advances by Cardinal Health&#8217;s subsidiaries to Cardinal Health
could be subject to statutory or contractual restrictions and taxes on distributions. Payments to Cardinal Health by its subsidiaries will also be contingent upon its subsidiaries&#8217; earnings and business considerations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2025, Cardinal Health had outstanding approximately $8.5&nbsp;billion of indebtedness and guarantees of subsidiary indebtedness for
borrowed money with which the notes would rank equally. As of such date, Cardinal Health&#8217;s subsidiaries had outstanding approximately $124.0&nbsp;million of indebtedness for borrowed money (which is guaranteed by Cardinal Health) and Cardinal
Health&#8217;s subsidiaries had an aggregate of approximately $34.7&nbsp;billion of trade payables to which the notes would be structurally subordinated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the notes are not secured by any of Cardinal Health&#8217;s assets or those of its subsidiaries. As a result, the notes are effectively
subordinated to any secured debt Cardinal Health or its subsidiaries may incur. Cardinal Health currently has no secured debt. To the extent Cardinal Health were to incur any secured debt, the notes would be effectively junior to such secured debt
of Cardinal Health to the extent of the value of the assets securing such debt. In any liquidation, dissolution, bankruptcy or other similar proceeding, holders of Cardinal Health&#8217;s secured debt may assert rights against any assets securing
such debt in order to receive full payment of their debt before those assets may be used to pay the holders of the notes. In such an event, Cardinal Health may not have sufficient assets remaining to pay amounts due on any or all of the notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We and our subsidiaries may not be able to generate sufficient cash to service all of our and their indebtedness, including the notes. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to make scheduled payments on or to refinance our debt obligations depends on our financial condition and the operating performance of our
subsidiaries, which are subject to prevailing economic and competitive conditions and to certain financial, business and other factors beyond our control. We cannot assure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
you that our subsidiaries will maintain a level of cash flows from operating activities sufficient to permit us and them to pay the principal, premium, if any, and interest on our indebtedness,
including the notes. If our and our subsidiaries&#8217; cash flows and capital resources are insufficient to fund our debt service obligations and those of our subsidiaries, we or they may be forced to reduce or delay investments and capital
expenditures, or to sell assets, seek additional capital or restructure or refinance our indebtedness, including the notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The notes do not restrict
our ability to incur additional unsecured debt. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture governing the notes does not restrict the amount of unsecured debt that we or our
subsidiaries may incur. If we or our subsidiaries incur additional debt, it may be more difficult for us to satisfy our obligations with respect to the notes. Furthermore, the incurrence of additional debt may cause a loss in the trading value of
the notes and the credit rating of the notes may be lowered or withdrawn. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>An actual or anticipated downgrade in our credit ratings could adversely
affect the trading value or liquidity of the notes, increase our borrowing costs and limit our ability to obtain future financing. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to
periodic review by independent credit rating agencies. Our credit ratings are an assessment by these rating agencies of our ability to pay our debts when due. As such, an increase in the level of our outstanding indebtedness, or the occurrence of
other events that could have an adverse impact on our financial condition or results of operations, may cause the rating agencies to downgrade, place on negative watch or change their outlook on our credit ratings generally or the ratings on the
notes, which could adversely impact the trading value or liquidity of the notes. Any such downgrade, placement on negative watch or change in outlook could also adversely affect our cost of borrowing, including under our revolving credit facility,
limit our access to the capital markets or result in more restrictive covenants in future debt agreements. The ratings on the notes reflect only the views of the rating agencies at the time the ratings are assigned and may not reflect the potential
impact of all risks that may affect the value of the notes. A credit rating is not a recommendation to buy, sell or hold securities and may be revised, suspended or withdrawn by the rating agency at any time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Active trading markets for the notes may not develop. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes are new issues of securities with no established trading market. We do not intend to apply for listing of either series of notes on any securities
exchange or for inclusion of either series of notes on any automated dealer quotation system. Active or liquid trading markets for the notes may not develop. If no active trading markets develop, you may not be able to resell your notes at their
fair market value or at all. Future trading prices of the notes will depend on many factors, including, among other things, prevailing interest rates, our financial condition and the markets for similar securities. The condition of the financial
markets and prevailing market rates have fluctuated in the past and are likely to fluctuate in the future, which could have an adverse effect on the market price of the notes. We have been informed by the underwriters that they currently intend to
make a market in the notes of each series after this offering is completed. However, the underwriters may cease their market-making at any time at their discretion without notice. If the underwriters cease to act as market makers for the notes, we
cannot assure you another firm or person will make markets in the notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may not be able to repurchase the notes upon a change of control. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the occurrence of a change of control repurchase event, we will be required to offer to repurchase all outstanding notes at 101% of the aggregate
principal amount plus accrued and unpaid interest, if any, to, but excluding, the date of repurchase. However, it is possible that we will not have sufficient funds at the time of the change of control (as defined herein) to make the required
repurchase of notes or that restrictions in our then-existing debt instruments will not allow such repurchases. See &#8220;Description of the Notes&#8212;Repurchase at the Option of Holders Upon a Change of Control.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If the Acquisition is not completed on or before the Special Mandatory Redemption End Date or we notify
the trustee under the indenture that we will not pursue the consummation of the Acquisition, we will be required to redeem the notes. If this occurs, you may realize a lower return on your investment than if the notes had been held through maturity.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If (i)&nbsp;the Acquisition is not consummated on or before the Special Mandatory Redemption End Date or (ii)&nbsp;we notify the trustee under the
indenture that we will not pursue the consummation of the Acquisition, then we will be required to redeem the notes, in whole, at a special mandatory redemption price equal to 101% of the aggregate principal amount of the notes being redeemed, plus
accrued and unpaid interest, if any, to, but excluding, the Special Mandatory Redemption Date. See &#8220;Description of Notes&#8212;Special Mandatory Redemption.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proceeds from this offering of the notes will not be deposited into an escrow account pending completion of the Acquisition or any Special Mandatory
Redemption, nor will we be required to grant any security interest or other lien on those proceeds to secure any redemption of the notes. If we are required to redeem the notes, the ability to pay the redemption price may be limited by our financial
resources at the time. In addition, whether or not a Special Mandatory Redemption of the notes is ultimately triggered, the existence of these redemption provisions may adversely affect the trading prices of the notes until such time, if any, as the
Acquisition is consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we redeem the notes pursuant to the special mandatory redemption provisions, you may not be able to reinvest the
redemption proceeds in a comparable security at an effective interest rate as high as that of the notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not be required to redeem the notes
pursuant to the Special Mandatory Redemption as long as the Acquisition closes on or before the Special Mandatory Redemption End Date, even if between the closing of this offering and the closing of the Acquisition we experience any changes
(including any material changes) in our business or financial condition. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to the Acquisition </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our pending acquisition of Solaris subjects us to various risks and uncertainties. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are successful in completing the Acquisition, we will be subject to additional risks, including the following: we may fail to realize the synergies and
other benefits we expect from the Acquisition; the use of the proceeds from the sale of the notes offered hereby may have an adverse effect on our liquidity, limit our flexibility in responding to other business opportunities, and increase our
vulnerability to adverse economic and industry conditions; we may fail to retain key personnel of the acquired businesses; future developments may impair the value of our purchased goodwill or intangible assets; we may face difficulties
establishing, appropriately integrating or combining operations and systems; we may encounter unforeseen internal control, regulatory, or compliance issues, including with respect to physician office management; and we may face other additional
risks relating to regulatory matters, legal proceedings (including medical malpractice suits), and tax laws or positions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Acquisition Agreement
and related documents may be amended or modified without your consent. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Between the time of the issuance of the notes and the consummation of the
Acquisition, the parties to the Acquisition Agreement (as defined under &#8220;&#8212;Special Mandatory Redemption&#8221;) or other related transaction documents may agree to modify or waive the terms or conditions of such documents without the
consent of the holders. The terms of the notes will not preclude the parties to the Acquisition Agreement from making certain changes to the terms of the Acquisition or from waiving certain conditions to the Acquisition, which may adversely affect
your investment in the notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc42072_6"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following table sets forth our short-term obligations and capitalization at June&nbsp;30, 2025 (1) on an actual basis and (2)&nbsp;as adjusted to
reflect the issuance and sale of the notes offered hereby, but not the expected use of proceeds. You should read this table together with our financial statements incorporated by reference in this prospectus supplement and the accompanying
prospectus. See &#8220;Where You Can Find More Information and Incorporation of Certain Documents by Reference&#8221; in this prospectus supplement. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term borrowings, excluding current portion of long-term obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term obligations, including current portion:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;% Notes due 20&#8195; offered hereby</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;% Notes due 20&#8195; offered hereby</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.750% Notes due 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.700% Notes due 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.410% Notes due 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.125% Notes due 2029</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.000% Notes due 2029</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.450% Notes due 2034</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.350% Notes due 2034</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.600% Notes due 2043</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.500% Notes due 2044</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.900% Notes due 2045</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.368% Notes due 2047</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.750% Notes due 2054</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.00% Debentures due 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Floating Rate Term Loan due 2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term obligations, including finance leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term obligations, including current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#8217; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred shares, without par value:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Authorized&#8212;500&nbsp;thousand shares, Issued&#8212;none</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares, without par value:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Authorized&#8212;755&nbsp;million shares, Issued&#8212;271&nbsp;million shares at June&nbsp;30,
2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retained earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares in treasury, at cost&#8212;32&nbsp;million shares at June&nbsp;30, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Cardinal Health, Inc. shareholders&#8217; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,781</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The As Adjusted Cash and Cash Equivalents includes $&#8195;&#8195; , being the estimated net proceeds of the
offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We expect to use amounts included in cash and cash equivalents to fund the remaining portion of the
consideration payable in connection with the Acquisition. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc42072_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that we will receive net proceeds from this offering of approximately $&#8195;&#8195;&#8195;&#8195;, after deducting our estimated offering
expenses and the underwriting discounts. We plan to use the net proceeds from the sale of the notes to fund a portion of the consideration payable in connection with the Acquisition and the fees and expenses in connection therewith. Pending
application of the proceeds to fund the consideration payable in connection with the Acquisition, we may temporarily use such funds for general corporate purposes. The sale of the notes is not conditioned upon the consummation of the Acquisition,
which, if completed, will occur subsequent to the closing of the sale of the notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If (i)&nbsp;the Acquisition is not consummated on or before the
Special Mandatory Redemption End Date or (ii)&nbsp;we notify the trustee under the indenture that we will not pursue the consummation of the Acquisition, then we will be required to redeem the notes in whole, at a special mandatory redemption price
equal to 101% of the aggregate principal amount of the notes being redeemed, plus accrued and unpaid interest, if any, to, but excluding, the Special Mandatory Redemption Date. See &#8220;Description of Notes&#8212;Special Mandatory
Redemption.&#8221; The proceeds from this offering of the notes will not be deposited into an escrow account pending completion of the Acquisition or any Special Mandatory Redemption, nor will we be required to grant any security interest or other
lien on those proceeds to secure any redemption of the notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc42072_8"></A>DESCRIPTION OF THE NOTES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following description of the particular terms of the notes offered hereby (referred to in the accompanying prospectus as the &#8220;debt
securities&#8221;) supplements, and to the extent inconsistent therewith replaces, the description of the general terms and provisions of the debt securities set forth in the accompanying prospectus under the heading &#8220;Description of Debt
Securities&#8221; to which description reference is hereby made. The following summaries of certain provisions of the indenture (as defined herein) do not purport to be complete, and are subject to, and are qualified in their entirety by reference
to, all the provisions of the indenture, including the definitions in the indenture of certain terms and other terms made part of the indenture. As used in this description, unless otherwise expressly stated or the context otherwise requires, all
references to &#8220;Cardinal Health,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221; mean Cardinal Health, Inc. excluding its subsidiaries. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 20&#8195; notes and the 20&#8195; notes
(which we refer to herein, collectively, as the &#8220;notes&#8221;) will be issued as separate series of senior unsecured debt securities under a base indenture, dated as of June&nbsp;2, 2008 (the &#8220;base indenture&#8221;), between Cardinal
Health and The Bank of New York Mellon Trust Company, N.A., as trustee (the &#8220;trustee&#8221;), as supplemented by a third supplemental indenture, dated as of &#8195;&#8195;&#8195;&#8195;, 2025 (together with the base indenture, the
&#8220;indenture&#8221;), between Cardinal Health and the trustee. The indenture provides that the debt securities may be issued from time to time in one or more series with different terms. The indenture does not limit the aggregate amount of debt
securities that may be issued or any other debt that may be incurred by Cardinal Health. A default in our obligations with respect to any other Indebtedness will not constitute a default or an event of default with respect to the debt securities.
The indenture does not contain any covenants or provisions that afford holders of debt securities protection in the event of a highly leveraged transaction. Reference is made to the accompanying prospectus for a description of other terms of the
debt securities. The indenture and the notes are governed by New York law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cardinal Health may from time to time issue other series of debt securities
under the indenture consisting of notes or other unsecured evidences of Indebtedness, but, unless otherwise indicated, such other series will be separate from and independent of the notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes will not be entitled to the benefit of any sinking fund. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes of each series will initially be represented by one or more global notes (each, a &#8220;global note&#8221;), in registered form, without coupons,
in denominations of $2,000 or an integral multiple of $1,000 in excess thereof as described under &#8220;&#8212;Book-Entry System.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no
public trading markets for the notes, and we do not intend to apply for listing of either series of the notes on a securities exchange or for inclusion of either series of the notes on an automated quotation system. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aggregate Principal Amount </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 20&#8195; notes will be
limited initially to $&#8195;&#8195;&#8195;&#8195;aggregate principal amount and the 20&#8195; notes will be limited initially to $&#8195;&#8195;&#8195;&#8195;aggregate principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cardinal Health may, at any time, without notice to or the consent of the holders of the notes, create and issue additional notes having the same priority and
the same interest rate, maturity and other terms as the notes of each series (other than the date of issuance, price to public, and, under certain circumstances, the first interest payment date following the issue date of such additional notes). Any
such additional notes, together with the notes of the applicable series offered by this prospectus supplement, will each form a single series of the notes under the indenture. If the additional notes are not fungible for U.S. federal income tax
purposes with the notes offered hereby, the additional notes will have a separate CUSIP number. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Maturity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 20&#8195; notes will mature on&#8195;&#8195;&#8195;&#8195;, 20&#8195; and the 20&#8195; notes will mature on&#8195;&#8195;&#8195;&#8195;, 20&#8195;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interest </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest on the notes will accrue from &#8195;,
2025 and will be payable semi-annually on &#8195;&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;&#8195;, commencing&#8195;&#8195;&#8195;&#8195;, 2026 to the persons in whose names the notes are registered at the close of business on
&#8195;&#8195;&#8195;&#8195; or &#8195;&#8195;&#8195;&#8195; (whether or not a business day) immediately proceeding the relevant interest payment date at the annual rate for each series set forth on the cover page of this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest payable on any interest payment date or the maturity date will be the amount of interest accrued from, and including, the next preceding interest
payment date in respect of which interest has been paid or duly provided for (or from and including the issue date, if no interest has been paid or duly provided for with respect to the notes) to, but not including, such interest payment date or
maturity date, as the case may be. If an interest payment date or the maturity date falls on a day that is not a business day, the related payment of principal or interest will be made on the next succeeding business day as if made on the date the
payment was due. No interest will accrue on such payment for the period from and after such interest payment date or the maturity date, as the case may be, to the date of such payment on the next succeeding business day. The term &#8220;business
day&#8221; means any day other than a Saturday, a Sunday or any other day on which banking institutions in New York, New York or the city where the corporate trust business of the trustee with respect to the indenture is principally administered at
any particular time are required or authorized to close or be closed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Priority of Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes will be senior unsecured debt obligations of Cardinal Health and will rank equally in right of payment with all of Cardinal Health&#8217;s existing
and future senior indebtedness. The notes will be senior to all of Cardinal Health&#8217;s existing and future subordinated indebtedness. As of June&nbsp;30, 2025, Cardinal Health had outstanding approximately $8.5&nbsp;billion of indebtedness and
guarantees of subsidiary indebtedness for borrowed money with which the notes would rank equally in right of payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cardinal Health conducts nearly all
of its operations through Subsidiaries and it expects that it will continue to do so. As a result, the right of Cardinal Health to participate as a shareholder in any distribution of assets of any Subsidiary upon its liquidation or reorganization or
otherwise and the ability of holders of the notes to benefit as creditors of Cardinal Health from any distribution are subject to the prior claims of creditors of the Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2025, Cardinal Health&#8217;s Subsidiaries had outstanding approximately $124&nbsp;million of indebtedness for borrowed money (which is
guaranteed by Cardinal Health) and Cardinal Health&#8217;s Subsidiaries had an aggregate of approximately $34.7&nbsp;billion of trade payables to which the notes would be structurally subordinated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cardinal Health currently has no secured debt. To the extent Cardinal Health were to incur any secured debt, the notes would be effectively junior to such
secured debt of Cardinal Health to the extent of the value of the assets securing such debt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Optional Redemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to &#8195;&#8195;&#8195;&#8195;, 20&#8195;(&#8195;&#8195; months prior to the maturity date for the 20&#8195; notes) (the &#8220;20&#8195; Par Call
Date&#8221;), Cardinal Health may redeem the 20&#8195; notes at its option, in whole or in part, at any time and from time to time; and prior to &#8195;&#8195;&#8195;&#8195;, 20&#8195; (&#8195;&#8195; months prior to the maturity date for the
20&#8195; notes) (the &#8220;20&#8195; Par Call Date&#8221; and, together with the 20&#8195; Par Call Date, the &#8220;Par Call Dates&#8221; and each, a &#8220;Par Call Date&#8221;), Cardinal Health may redeem the 20&#8195; notes at its option, in
whole or in part, at any time and from time to time, in each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
case, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(a) the sum of the present values of the remaining scheduled payments of principal and interest on the notes
being redeemed discounted to the redemption date (assuming the notes being redeemed matured on the applicable Par Call Date) on a semi-annual basis (assuming a <FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT
STYLE="white-space:nowrap">30-day</FONT> months) at the Treasury Rate plus (i)&#8195;&#8195;&#8195; basis points in the case of the 20&#8195; notes and (ii)&#8195;&#8195;&#8195; basis points in the case of the 20&#8195; notes, less (b)&nbsp;interest
accrued to, but excluding, the date of redemption, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">100% of the principal amount of the notes being redeemed on such redemption date, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">plus,&#8195;in either case, accrued and unpaid interest thereon to, but excluding, the redemption date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On or after the applicable Par Call Date, Cardinal Health may redeem the applicable series of notes, in whole or in part, at any time and from time to time,
at a redemption price equal to 100% of the principal amount of such series of notes being redeemed plus accrued and unpaid interest thereon to, but excluding, the redemption date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;Treasury Rate&#8221; means, with respect to any redemption date for a series of notes, the yield determined by Cardinal Health in accordance with the
following two paragraphs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Treasury Rate shall be determined by Cardinal Health after 4:15 p.m., New York City time (or after such time as yields on
U.S. government securities are posted daily by the Board of Governors of the Federal Reserve System), on the third business day preceding the redemption date based upon the yield or yields for the most recent day that appear after such time on such
day in the most recent statistical release published by the Board of Governors of the Federal Reserve System designated as &#8220;Selected Interest Rates (Daily)&#8212;H.15&#8221; (or any successor designation or publication) (&#8220;H.15&#8221;)
under the caption &#8220;U.S. government securities&#8212;Treasury constant maturities&#8212;Nominal&#8221; (or any successor caption or heading) (&#8220;H.15 TCM&#8221;). In determining the Treasury Rate, Cardinal Health shall select, as
applicable: (1)&nbsp;the yield for the Treasury constant maturity on H.15 exactly equal to the period from the redemption date to the applicable Par Call Date (the &#8220;Remaining Life&#8221;); or (2)&nbsp;if there is no such Treasury constant
maturity on H.15 exactly equal to the Remaining Life, the two yields &#8211; one yield corresponding to the Treasury constant maturity on H.15 immediately shorter than and one yield corresponding to the Treasury constant maturity on H.15 immediately
longer than the Remaining Life &#8211; and shall interpolate to the applicable Par Call Date on a straight-line basis (using the actual number of days) using such yields and rounding the result to three decimal places; or (3)&nbsp;if there is no
such Treasury constant maturity on H.15 shorter than or longer than the Remaining Life, the yield for the single Treasury constant maturity on H.15 closest to the Remaining Life. For purposes of this paragraph, the applicable Treasury constant
maturity or maturities on H.15 shall be deemed to have a maturity date equal to the relevant number of months or years, as applicable, of such Treasury constant maturity from the redemption date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If on the third business day preceding the redemption date H.15 TCM is no longer published, Cardinal Health shall calculate the Treasury Rate based on the
rate per annum equal to the semi-annual equivalent yield to maturity at 11:00 a.m., New York City time, on the second business day preceding such redemption date of the United States Treasury security maturing on, or with a maturity that is closest
to, the applicable Par Call Date, as applicable. If there is no United States Treasury security maturing on the applicable Par Call Date but there are two or more United States Treasury securities with a maturity date equally distant from the
applicable Par Call Date, one with a maturity date preceding the applicable Par Call Date and one with a maturity date following the applicable Par Call Date (or, in the case of the 20&#8195; notes, the maturity date for the 20&#8195; notes),
Cardinal Health shall select the United States Treasury security with a maturity date preceding the applicable Par Call Date (or, in the case of the 20&#8195; notes, the maturity date for the 20&#8195; notes). If there are two or more United States
Treasury securities maturing on the applicable Par Call Date (or, in the case of the 20&#8195; notes, the maturity date for the 20&#8195; notes) or two or more United States Treasury securities meeting the criteria of the preceding sentence,
Cardinal Health shall select from among these two or more United States Treasury securities the United States </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Treasury security that is trading closest to par based upon the average of the bid and asked prices for such United States Treasury securities at 11:00 a.m., New York City time. In determining
the Treasury Rate in accordance with the terms of this paragraph, the semi-annual yield to maturity of the applicable United States Treasury security shall be based upon the average of the bid and asked prices (expressed as a percentage of principal
amount) at 11:00 a.m., New York City time, of such United States Treasury security, and rounded to three decimal places. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cardinal Health&#8217;s actions
and determinations in determining the redemption price shall be conclusive and binding for all purposes, absent manifest error. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the
foregoing, installments of interest on notes that are due and payable on an interest payment date falling on or prior to a redemption date will be payable on such interest payment date to the registered holders as of the close of business on the
relevant record date immediately preceding such interest payment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notice of any redemption will be mailed or electronically delivered (or otherwise
transmitted in accordance with the depositary&#8217;s procedures) at least 10 days but not more than 60 days before the redemption date to each holder of notes to be redeemed. Subject to any delay in the redemption date or rescission of the notice
of redemption described below, once notice of redemption is mailed or delivered, the notes called for redemption will become due and payable on the applicable redemption date; <I>provided </I>that any notice of redemption may, at our discretion, be
subject to one or more conditions precedent, including completion of a corporate transaction. In such event, the related notice of redemption will describe each such condition and, if applicable, will state that, at our discretion, the redemption
date may be delayed until such time (including more than 60 days after the notice of redemption was given) as any or all such conditions are satisfied (or waived by us in our sole discretion), or such redemption may not occur and such notice may be
rescinded in the event that any or all such conditions have not been satisfied (or waived by us in our sole discretion) by the redemption date, or by the redemption date as so delayed. If any such redemption has been rescinded or delayed, we will
provide written notice to the trustee prior to the close of business on the business day prior to the redemption date and, upon receipt, the trustee will provide such notice to each registered holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of a partial redemption, selection of the notes for redemption will be made by lot or pursuant to applicable depositary procedures. No notes of a
principal amount of $2,000 or less will be redeemed in part. If any note is to be redeemed in part only, the notice of redemption that relates to the note will state the portion of the principal amount of the note to be redeemed. A new note in a
principal amount equal to the unredeemed portion of the note will be issued in the name of the holder of the note upon surrender for cancellation of the original note. For so long as the notes are held by The Depository Trust Company
(&#8220;DTC&#8221;) (or another depositary), the redemption of the notes shall be done in accordance with the policies and procedures of the depositary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless Cardinal Health defaults in payment of the redemption price, on and after the redemption date interest will cease to accrue on the notes or portions
thereof called for redemption. In addition, we may at any time purchase the notes by tender, in the open market or by private agreement, subject to applicable laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Mandatory Redemption </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If (i)&nbsp;the Acquisition
is not consummated on or before the later of (x) August&nbsp;12, 2026 (the &#8220;End Date&#8221;) and (y)&nbsp;the date that is five business days after any later date to which the End Date may be extended in the Acquisition Agreement (such later
date, the &#8220;Special Mandatory Redemption End Date&#8221;) or (ii)&nbsp;we notify the trustee under the indenture that we will not pursue the consummation of the Acquisition (the earlier of the date of delivery of such notice described in this
clause (ii)&nbsp;and the Special Mandatory Redemption End Date, a &#8220;Special Mandatory Redemption Trigger&#8221;), then we will be required to redeem the notes (the &#8220;Special Mandatory Redemption&#8221;), in whole, at a special mandatory
redemption price equal to 101% of the aggregate principal amount of the notes being redeemed, plus accrued and unpaid interest, if any, to, but excluding, the Special </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Mandatory Redemption Date (as defined herein) (subject to the right of holders of the notes of record on the relevant record date to receive interest due on an interest payment date falling prior
to the Special Mandatory Redemption Date) (the &#8220;Special Mandatory Redemption Price&#8221;). Unless we default in payment of the Special Mandatory Redemption Price, on and after such Special Mandatory Redemption Date, interest will cease to
accrue on the notes to be redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that we become obligated to redeem the notes pursuant to the Special Mandatory Redemption, we will
promptly, and in any event not more than five business days after the Special Mandatory Redemption Trigger, deliver notice to the trustee of the Special Mandatory Redemption and the date upon which the notes will be redeemed (the &#8220;Special
Mandatory Redemption Date&#8221;), which date shall be no later than the tenth business day following the date of such notice unless some longer minimum period may be required by DTC (or any successor depositary), together with a notice of Special
Mandatory Redemption for the trustee to deliver to each registered holder of notes. The trustee will then promptly mail or deliver electronically if such notes are held by any depositary (including, without limitation, DTC) in accordance with such
depositary&#8217;s customary procedures, such notice of Special Mandatory Redemption to each registered holder of the notes to be redeemed at its registered address. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On or before the Special Mandatory Redemption Date, we will pay to a paying agent for payment to each holder of the notes the Special Mandatory Redemption
Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to make the Special Mandatory Redemption, if required in accordance with the terms described above, will constitute an event of default
with respect to the notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proceeds from this offering of the notes will not be deposited into an escrow account pending completion of the
Acquisition or any Special Mandatory Redemption, nor will we be required to grant any security interest or other lien on those proceeds to secure any redemption of the notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the consummation of the Acquisition, the foregoing provisions regarding Special Mandatory Redemption will cease to apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing discussion, the following definitions apply: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;Acquisition&#8221; means the proposed acquisition of the outstanding equity interests of Solaris pursuant to the Acquisition Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;Acquisition Agreement&#8221; means the Agreement and Plan of Merger, dated August&nbsp;12, 2025, by and among GIA, our majority-owned subsidiary, Lee
Equity Partners and Solaris Health physician owners named therein, as may be amended or modified or any provision thereof waived. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;GIA&#8221; means
The GI Alliance Holdings, LLC, a Delaware limited liability company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Repurchase at the Option of Holders Upon a Change of Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a &#8220;change of control repurchase event&#8221; occurs, unless we have exercised our right to redeem the notes in full as described above under
&#8220;&#8212;Optional Redemption&#8221; or we have redeemed the notes as described above under &#8220;&#8212;Special Mandatory Redemption,&#8221; we will make an offer to each holder of notes to repurchase all or any part (equal to $2,000 or in
integral multiples of $1,000 in excess thereof) of that holder&#8217;s notes at a repurchase price in cash equal to 101% of the aggregate principal amount of notes repurchased plus accrued and unpaid interest, if any, on the notes repurchased to,
but excluding, the date of purchase. Within 30 days following any change of control repurchase event or, at our option, prior to any change of control, but after the public announcement of the change of control, we will deliver a notice to each
holder, with a copy to the trustee, describing the transaction or transactions that constitute or may constitute the change of control repurchase event and offering to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
repurchase notes on the payment date specified in the notice, which date will be no earlier than 30 days and no later than 60 days from the date such notice is delivered. The notice shall, if
delivered prior to the date of consummation of the change of control, state that the offer to purchase is conditioned on the change of control repurchase event occurring on or prior to the payment date specified in the notice. We will comply with
the requirements of Rule <FONT STYLE="white-space:nowrap">14e-1</FONT> under the Exchange Act and any other securities laws and regulations under the Exchange Act to the extent those laws and regulations are applicable in connection with the
repurchase of the notes as a result of a change of control repurchase event. To the extent that the provisions of any securities laws or regulations conflict with the change of control repurchase event provisions of the notes, we will comply with
the applicable securities laws and regulations and will not be deemed to have breached our obligations under the change of control repurchase event provisions of the notes by virtue of such conflict. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the change of control repurchase event payment date, we will, to the extent lawful: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">accept for payment all notes or portions of notes properly tendered pursuant to our offer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deposit with the paying agent an amount equal to the aggregate purchase price in respect of all notes or portions
of notes properly tendered; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deliver or cause to be delivered to the trustee the notes properly accepted, together with an officers&#8217;
certificate stating the aggregate principal amount of notes being purchased by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The paying agent will promptly deliver to each
holder of notes properly tendered the purchase price for the notes, and the trustee will promptly authenticate and mail (or cause to be transferred by book-entry) to each holder a new note equal in principal amount to any unpurchased portion of any
notes surrendered; <I>provided </I>that each new note will be in a principal amount of $2,000 or an integral multiple of $1,000 in excess thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
will not be required to make an offer to repurchase the notes upon a change of control repurchase event if a third party makes such an offer in the manner, at the times and otherwise in compliance with the requirements for an offer made by us and
such third party purchases all notes properly tendered and not withdrawn under its offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#8220;below investment grade rating event&#8221;
means the notes are rated below investment grade (as defined herein) by each of the rating agencies (as defined herein) on any date from the date of the public notice of an arrangement that could result in a change of control until the end of the <FONT
STYLE="white-space:nowrap">60-day</FONT> period following public notice of the occurrence of a change of control (which period shall be extended so long as the rating of the notes is under publicly announced consideration for possible downgrade by
any of the rating agencies). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#8220;change of control&#8221; means the occurrence of any one of the following: (1)&nbsp;the direct or indirect
sale, lease, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or a series of related transactions, of all or substantially all of our assets taken as a whole to any &#8220;person&#8221; (as that term
is used in Section&nbsp;13(d)(3) of the Exchange Act) other than to Cardinal Health or one of its Subsidiaries; or (2)&nbsp;the consummation of any transaction (including, without limitation, any merger or consolidation) the result of which is that
any &#8220;person&#8221; (as that term is used in Section&nbsp;13(d)(3) of the Exchange Act) becomes the beneficial owner, directly or indirectly, of more than 50% of Cardinal Health&#8217;s voting stock (as defined herein), measured by voting power
rather than number of shares. Notwithstanding the foregoing, a transaction will not be deemed to involve a change of control if (i)&nbsp;Cardinal Health becomes a wholly owned subsidiary of a holding company and (ii)&nbsp;the holders of the voting
stock of such holding company immediately following that transaction are substantially the same as the holders of Cardinal Health&#8217;s voting stock immediately prior to that transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The definition of change of control includes a phrase relating to the direct or indirect sale, lease, transfer, conveyance or other disposition of &#8220;all
or substantially all&#8221; of the properties or assets of Cardinal Health and its Subsidiaries, taken as a whole. Although there is a limited body of case law interpreting the phrase &#8220;substantially all,&#8221; there is no precise established
definition of the phrase under applicable law. Accordingly, the applicability of the requirement that we offer to repurchase the notes as a result of a sale, lease, transfer, conveyance or other disposition of less than all of the assets of Cardinal
Health and its Subsidiaries taken as a whole to another person or group may be uncertain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#8220;<I>change of control repurchase event</I>&#8221; means the occurrence of both a change of
control and a below investment grade rating event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#8220;<I>Fitch</I>,&#8221; &#8220;<I>Moody&#8217;s</I>&#8221; and
&#8220;<I>S&amp;P</I>&#8221; mean Fitch Ratings, Moody&#8217;s Investors Service, Inc. and S&amp;P Global Ratings, a division of S&amp;P Global Inc., respectively, or any successors thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#8220;<I>investment grade</I>&#8221; means a rating of <FONT STYLE="white-space:nowrap">BBB-</FONT> or better by Fitch (or its equivalent under any
successor rating categories of Fitch); a rating of Baa3 or better by Moody&#8217;s (or its equivalent under any successor rating categories of Moody&#8217;s); a rating of <FONT STYLE="white-space:nowrap">BBB-</FONT> or better by S&amp;P (or its
equivalent under any successor rating categories of S&amp;P); or the equivalent investment grade credit rating from any additional rating agency (defined below) or rating agencies selected by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#8220;<I>rating agency</I>&#8221; means (1)&nbsp;each of Fitch, Moody&#8217;s and S&amp;P; and (2)&nbsp;if any of Fitch, Moody&#8217;s or S&amp;P
ceases to rate the notes or fails to make a rating of the notes publicly available for reasons outside of our control, a &#8220;nationally recognized statistical rating organization&#8221; within the meaning of Rule
<FONT STYLE="white-space:nowrap">15c3-1(c)(2)(vi)(F)</FONT> under the Exchange Act, selected by Cardinal Health as a replacement agency for Fitch, Moody&#8217;s or S&amp;P, or all of them, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#8220;<I>voting stock</I>&#8221; of any specified &#8220;person&#8221; (as that term is used in Section&nbsp;13(d)(3) of the Exchange Act) as of any
date means the capital stock of such person that is at the time entitled to vote generally in the election of the board of directors of such person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we default in the change of control payment, on and after the change of control payment date, interest will cease to accrue on the notes or portions of
the notes tendered for repurchase pursuant to the change of control offer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Covenants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of the material covenants contained in the indenture, which have been amended from those described in the accompanying prospectus.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Limitations on Liens </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So long
as any of the notes remain outstanding, Cardinal Health will not, and it will not permit any Consolidated Subsidiary to, create or assume any Indebtedness for borrowed money that is secured by a mortgage, pledge, security interest or lien (the
&#8220;liens&#8221;) of or upon any assets of Cardinal Health or any Consolidated Subsidiary, whether now owned or hereafter acquired, without equally and ratably securing the notes by a lien upon such assets. The foregoing restriction does not
apply to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liens existing on the date of first issuance of the notes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liens on assets of any person existing at the time it becomes a Consolidated Subsidiary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liens on assets existing at the time Cardinal Health or a Consolidated Subsidiary acquires them, or to secure
the payment of the purchase price for them, or to secure Indebtedness incurred or guaranteed by Cardinal Health or a Consolidated Subsidiary for the purpose of financing the purchase price of assets, or, in the case of real property, construction or
improvements thereon, which Indebtedness is incurred or guaranteed prior to, at the time of, or within 360 days after the acquisition (or in the case of real property, completion of construction or improvements or commencement of full operation of
such asset, whichever is later), provided that the lien shall not apply to any assets theretofore owned by Cardinal Health or a Consolidated Subsidiary other than, in the case of any such construction or improvements, any real property on which the
construction or improvement is located; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liens securing Indebtedness owing by any Consolidated Subsidiary to Cardinal Health or another wholly owned
domestic Subsidiary; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liens on any assets of a person existing at the time such person is merged into or consolidated with Cardinal
Health or a Subsidiary or at the time of a purchase, lease or other acquisition of the assets of a person as an entirety or substantially as an entirety by Cardinal Health or a Subsidiary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liens on any assets of Cardinal Health or a Consolidated Subsidiary in favor of the United States of America or
any State or political subdivision thereof, or in favor of any other country, or political subdivision thereof, to secure certain payments pursuant to any contract or statute or to secure any Indebtedness incurred or guaranteed for the purpose of
financing all or any part of the purchase price (or, in the case of real property, the cost of construction) of the assets subject to such liens (including, but not limited to, liens incurred in connection with pollution control, industrial revenue
or similar financings); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Liens securing Rate Hedging Obligations in an aggregate amount at no time exceeding $100,000,000, which Liens
(i)&nbsp;arise pursuant to Specified Rate Hedging Agreements and (ii)&nbsp;are required as a condition of such Specified Rate Hedging Agreement by Dodd-Frank (and not merely as a matter of contract or pricing); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any extension, renewal or replacement (or successive extensions, renewals or replacements) in whole or in part,
of any lien referred to in the foregoing clauses (a)&nbsp;to (g), inclusive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">certain statutory liens or other similar liens arising in the ordinary course of business or certain liens
arising out of governmental contracts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">certain pledges, deposits or liens made or arising under workers&#8217; compensation or similar legislation or
in certain other circumstances; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liens created by or resulting from certain legal proceedings, including certain liens arising out of judgments
or awards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liens for certain taxes, assessments or governmental charges or levies; landlord&#8217;s liens; and other liens
and charges incidental to the conduct of our business, or our ownership of our assets which were not incurred in connection with the borrowing of money and which do not, in Cardinal Health&#8217;s opinion, materially impair our use of such assets in
our operations or the value of the assets for its purposes; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liens on any assets of a Financing Subsidiary. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing restrictions, Cardinal Health or any Consolidated Subsidiary may create or assume any Indebtedness which is secured by a lien
without securing the notes, provided that at the time of such creation or assumption, and immediately after giving effect thereto, the Exempted Debt then outstanding at such time does not exceed 3.0% of Consolidated Total Assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Limitations on Subsidiary Indebtedness </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cardinal Health will not permit any Restricted Subsidiary directly or indirectly to incur any Indebtedness for borrowed money, except that the foregoing
limitations will not apply to the incurrence of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness outstanding on the date of first issuance of the notes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness of a Restricted Subsidiary that represents its assumption of Indebtedness of another Subsidiary,
and Indebtedness owed by any Restricted Subsidiary to Cardinal Health or to another Subsidiary; <I>provided </I>that such Indebtedness will be held at all times by either Cardinal Health or a Subsidiary; and <I>provided further </I>that upon the
transfer or disposition of such Indebtedness to someone other than Cardinal Health or another Subsidiary, the incurrence of such Indebtedness will be deemed to be an incurrence that is not permitted by this clause (b); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness arising from (i)&nbsp;the endorsement of negotiable instruments for deposit or collection or
similar transactions in the ordinary course of business or (ii)&nbsp;the honoring by a bank or other financial </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
institution of a check, draft or similar instrument inadvertently (except in the case of daylight overdrafts) drawn against insufficient funds in the ordinary course of business;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness arising from guarantees of loans and advances by third parties to employees and officers of a
Restricted Subsidiary in the ordinary course of business for bona fide business purposes; <I>provided </I>that the aggregate amount of such guarantees by all Restricted Subsidiaries does not exceed $100,000,000; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness incurred by a foreign Restricted Subsidiary in the ordinary course of business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness of any person existing at the time such person becomes a Restricted Subsidiary or is merged into a
Restricted Subsidiary or at the time of a purchase, lease or other acquisition by a Restricted Subsidiary of all or substantially all of the assets of such person; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness of a Restricted Subsidiary arising from agreements providing for indemnification, adjustment of
purchase price or similar obligations or from guarantees, letters of credit, surety bonds or performance bonds securing any obligations of Cardinal Health or any of its Subsidiaries incurred in connection with the disposition of any business,
property or Subsidiary, excluding guarantees or similar credit support by a Restricted Subsidiary of indebtedness incurred by the acquirer of such business, property or Subsidiary for the purpose of financing such acquisition; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness of a Restricted Subsidiary with respect to bonds, bankers&#8217; acceptances or letters of credit
provided by such Subsidiary in the ordinary course of business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness secured by a lien permitted by the provisions regarding limitations on liens or arising in respect
of a sale and lease-back transaction permitted by the provisions regarding such transactions, or any Indebtedness incurred to finance the purchase price or cost of construction of improvements with respect to certain property or assets acquired
after the date of the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness that is issued, assumed or guaranteed in connection with compliance by a Restricted Subsidiary
with the requirements of any program, applicable to such Restricted Subsidiary, adopted by any governmental authority that provides for financial or tax benefits which are not available directly to Cardinal Health; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness arising from Rate Hedging Obligations incurred to limit risks of currency or interest rate
fluctuations to which a Subsidiary is otherwise subject by virtue of the operations of its business, and not for speculative purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness outstanding under investment grade commercial paper programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness consisting of the financing of insurance premiums in the ordinary course of business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness incurred by any Financing Subsidiary; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness incurred in connection with refinancing of any Indebtedness described in clauses (a), (b), (f),
(g), and (i)&nbsp;above (the &#8220;Refinancing Indebtedness&#8221;), provided that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the principal amount of the Refinancing Indebtedness does not exceed the principal amount of the Indebtedness
refinanced (plus the premiums paid and expenses incurred in connection therewith), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Refinancing Indebtedness has a weighted average life to maturity equal to or greater than the weighted
average life to maturity of the Indebtedness being refinanced, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Refinancing Indebtedness ranks no more senior, and is at least as subordinated in right of payment, as the
Indebtedness being refinanced. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing restrictions, Restricted Subsidiaries may incur any Indebtedness for
borrowed money that would otherwise be subject to the foregoing restrictions in an aggregate principal amount which, together with the aggregate principal amount of other Indebtedness (not including the Indebtedness permitted above), does not, at
the time such Indebtedness is incurred, exceed 3.0% of Consolidated Total Assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Limitation on Sale and Lease-Back Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sale and lease-back transactions (except those transactions involving leases for less than three years) by Cardinal Health or any Consolidated Subsidiary of
any assets are prohibited unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cardinal Health or the Consolidated Subsidiary would be entitled to incur Indebtedness secured by a lien on the
assets to be leased in an amount at least equal to the Attributable Debt with respect to such transaction without equally and ratably securing the notes; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proceeds of the sale of the assets to be leased are at least equal to their fair value as determined by
Cardinal Health&#8217;s board of directors and the proceeds are applied to the purchase or acquisition (or, in the case of real property, the construction) of assets or to the retirement of Senior Funded Indebtedness. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing limitation will not apply if at the time Cardinal Health or any Consolidated Subsidiary enters into such sale and lease-back transaction, and
immediately after giving effect thereto, Exempted Debt then outstanding at such time does not exceed 3.0% of Consolidated Total Assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Merger, Consolidation, Sale, Lease or Conveyance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cardinal Health will not merge or consolidate with any other person and will not sell, lease or convey all or substantially all its assets to any person,
unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cardinal Health will be the continuing corporation; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a) the successor person formed by such consolidation, or into which Cardinal Health is merged, or that acquires
all or substantially all of Cardinal Health&#8217;s assets is a corporation, partnership, limited liability company, business trust, trust or other legal entity organized under the laws of the United States or a State thereof or the District of
Columbia; and (b)&nbsp;such successor person expressly assumes all of Cardinal Health&#8217;s obligations under the indenture and the debt securities; and (c)&nbsp;immediately after such merger, consolidation, sale, lease or conveyance, such
successor person is not in default in the performance of the covenants and conditions of the indenture to be performed or observed by Cardinal Health. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of the Indenture </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture contains
certain provisions related to the modification of the indenture both with and without consent of holders of debt securities issued under the indenture and affected by the modification. See &#8220;Description of Debt Securities&#8212;Modification of
the Indenture&#8221; in the accompanying prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the circumstances under which Cardinal Health and the trustee will be able to modify
the indenture or enter into supplemental indentures without the consent of the holders of the notes of either series that are described in the accompanying prospectus, Cardinal Health and the trustee will also able to modify the indenture or enter
into supplemental indentures without the consent of the holders of the notes of either series to conform the text of the indenture, any guarantee or any applicable series of notes to any provision of the description thereof set forth in a prospectus
supplement to the extent that such provision in a prospectus supplement was intended to be a verbatim recitation of a provision in the applicable indenture, any guarantee or any applicable series of notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture contains certain events
of default. See &#8220;Description of Debt Securities&#8212;Event of Default&#8221; in the accompanying prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definitions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set forth below are certain defined terms used in this prospectus supplement and the indenture. We refer you to the indenture for a full disclosure of all such
terms, as well as any other capitalized terms used in this prospectus supplement for which no definition is provided. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<I>Attributable Debt</I>&#8221; means, in connection with a sale and lease-back transaction, the
lesser of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fair value of the assets subject to the transaction; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate of present values (discounted at a rate per annum equal to the weighted average Yield to Maturity
of the debt securities of all series then outstanding and compounded semiannually) of Cardinal Health&#8217;s or any Consolidated Subsidiary&#8217;s obligations for net rental payments during the remaining term of all leases. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<I>Consolidated Subsidiary</I>&#8221; means any Subsidiary substantially all the property of which is located, and substantially all the operations of
which are conducted, in the United States of America whose financial statements are consolidated with those of Cardinal Health in accordance with U.S. generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<I>Consolidated Total Assets</I>&#8221; means, as of any date of determination, the total amount of all of the assets of Cardinal Health and its
Subsidiaries, determined on a consolidated basis and in accordance with U.S. generally accepted accounting principles, as set forth in our most recently available balance sheet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<I>Exempted Debt</I>&#8221; means the sum of the following as of the date of determination: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Indebtedness incurred after the date of first issuance of the notes and secured by liens not permitted by the
limitation on liens provisions of the indenture; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Attributable Debt in respect of every sale and lease-back transaction entered into after the date of first
issuance of the notes, other than leases permitted by the limitation on sale and lease-back provisions of the indenture. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<I>Financing Subsidiary</I>&#8221; means any Subsidiary, including its Subsidiaries, engaged in one or more of the following activities: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the business of making loans or advances, extending credit or providing financial accommodations (including
leasing new or used products) to others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the business of purchasing notes, accounts receivable (whether or not payable in installments), conditional sale
contracts or other obligations of others originating in sales at wholesale or retail; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other business as may be reasonably incidental to those described herein, including the ownership and use of
property in connection therewith. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<I>Funded Indebtedness</I>&#8221; means all Indebtedness having a maturity of more than 12
months from the date as of which the amount of Indebtedness is to be determined or having a maturity of less than 12 months but by its terms being renewable or extendible beyond 12 months from such date at the option of the borrower. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<I>Indebtedness</I>&#8221; means all items classified as indebtedness on our most recently available balance sheet in accordance with U.S. generally
accepted accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<I>Original Issue Discount Security</I>&#8221; means any debt security that provides for an amount less than the
principal amount thereof to be due and payable upon a declaration of acceleration of the maturity thereof following an event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<I>Rate
Hedging Agreement</I>&#8221; means an agreement, device or arrangement providing for payments which are related to fluctuations of interest rates, exchange rates, commodity prices or forward rates, including, but not limited to, dollar-denominated
or cross-currency interest rate exchange agreements, forward currency exchange agreements, interest rate cap or collar protection agreements, forward rate currency or interest rate options, puts and warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<I>Rate Hedging Obligations</I>&#8221; means any and all obligations of anyone arising under: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any and all agreements, devices or arrangements designed to protect at least one of the parties thereto from the
fluctuations of interest rates, exchange rates or forward rates applicable to such party&#8217;s assets, liabilities or exchange transactions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any and all cancellations, buybacks, reversals, terminations or assignments of the same. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<I>Restricted Subsidiary</I>&#8221; means a &#8220;significant subsidiary&#8221; as defined in Article 1, Rule
<FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X,</FONT> promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<I>Senior Funded Indebtedness</I>&#8221; means any of Cardinal Health&#8217;s Funded Indebtedness that is not subordinated in right of payment to any
of Cardinal Health&#8217;s other Indebtedness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<I>Specified Rate Hedging Agreement</I>&#8221; means a Rate Hedging Agreement which is
(a)&nbsp;entered into to hedge or mitigate risks to which Cardinal Health or any Subsidiary has actual exposure (other than those in respect of equity interests of Cardinal Health or any of its Subsidiaries) or (b)&nbsp;entered into in order to
effectively cap, collar or exchange interest rates (from fixed to floating rates, from one floating rate to another floating rate or otherwise) with respect to any interest-bearing liability or investment of Cardinal Health or any Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<I>Subsidiary</I>&#8221; means any corporation, partnership, limited liability company, business trust, trust or other legal entity of which at least a
majority of the outstanding stock or other ownership interests having voting power to elect a majority of the board of directors, managers or trustees of that corporation, partnership, limited liability company, business trust, trust or other legal
entity (irrespective of whether or not at the time stock or other ownership interests of any other class or classes of such corporation, partnership, limited liability company, business trust, trust or other legal entity shall have or might have
voting power by reason of the happening of any contingency) is at the time owned or controlled by Cardinal Health or by Cardinal Health and one or more Subsidiaries or by one or more Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<I>Yield to Maturity</I>&#8221; means the yield to maturity on a series of debt securities, calculated at the time of issuance of such series, or, if
applicable, at the most recent redetermination of interest on such series, and calculated in accordance with accepted financial practice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regarding
the Trustee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bank of New York Mellon Trust Company, N.A., as trustee under the indenture, has been appointed by us as paying agent, registrar and
DTC custodian with regard to the notes. The trustee or its affiliates may from time to time in the future provide banking and other services to us in the ordinary course of their business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry System </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes of each series will be
issued initially in the form of one or more global notes, in the aggregate principal amount of the issue, that will be deposited with, or on behalf of, DTC, which will act as securities depository for the notes. The notes will be issued as fully
registered securities registered in the name of Cede&nbsp;&amp; Co. (DTC&#8217;s partnership nominee) or such other name as may be requested by an authorized representative of DTC. DTC and any other depository which may replace DTC as depository for
the notes are sometimes referred to herein as the &#8220;depository.&#8221; Except under the limited circumstances described below, notes represented by global notes will not be exchangeable for certificated notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So long as the depository, or its nominee, is the registered owner of a global note, such depository or such nominee, as the case may be, will be considered
the sole registered holder of the individual notes represented by such global note for all purposes under the indenture. Payments of principal of and premium, if any, and any interest on individual notes represented by a global note will be made to
the depository or its nominee, as the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
case may be, as the registered holder of such global note in accordance with DTC rules and using the procedures applicable to United States corporate debt obligations in DTC&#8217;s Settlement
System. Except as set forth below, owners of beneficial interests in a global note will not be entitled to have any of the individual notes represented by such global note registered in their names, will not receive or be entitled to receive
physical delivery of any such note and will not be considered the registered holder thereof under the indenture, including, without limitation, for purposes of consenting to any amendment thereof or supplement thereto as described in the
accompanying prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial interests in the global notes will be represented through book-entry accounts of financial institutions acting on
behalf of beneficial owners as direct and indirect participants in DTC. Investors may hold interests in the global notes through either DTC (in the United States), Clearstream Banking, soci&eacute;t&eacute; anonyme, Luxembourg
(&#8220;Clearstream&#8221;), or Euroclear Bank S.A./N.V., as operator of the Euroclear System (&#8220;Euroclear&#8221;), in Europe, either directly if they are participants in such systems or indirectly through organizations that are participants in
such systems. Clearstream and Euroclear will hold interests on behalf of their participants through customers&#8217; securities accounts in Clearstream&#8217;s and Euroclear&#8217;s names on the books of their United States depositaries, which in
turn will hold such interests in customers&#8217; securities accounts in the United States depositaries&#8217; names on the books of DTC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
is based on information furnished by DTC: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DTC is a limited-purpose trust company organized under the New York Banking Law, a &#8220;banking
organization&#8221; within the meaning of the New York Banking Law, a member of the Federal Reserve System, a &#8220;clearing corporation&#8221; within the meaning of the New York Uniform Commercial Code, and a &#8220;clearing agency&#8221;
registered pursuant to the provisions of Section&nbsp;17A of the Exchange Act. DTC was created to hold securities of its participants and to facilitate the clearance and settlement of securities transactions among its participants in such securities
through electronic book-entry changes in accounts of the participants, thereby eliminating the need for physical movement of securities certificates. Direct participants include securities brokers and dealers (including the underwriters), banks,
trust companies, clearing corporations, and certain other organizations (&#8220;Direct Participants&#8221;). DTC is a wholly owned subsidiary of The Depository Trust&nbsp;&amp; Clearing Corporation (&#8220;DTCC&#8221;). DTCC is the holding company
for DTC, National Securities Clearing Corporation and Fixed Income </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clearing Corporation, all of which are registered clearing agencies. DTCC is owned by
the users of its regulated subsidiaries. Access to DTC&#8217;s book-entry system is also available to others such as both U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> securities brokers and dealers, banks, trust companies and clearing
corporations that clear through or maintain a custodial relationship with a Direct Participant, either directly or indirectly (&#8220;Indirect Participants&#8221;). The rules applicable to DTC and its Direct and Indirect Participants are on file
with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchases of notes under the DTC system must be made by or through Direct Participants, which will receive a credit for the notes on
DTC&#8217;s records. The ownership interest of each actual purchaser of each note (&#8220;Beneficial Owner&#8221;) is in turn to be recorded on the Direct and Indirect Participants&#8217; records. Beneficial Owners will not receive written
confirmation from DTC of their purchase, but Beneficial Owners are, however, expected to receive written confirmations providing details of the transaction, as well as periodic statements of their holdings, from the Direct or Indirect Participant
through which the Beneficial Owner entered into the transaction. Transfers of ownership interests in the notes are to be accomplished by entries made on the books of Direct and Indirect Participants acting on behalf of Beneficial Owners. Beneficial
Owners will not receive certificates representing their ownership interests in notes, except in the event that use of the book-entry system for the notes is discontinued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To facilitate subsequent transfers, all global notes deposited by Direct Participants with DTC are registered in the name of DTC&#8217;s partnership nominee,
Cede&nbsp;&amp; Co., or such other name as may be requested by an authorized representative of DTC. The deposit of global notes with DTC and their registration in the name of Cede&nbsp;&amp; Co. or such other DTC nominee do not effect any change in
beneficial ownership. DTC has no knowledge of the actual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Beneficial Owners of the notes; DTC&#8217;s records reflect only the identity of the Direct Participants to whose accounts such notes are credited, which may or may not be the Beneficial Owners.
The Direct and Indirect Participants will remain responsible for keeping account of their holdings on behalf of their customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The laws of some
jurisdictions may require that purchasers of securities take physical delivery of those securities in definitive form. Accordingly, the ability to transfer interests in the notes represented by a global note to those persons may be limited. In
addition, because DTC can act only on behalf of its participants, who in turn act on behalf of persons who hold interests through participants, the ability of a person having an interest in notes represented by a global note to pledge or transfer
those interests to persons or entities that do not participate in DTC&#8217;s system, or otherwise to take actions in respect of such interest, may be affected by the lack of a physical definitive security in respect of such interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conveyance of notices and other communications by DTC to Direct Participants, by Direct Participants to Indirect Participants, and by Direct Participants and
Indirect Participants to Beneficial Owners will be governed by arrangements among them, subject to any statutory or regulatory requirements as may be in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither DTC nor Cede&nbsp;&amp; Co. (nor any other DTC nominee) will consent or vote with respect to the notes unless authorized by a Direct Participant in
accordance with DTC&#8217;s procedures. Under its usual procedures, DTC mails an Omnibus Proxy to Cardinal Health as soon as possible after the record date. The Omnibus Proxy assigns Cede&nbsp;&amp; Co.&#8217;s consenting or voting rights to those
Direct Participants to whose accounts the notes are credited on the record date (identified in a listing attached to the Omnibus Proxy). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Principal,
interest payments and redemption proceeds on the notes will be made to Cede&nbsp;&amp; Co., or such other nominee, as may be requested by an authorized representative of DTC, by wire transfer or other applicable electronic funds delivery method as
specified by the trustee or applicable depositary. DTC&#8217;s practice is to credit Direct Participants&#8217; accounts upon DTC&#8217;s receipt of funds and corresponding detail information from us or the trustee, on the payment date in accordance
with their respective holdings shown on DTC&#8217;s records. Payments by Participants to Beneficial Owners will be governed by standing instructions and customary practices, as is the case with securities held for the accounts of customers in bearer
form or registered in &#8220;street name&#8221; and will be the responsibility of such Participant and not of DTC or its nominee, any Agents, the trustee or Cardinal Health, subject to any statutory or regulatory requirements as may be in effect
from time to time. Payment of principal, interest and redemption proceeds to Cede&nbsp;&amp; Co. (or such other nominee as may be requested by an authorized representative of DTC) is the responsibility of Cardinal Health or the trustee, disbursement
of such payments to Direct Participants will be the responsibility of DTC, and disbursement of such payments to the Beneficial Owners will be the responsibility of Direct and Indirect Participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of Cardinal Health, the underwriters or the trustee will have any responsibility or liability for any aspect of the records relating to or payments made
on account of notes by DTC, Clearstream or Euroclear, or for maintaining, supervising or reviewing any records of those organizations relating to the notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DTC may discontinue providing its services as depository with respect to the notes at any time by giving reasonable notice to Cardinal Health or the trustee.
Under such circumstances, in the event that a successor depository is not obtained, certificated notes are required to be printed and delivered in exchange for the notes represented by the global notes held by DTC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Cardinal Health may decide to discontinue use of the system of book-entry-only transfers through DTC (or a successor securities depositary). In
that event, certificated notes will be printed and delivered in exchange for the notes represented by the global notes held by DTC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Distributions on the
notes held beneficially through Clearstream will be credited to cash accounts of its customers in accordance with its rules and procedures, to the extent received by the United States depositary for Clearstream. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities clearance accounts and cash accounts with Euroclear Bank S.A./N.V., as operator of the Euroclear
System, are governed by the Terms and Conditions Governing Use of Euroclear and the related Operating Procedures of the Euroclear System, and applicable Belgian law (collectively, the &#8220;Terms and Conditions&#8221;). The Terms and Conditions
govern transfers of securities and cash within Euroclear, withdrawals of securities and cash from Euroclear, and receipts of payments with respect to securities in Euroclear. All securities in Euroclear are held on a fungible basis without
attribution of specific certificates to specific securities clearance accounts. The Euroclear Operator acts under the Terms and Conditions only on behalf of Euroclear participants and has no record of or relationship with persons holding through
Euroclear participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Distributions on the notes held beneficially through Euroclear will be credited to the cash accounts of its participants in
accordance with the Terms and Conditions, to the extent received by the United States depositary for Euroclear. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Same-Day</FONT> Settlement and Payment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Settlement for the notes will be made by the underwriters in immediately available funds. All payments of principal and interest will be made by us in
immediately available funds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Secondary trading in long-term notes of corporate issuers is generally settled in clearing-house or <FONT
STYLE="white-space:nowrap">next-day</FONT> funds. In contrast, the notes will trade in the <FONT STYLE="white-space:nowrap">Same-Day</FONT> Funds Settlement System maintained by DTC until maturity, and secondary market trading activity in the notes
will therefore be required by DTC to settle in immediately available funds. No assurance can be given as to the effect, if any, of settlement in immediately available funds on trading activity in the notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cross-market transfers between persons holding directly or indirectly through DTC, on the one hand, and directly or indirectly through Clearstream customers
or Euroclear participants, on the other, will be effected through DTC in accordance with DTC rules on behalf of the relevant European international clearing system by the United States depositary. Such cross-market transactions, however, will
require delivery of instructions to the relevant European international clearing system by the counterparty in such system in accordance with its rules and procedures and within its established deadlines (European time). The relevant European
international clearing system will, if the transaction meets its settlement requirements, deliver instructions to the United States depositary to take action to effect final settlement on its behalf by delivering or receiving the notes in DTC, and
making or receiving payment in accordance with normal procedures for <FONT STYLE="white-space:nowrap">same-day</FONT> funds settlement applicable to DTC. Clearstream customers and Euroclear participants may not deliver instructions directly to their
United States depositaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of time-zone differences, credits of notes received in Clearstream or Euroclear, as a result of a transaction with a
DTC participant will be made during subsequent securities settlement processing and dated the business day following the DTC settlement date. Such credits or any transactions in such notes settled during such processing will be reported to the
relevant Clearstream or Euroclear participants on such business day. Cash received in Clearstream or Euroclear as a result of sales of notes by or through a Clearstream participant or a Euroclear participant to a DTC participant will be received
with value on the DTC settlement date but will be available in the relevant Clearstream or Euroclear cash account only as of the business day following settlement in DTC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although DTC, Clearstream and Euroclear have agreed to the foregoing procedures in order to facilitate transfers of notes among participants of DTC,
Clearstream and Euroclear, they are under no obligation to perform or continue to perform such procedures, and such procedures may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this section concerning DTC and DTC&#8217;s book-entry system has been obtained from sources that Cardinal Health believes to be reliable,
but Cardinal Health takes no responsibility for the accuracy thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cardinal Health has provided the descriptions of the operations and procedures of DTC, Clearstream and
Euroclear in this prospectus supplement solely as a matter of convenience, and Cardinal Health makes no representation or warranty of any kind with respect to these operations and procedures. These operations and procedures are solely within the
control of those organizations and are subject to change by them from time to time. None of Cardinal Health, the underwriters, the trustee, any paying agent or the registrar for the notes will have any responsibility or liability for any aspect of
the records relating to or payments made on account of beneficial ownership interests in a global note or for maintaining, supervising or reviewing any records relating to such beneficial ownership interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc42072_9"></A>U.S. FEDERAL INCOME TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of the U.S. federal income tax considerations generally applicable to the ownership and disposition of the notes. This
discussion is limited to holders that acquire notes for cash at their original issue price pursuant to the initial offering. This discussion is based upon the provisions of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;),
applicable U.S. Treasury regulations promulgated thereunder, judicial decisions, published positions of the U.S. Internal Revenue Service (&#8220;IRS&#8221;), and other applicable authorities, all in effect as of the date hereof, all of which are
subject to change or differing interpretations (possibly with retroactive effect). This discussion does not address all of the tax considerations that may be relevant to a particular person or to persons subject to special treatment under U.S.
federal income tax laws (such as banks and other financial institutions, broker-dealers, insurance companies, regulated investment companies, real estate investment trusts, corporations that accumulated earnings to avoid U.S. federal income tax,
cooperatives, controlled foreign corporations, passive foreign investment companies, persons required to accelerate the recognition of any item of gross income as a result of such income being recognized on an &#8220;applicable financial
statement&#8221;, traders in securities who elect to apply a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting, expatriates, governmental entities or organizations or <FONT
STYLE="white-space:nowrap">tax-exempt</FONT> entities or organizations), or to persons who hold the notes as part of a straddle, hedge, conversion, synthetic security, or constructive sale transaction for U.S. federal income tax purposes, all of
whom may be subject to tax rules that differ from those summarized below. In addition, this discussion does not address the considerations of any alternative minimum, gift, estate, state, local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
tax or any tax considerations other than U.S. federal income tax considerations. This summary deals only with persons who hold the notes as capital assets within the meaning of the Code (generally, property held for investment purposes). There can
be no assurance that the IRS will not challenge one or more of the tax considerations described herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a partnership (including any entity or
arrangement treated as a partnership or other pass-through entity for U.S. federal income tax purposes) is a holder of a note, the U.S. federal income tax treatment of a partner in the partnership generally will depend on the status of the partners
and the activities of the partnership. Partners and partnerships should consult their tax advisors as to the particular U.S. federal income tax considerations applicable to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This summary is intended for general information purposes only. Potential investors are urged to consult their tax advisors regarding the U.S. federal,
state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of the acquisition, ownership and disposition of the notes and the possible effect of changes in tax laws. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a &#8220;U.S. holder&#8221; is any beneficial owner of a note that is, for U.S. federal income tax purposes, (i)&nbsp;an
individual who is a citizen or resident of the United States; (ii)&nbsp;a corporation or other entity treated as a corporation for U.S. federal income tax purposes that is created or organized under the laws of the United States, any state thereof
or the District of Columbia; (iii)&nbsp;an estate whose income is subject to U.S. federal income tax regardless of its source; or (iv)&nbsp;a trust (A)&nbsp;if a U.S. court can exercise primary supervision over the trust&#8217;s administration and
one or more U.S. persons are authorized to control all substantial decisions of the trust, or (B)&nbsp;that has a valid election in effect under applicable Treasury regulations to be treated as a U.S. person for U.S. federal income tax purposes.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A &#8220;non-U.S. holder&#8221; is any beneficial owner of a note (other than an entity or arrangement treated as a partnership or other pass-through
entity for U.S. federal income tax purposes) that is not a U.S. holder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Characterization of the Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In certain circumstances (see &#8220;Description of the Notes&#8212;Optional Redemption,&#8221; &#8220;Description of the Notes&#8212;Special Mandatory
Redemption&#8221; and &#8220;Description of the Notes&#8212;Repurchase at the Option of Holders Upon a Change of Control&#8221; above) we may or may be obligated to redeem or to offer to repurchase the notes prior to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
their maturity or to pay amounts on the notes that are in excess of stated interest or principal on the notes. These potential payments may implicate the provisions of U.S. Treasury regulations
relating to &#8220;contingent payment debt instruments,&#8221; but we do not intend to treat the possibility of such contingent payments on the notes as subjecting the notes to the contingent payment debt instrument rules. Our determination that the
notes are not subject to the contingent payment debt instrument rules is binding on a holder, unless such holder discloses its contrary position in the matter required by applicable U.S. Treasury regulations. It is possible that the IRS may take a
different position, in which case, if such position is sustained, a holder might be required to accrue ordinary interest income at a higher rate than the stated interest rate and to treat as ordinary income rather than capital gain any gain realized
on the taxable disposition of the notes. The remainder of this discussion assumes that the notes will not be treated as contingent payment debt instruments. Holders are encouraged to consult their own tax advisors regarding the possible application
of the contingent payment debt instrument rules to the notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Considerations for U.S. Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest on the Notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments of stated interest
on the notes will be includible in the gross income of a U.S. holder as ordinary interest income at the time such payments are received or accrued, in accordance with such U.S. holder&#8217;s regular method of accounting for U.S. federal income tax
purposes. It is expected, and this discussion assumes, that the notes will be treated as being issued without original issue discount for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxable Disposition of the Notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the sale,
exchange, retirement, redemption or other taxable disposition of a note (collectively, a &#8220;Disposition&#8221;), a U.S. holder generally will recognize taxable gain or loss equal to the difference, if any, between (i)&nbsp;the amount realized
upon such Disposition (other than any amount equal to any accrued but unpaid stated interest, which, if not previously included in such U.S. holder&#8217;s income, will be treated as described above under &#8220;&#8212;Interest on the Notes&#8221;)
and (ii)&nbsp;such U.S. holder&#8217;s adjusted tax basis in the note. A U.S. holder&#8217;s adjusted tax basis in a note will generally equal the amount such U.S. holder paid for such note. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
general, information reporting requirements will apply to payments of interest on the notes and to the proceeds from a Disposition paid to a U.S. holder unless such U.S. holder is an exempt recipient and, when required, provides evidence of such
exemption. Backup withholding may apply to such payments if the U.S. holder fails to provide a taxpayer identification number or a certification that it is not subject to backup withholding and otherwise comply with any applicable requirements of
the backup withholding rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax, and any amounts withheld under the backup withholding rules may be allowed as
a refund or a credit against a U.S. holder&#8217;s U.S. federal income tax liability provided the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. holders should consult their own tax advisors regarding their qualification for an exemption from backup withholding and information reporting and the
procedures for obtaining such an exemption, if applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Considerations for Non-U.S. Holders</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interest on the Notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussions below
under &#8220;&#8212;Information Reporting and Backup Withholding&#8221; and &#8220;&#8212;Additional Withholding Requirements under FATCA,&#8221; a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will generally not be subject to U.S. federal
income or withholding tax on interest paid on a note, unless the interest is effectively connected with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s conduct of a U.S. trade or business (and, if certain tax treaties apply, is attributable to a permanent establishment or fixed base
within the United States); <I>provided </I>that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">does not actually or constructively, directly or indirectly, own 10% or more of the total combined voting power
of all classes of our voting stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is not a controlled foreign corporation that is related to us (directly or indirectly) through stock ownership;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certifies to its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status and that no withholding is required
pursuant to FATCA (see &#8220;&#8212;Additional Withholding Requirements under FATCA&#8221; below) on an IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable form). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder cannot satisfy the above requirements, such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will generally be exempt from U.S. federal withholding tax with respect to interest paid on the
notes if the holder establishes that such interest is not subject to withholding tax because it is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s conduct of a trade or business in the United States
(and, if certain tax treaties apply, is attributable to a permanent establishment or fixed base within the United States) (generally, by providing an IRS Form <FONT STYLE="white-space:nowrap">W-8ECI).</FONT> However, to the extent that such interest
is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s conduct of a trade or business (and, if certain tax treaties apply, is attributable to a permanent establishment or fixed base within the United
States), the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to U.S. federal income tax on a net basis and, if it is treated as a corporation for U.S. federal income tax purposes, may be subject to a branch profits tax equal
to 30% of its effectively connected earnings and profits, subject to certain adjustments, unless such holder qualifies for a lower rate under an applicable income tax treaty. In addition, under certain income tax treaties, the U.S. withholding rate
on interest payments may be reduced or eliminated, provided the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder complies with the applicable certification requirements (generally, by providing an IRS Form
<FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E).</FONT></FONT> If a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder does not satisfy the requirements
described above and does not establish that the interest is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s conduct of a trade or business in the United States (and, if certain tax treaties apply, is
attributable to a permanent establishment or fixed base within the United States), the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will generally be subject to U.S. withholding tax on payments of stated interest, currently imposed at a
rate of 30%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taxable Disposition of the Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussions below under &#8220;&#8212;Information Reporting and Backup Withholding&#8221; and &#8220;&#8212;Additional Withholding Requirements
under FATCA,&#8221; and except with respect to accrued but unpaid interest, which will be treated as described above under &#8220;&#8212;Interest on the Notes,&#8221; a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will generally not be
subject to U.S. federal income taxation or withholding tax with respect to gain realized upon a Disposition unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the gain is effectively connected with the conduct by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder of a U.S. trade or business (and, if required by an applicable income tax treaty, is attributable to a U.S. permanent establishment or fixed base within the United States), in which case such gain will be taxed on a net income basis in the
same manner as interest that is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s conduct of a trade or business within the United States; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is an individual who has been present in the
United States for 183 days or more in the taxable year of Disposition and certain other requirements are met. Such individual <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a tax, currently at a rate of 30% (or reduced
rate under an applicable income tax treaty), on the excess, if any, of such gain <I>plus </I>all other U.S. source capital gains recognized by such holder during the same taxable year over the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder&#8217;s U.S. source capital losses recognized during such taxable year. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup withholding will not apply to payments of principal or interest made by us or our paying agent to a non-U.S. holder of a note if the
non-U.S. holder meets the identification and certification requirements discussed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
above under the subheading &#8220;&#8212;Interest on the Notes&#8221; for exemption from U.S. federal withholding tax or otherwise establishes an exemption. However, information reporting on IRS
Form&nbsp;1042-S may still apply with respect to interest payments. Copies of these information returns may be made available to the tax authorities of the country in which the non-U.S. holder resides under the provisions of various treaties or
agreements for the exchange of information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup withholding and information reporting generally will not apply to payments of proceeds from the
Disposition of a note made to a non-U.S. holder by or through the foreign office of a broker. However, information reporting requirements will apply if such broker is, for U.S. federal income tax purposes, a U.S. person or has certain other
enumerated connections with the United States, unless such broker has documentary evidence in its records that the holder is a non-U.S. person and certain other conditions are met, or the holder otherwise establishes an exemption. Payments of
proceeds from the sale or other taxable disposition of a note made to a non-U.S. holder by or through the United States office of a broker are subject to information reporting and backup withholding at the applicable rate unless the holder
certifies, under penalty of perjury, that it is a non-U.S. person and that it satisfies certain other conditions, such as by providing an applicable properly executed IRS Form W-8, or otherwise establishes an exemption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax, and a non-U.S. holder may obtain a refund or a credit against such non-U.S. holder U.S. federal income tax
liability of any amounts withheld under the backup withholding rules, provided the required information is furnished to the IRS in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-U.S. holders should consult their own tax advisors regarding the application of information reporting and backup withholding rules in their particular
situations, the availability of an exemption therefrom and the procedure for obtaining such an exemption, if available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Withholding
Requirements under FATCA </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Foreign Account Tax Compliance Act and the regulations and administrative guidance promulgated thereunder
(&#8220;FATCA&#8221;), withholding at a rate of 30% will generally be required in certain circumstances on interest payments in respect of notes held by or through certain &#8220;foreign financial institutions&#8221; (as defined in the Code, which
may include investment funds) unless such institution otherwise qualifies for an exemption or (i) enters into, and complies with, an agreement with the IRS to report, on an annual basis, information with respect to interests in, and accounts
maintained by, the institution that are owned by certain U.S. persons and by certain non-U.S. entities that are wholly or partially owned by U.S. persons and to withhold on certain payments, or (ii)&nbsp;if required under an intergovernmental
agreement between the United States and an applicable foreign country, reports such information to its local tax authority, which will exchange such information with the U.S. authorities. An intergovernmental agreement between the United States and
an applicable foreign country, or other guidance, may modify these requirements. Similarly, in certain circumstances, interest payments in respect of notes held by an investor that is a <FONT STYLE="white-space:nowrap">non-financial</FONT> <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> entity that do not qualify under certain exemptions will generally be subject to withholding at a rate of 30%, unless such entity either (i)&nbsp;certifies that such entity does not have any
&#8220;substantial United States owners&#8221; or (ii)&nbsp;provides certain information regarding the entity&#8217;s &#8220;substantial United States owners,&#8221; which we will in turn provide to the IRS. Accordingly, the entity through which the
notes are held will affect the determination of whether withholding under the rules described in this paragraph is required. Prospective investors should consult their tax advisors regarding the possible implications of these rules on their
investment in the notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc42072_10"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions contained in an underwriting agreement among us and Goldman Sachs&nbsp;&amp; Co. LLC, BofA Securities, Inc. and Wells
Fargo Securities, LLC, as representatives of the several underwriters, we have agreed to sell to the underwriters, and the underwriters have severally and not jointly agreed to purchase from us, the principal amount of the notes listed opposite
their respective names below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Underwriter</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal<BR>Amount&nbsp;of&nbsp;the<BR>20&#8195; Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal<BR>Amount&nbsp;of&nbsp;the<BR>20&#8195; Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters have agreed to purchase all of the notes sold pursuant to the underwriting agreement if any of these notes
are purchased. The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may be increased or the offering may be terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters are offering the notes, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their
counsel, including the validity of the notes, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer&#8217;s certificates and legal opinions. The underwriters reserve the right to withdraw,
cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the several underwriters against certain
liabilities, including liabilities under the Securities Act, as amended, or, if such indemnification is not available, to contribute to payments the underwriters may be required to make in respect of these liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters have advised us that they propose initially to offer the notes of each series at the applicable public offering price on the cover page of
this prospectus supplement, and may offer the notes to dealers at that price less a concession not in excess of&#8195;&#8195;&#8195;&#8195;% of the principal amount of the 20&#8195; notes and&#8195;&#8195;&#8195;&#8195;% of the principal amount of
the 20&#8195; notes. The underwriters may allow, and the dealers may reallow, a discount not in excess of&#8195;&#8195;&#8195;&#8195;% of the principal amount of the 20&#8195; notes and&#8195;&#8195;&#8195;&#8195;% of the principal amount of the
20&#8195; notes to other dealers. After the initial public offering, the applicable public offering price, concession and discount may be changed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following table shows the underwriting discounts we will pay to the underwriters in respect to this offering: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Paid&nbsp;by&nbsp;Us</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per 20&#8195; note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per 20&#8195; note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes are new issues of securities with no established trading markets. We do not intend to apply for listing of either
series of the notes on any national securities exchange or for inclusion of either series of the notes on any automated dealer quotation system. We have been advised by the underwriters that the underwriters presently intend to make a market in the
notes of each series after completion of the offering. However, the underwriters are under no obligation to do so and may discontinue any market-making activities at any time without notice. We cannot assure the liquidity of the trading markets for
the notes or that active public markets for the notes will develop. If active public trading markets for the notes do not develop, the market prices and liquidity of the notes may be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this offering, the underwriters may, subject to applicable laws and regulations, purchase
and sell the notes in the open market. These transactions may include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of notes than
they are required to purchase in this offering. Stabilizing transactions consist of certain bids or purchases made for the purpose of preventing or retarding a decline in the market prices of the notes while the offering is in progress. Finally, the
underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the notes in the offering, if the syndicate repurchases previously distributed notes in transactions to cover syndicate short positions, in
stabilization transactions or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These activities by the underwriters may stabilize, maintain or otherwise affect the market price of the notes.
As a result, the price of the notes may be higher than the price that otherwise might exist in the open market. If these activities are commenced, they may be discontinued by the underwriters at any time. Neither we nor the underwriters make any
representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the prices of the notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expenses of the offering, not including the underwriting discount, are estimated to be approximately $&#8195;&#8195;&#8195;&#8195;. In connection with
this offering, the underwriters have agreed to reimburse us for certain expenses relating to the offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters and their affiliates are full service financial institutions and have provided, and expect to provide in the future, certain activities which
may include sales and trading, investment banking, commercial banking and other financial and <FONT STYLE="white-space:nowrap">non-financial</FONT> activities and services to us and our affiliates, for which they have received, and may continue to
receive, customary fees and commissions. For example, affiliates of certain of the underwriters are members of the lending syndicate under the Company&#8217;s revolving credit facility. Additionally, Goldman Sachs&nbsp;&amp; Co. LLC served as a
financial advisor to the Company for the acquisition of Solaris. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and
their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities), currencies, commodities, credit default swaps, and other financial instruments (including bank loans)
for their own account and for the accounts of their customers. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. If any of the underwriters or their affiliates have a lending relationship
with us, certain of those underwriters or their affiliates routinely hedge, and certain other of those underwriters may hedge, their credit exposure to us consistent with their customary risk management policies. Typically, these underwriters and
their affiliates would hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions, including potentially the notes offered hereby. Any such credit default swaps
or short positions could adversely affect future trading prices of the notes offered hereby. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such
securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Extended Settlement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that delivery of the notes
will be made against payment therefor on or about&#8195;&#8195;&#8195;&#8195;&#8195;, 2025, which will be the&#8195;&#8195;&#8195;&#8195;business day following the date of pricing of the notes, or &#8220;T+&#8195;&#8195;&#8195;&#8195;.&#8221; Under
Rule <FONT STYLE="white-space:nowrap">15c6-1</FONT> of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who
wish to trade the notes prior to the business day immediately before delivery will be required, by virtue of the fact that the notes initially will settle in T+&#8195;&#8195;&#8195;&#8195;, to specify an alternate settlement arrangement at the time
of any such trade to prevent a failed settlement. Purchasers of the notes who wish to trade the notes prior to the second business day before delivery should consult their advisors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than in the United States, to the best of our knowledge, no action has been taken by us or the underwriters that would permit a public offering of the
notes in any jurisdiction where action for that purpose is required. The notes may not be offered or sold, directly or indirectly, nor may this prospectus supplement or any other offering material or advertisements in connection with the offer and
sale of any such notes be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus
supplement comes are advised to inform themselves about and to observe any restrictions relating to the offering of the notes and the distribution of this prospectus supplement. This prospectus supplement does not constitute an offer to sell or a
solicitation of an offer to buy any notes offered by this prospectus supplement in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of the notes in the United States by any underwriter that is not a broker-dealer registered with the SEC will be made only through one or more <FONT
STYLE="white-space:nowrap">SEC-registered</FONT> broker-dealers in compliance with applicable securities laws and the rules of the Financial Industry Regulatory Authority, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australia </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product
disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission (&#8220;ASIC&#8221;), in relation to the offering. This prospectus supplement and accompanying prospectus do not constitute a
prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the &#8220;Corporations Act&#8221;), and does not purport to include the information required for a prospectus, product disclosure statement or
other disclosure document under the Corporations Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the notes may only be made to persons (the &#8220;Exempt
Investors&#8221;) who are &#8220;sophisticated investors&#8221; (within the meaning of section 708(8) of the Corporations Act), &#8220;professional investors&#8221; (within the meaning of section 708(11) of the Corporations Act) or otherwise
pursuant to one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the notes without disclosure to investors under Chapter 6D of the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under
the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a
disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring the notes must observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Canada </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes may be sold only to purchasers
purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are
permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the notes must be made in accordance with an exemption from,
or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories
of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement and the accompanying prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or
damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal
advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of a non-Canadian jurisdiction,
section&nbsp;3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT
STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dubai International Finance
Center (&#8220;DIFC&#8221;) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services
Authority (&#8220;DFSA&#8221;). This document is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for
reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for this document. The notes to which
this document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the notes offered should conduct their own due diligence on the notes. If you do not understand the contents of this document you should
consult an authorized financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to its use in the DIFC, this document is strictly private and confidential and is being distributed
to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the notes may not be offered or sold directly or indirectly to the
public in the DIFC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European Economic Area (&#8220;EEA&#8221;) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail
investor in the European Economic Area (the &#8220;EEA&#8221;). For the purposes of this provision: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the expression &#8220;retail investor&#8221; means a person who is one (or more) of the following:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a retail client as defined in point (11)&nbsp;of Article 4(1) of Directive 2014/65/EU (as amended, &#8220;MiFID
II&#8221;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a customer within the meaning of Directive (EU) 2016/97 (the &#8220;Insurance Distribution Directive&#8221;),
where that customer would not qualify as a professional client as defined in point (10)&nbsp;of Article 4(1) of MiFID II; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not a qualified investor as defined in Regulation (EU) No 2017/1129 (as amended, the &#8220;Prospectus
Regulation&#8221;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the expression &#8220;offer&#8221; includes the communication in any form and by any means of sufficient
information on the terms of the offer and the notes to be offered so as to enable an investor to decide to purchase or subscribe for the notes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consequently, no key information document required by Regulation (EU) No 1286/2014 (as amended, the &#8220;PRIIPs Regulation&#8221;) for offering or selling
the notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs
Regulation. This prospectus supplement and the accompanying prospectus have been prepared on the basis that any offer of notes in any Member State of the EEA will be made pursuant to an exemption under the Prospectus Regulation from the requirement
to publish a prospectus for offers of notes. This prospectus supplement and the accompanying prospectus are not a prospectus for the purposes of the Prospectus Regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hong Kong </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes offered hereby have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the &#8220;SFO&#8221;) of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in
the document being a &#8220;prospectus&#8221; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong (the &#8220;CO&#8221;), or which do not constitute an offer to the public within the meaning of the
CO. No advertisement, invitation or document relating to the notes has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of
which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to notes which are or are intended to be disposed of only to persons outside Hong Kong
or only to &#8220;professional investors&#8221; as defined in the SFO and any rules made thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Japan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the
notes nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#8220;resident&#8221; of Japan (which term as used herein means any person resident in Japan, including any corporation or
other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from
the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Singapore </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the
accompanying prospectus have not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, the Notes may not be offered or sold, or made the subject of an invitation for subscription or purchase, nor may this prospectus
supplement, the accompanying prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase of the Notes be circulated, whether directly or indirectly, to any person in Singapore other
than (i)&nbsp;to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act 2001 of Singapore, as modified or amended from time to time (the &#8220;SFA&#8221;)) pursuant to Section&nbsp;274 of the SFA or (ii)&nbsp;to
an accredited investor (as defined in Section&nbsp;4A of the SFA) pursuant to and in accordance with the conditions specified in Section&nbsp;275 of the SFA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Switzerland </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is not intended to constitute
an offer or solicitation to purchase or invest in the notes. The notes may not be publicly offered, directly or indirectly, in Switzerland within the meaning of the Swiss Financial Services Act (&#8220;FinSA&#8221;) and no application has or will be
made to admit the notes to trading on any trading venue (exchange or multilateral trading facility) in Switzerland. Neither this document nor any other offering or marketing material relating to the notes constitutes a prospectus pursuant to the
FinSA, and neither this document nor any other offering or marketing material relating to the notes may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taiwan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes have not been and will not be
registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within
the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding or otherwise
intermediate the offering and sale of the notes in Taiwan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail
investor in the United Kingdom (the &#8220;UK&#8221;). For the purposes of this provision: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the expression &#8220;retail investor&#8221; means a person who is one (or more) of the following:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a retail client, as defined in point (8)&nbsp;of Article 2 of Regulation (EU) No 2017/565 as it forms part of
domestic law by virtue of the European Union (Withdrawal) Act 2018 (the &#8220;EUWA&#8221;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a customer within the meaning of the provisions of the Financial Services and Markets Act 2000 (the
&#8220;FSMA&#8221;) and any rules or regulations made under the FSMA to implement Directive (EU) 2016/97, where that customer would not qualify as a professional client, as defined in point (8)&nbsp;of Article 2(1) of Regulation (EU) No 600/2014 as
it forms part of domestic law by virtue of the EUWA; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not a qualified investor as defined in Article 2 of Regulation (EU) 2017/1129 as it forms part of domestic law
by virtue of the EUWA (as amended, the &#8220;UK Prospectus Regulation&#8221;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the expression &#8220;offer&#8221; includes the communication in any form and by any means of sufficient
information on the terms of the offer and the Notes to be offered so as to enable an investor to decide to purchase or subscribe for the Notes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consequently, no key information document required by Regulation (EU) No 1286/2014 as it forms part of UK domestic law by virtue of the EUWA (the &#8220;UK
PRIIPs Regulation&#8221;) for offering or selling the notes or otherwise making them available to retail investors in the UK has been prepared and therefore offering or selling the notes or otherwise making them available to any retail investor in
the UK may be unlawful under the UK PRIIPs Regulation. This prospectus supplement and the accompanying prospectus have been prepared on the basis that any offer of notes in the UK will be made pursuant to an exemption under the UK Prospectus
Regulation from the requirement to publish a prospectus for offers of notes. This prospectus supplement and the accompanying prospectus are not a prospectus for the purposes of the UK Prospectus Regulation. This prospectus supplement and the
accompanying prospectus are being distributed only to, and are directed only at, persons in the UK who are &#8220;qualified investors&#8221; (as defined in the UK Prospectus Regulation) who are also (i)&nbsp;persons having professional experience in
matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (as amended, the &#8220;Order&#8221;), (ii) high net worth entities or other persons falling within Articles 49(2)(a) to (d)&nbsp;of the Order,
or (iii)&nbsp;persons to whom it would otherwise be lawful to distribute them, all such persons together being referred to as &#8220;Relevant Persons.&#8221; The notes are only available to, and any invitation, offer or agreement to subscribe,
purchase or otherwise acquire such notes will be engaged in only with, Relevant Persons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc42072_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the notes will be passed upon for us by White&nbsp;&amp; Case LLP, New York, New York and Patrick Pope, Esq., Executive Vice President,
General Counsel of Cardinal Health. Mr.&nbsp;Pope is paid a salary by Cardinal Health and participates in various employee benefit plans offered to Cardinal Health&#8217;s employees generally. Mr.&nbsp;Pope holds equity incentive awards with respect
to Cardinal Health&#8217;s common shares valued at greater than $50,000. Davis Polk&nbsp;&amp; Wardwell LLP, New York, New York is counsel for the underwriters in connection with this offering. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc42072_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Cardinal Health, Inc. and Subsidiaries appearing in Cardinal Health, Inc.&#8217;s Annual Report (Form <FONT
STYLE="white-space:nowrap">10-K)</FONT> for the year ended June&nbsp;30, 2025 (including the schedule appearing therein) and the effectiveness of Cardinal Health, Inc.&#8217;s internal control over financial reporting as of June&nbsp;30, 2025, have
been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their reports thereon included therein, and incorporated herein by reference. Such consolidated financial statements and Cardinal Health, Inc.
management&#8217;s assessment of the effectiveness of internal control over financial reporting as of June&nbsp;30, 2025 are, and audited consolidated financial statements and Cardinal Health, Inc. management&#8217;s assessment of internal control
over financial reporting to be included in subsequently filed documents will be, incorporated herein in reliance upon the reports of Ernst&nbsp;&amp; Young LLP pertaining to such consolidated financial statements and the effectiveness of our
internal control over financial reporting as of the respective dates (to the extent covered by consents filed with the Securities and Exchange Commission) given on the authority of such firm as experts in accounting and auditing. </P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42072g01a10.jpg" ALT="LOGO" STYLE="width:2.98917in;height:1.17041in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>COMMON SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>PREFERRED SHARES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>DEBT
SECURITIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cardinal Health may offer and sell from time to time, together or separately, the following securities: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Class A common shares (&#8220;<U>common shares</U>&#8221;), </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">preferred shares, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">unsecured debt securities, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">units, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any combination of these securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will provide the terms of any offering and the specific terms of the securities offered in supplements to this prospectus. You should read this prospectus
and any accompanying prospectus supplement together with the information incorporated by reference and any additional information described under the heading &#8220;Where You Can Find More Information and Incorporation of Certain Documents by
Reference&#8221; carefully before you invest in our securities. This prospectus may not be used to sell any of these securities unless accompanied by a prospectus supplement or term sheet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>See &#8220;</B><I><U><A HREF="#tx42072_3">Risk Factors</A></U></I><B>&#8221; beginning on page 4 as well as the risk factors and other information
contained or incorporated by reference in this prospectus and the applicable prospectus supplement for a discussion of certain risks that you should consider in connection with an investment in Cardinal Health&#8217;s securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cardinal Health&#8217;s common shares are listed on the New York Stock Exchange (&#8220;<U>NYSE</U>&#8221;) under the symbol &#8220;CAH.&#8221; Any common
shares sold pursuant to a prospectus supplement will be listed, subject to notice of issuance, on the NYSE.&nbsp;If we decide to list or seek a quotation for any other securities we may offer and sell from time to time, the prospectus supplement
relating to those securities will disclose the exchange or market on which those securities will be listed or quoted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The address of Cardinal
Health&#8217;s principal executive office is 7000 Cardinal Place, Dublin, Ohio 43017 and the telephone number at the principal executive office is (614) <FONT STYLE="white-space:nowrap">757-5000.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or
adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer and sell these securities to or through one or
more underwriters, dealers or agents, or directly to purchasers, on a continuous or delayed basis. The prospectus supplement for each offering will describe in detail the plan of distribution for that offering and will set forth the names of any
underwriters, dealers or agents involved in the offering and any applicable fees, commissions or discount arrangements. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is August 12, 2025. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_2">WHERE YOU CAN FIND MORE INFORMATION AND INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_4">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_5">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_7">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_8">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_9">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_10">VALIDITY OF THE SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx42072_12">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx42072_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of an automatically effective registration statement that we filed with the Securities and Exchange Commission (the
&#8220;<U>SEC</U>&#8221;) using a &#8220;shelf&#8221; registration process. Under this shelf process, Cardinal Health may sell in one or more offerings any combination of Cardinal Health&#8217;s common shares, preferred shares, unsecured debt
securities in one or more series, which may be senior or subordinated debt securities, units or any combination of these securities. This prospectus provides you with a general description of the securities Cardinal Health may offer. Each time
Cardinal Health sells securities, we will provide a prospectus supplement, which may be in the form of a term sheet, that will contain specific information about the terms of that offering and the specific terms of the securities. The prospectus
supplement may also add, update or change information contained in this prospectus, and accordingly, to the extent inconsistent, information in this prospectus is superseded by the information in the prospectus supplement. You should read both this
prospectus and the applicable prospectus supplement together with additional information described under the heading &#8220;Where You Can Find More Information and Incorporation of Certain Documents by Reference.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because Cardinal Health is a &#8220;well-known seasoned issuer,&#8221; as defined in Rule 405 of the Securities Act of 1933, as amended (the
&#8220;<U>Securities Act</U>&#8221;), Cardinal Health may add to and offer additional securities, including securities to be offered and sold by selling security holders, by filing a prospectus supplement with the SEC at the time of the offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may prepare and deliver one or more &#8220;free writing prospectuses&#8221; to you in connection with any offering of
securities under this prospectus. Any such free writing prospectus may contain additional information about us, our business, the offered securities, the manner in which such securities are being offered, our intended use of the proceeds from the
sale of such securities, risks relating to our business or an investment in such securities or other information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not authorized
any person to provide you with any information or to make any representation other than as contained in this prospectus or in any prospectus supplement and the information incorporated by reference herein and therein. We do not take any
responsibility for, and can provide no assurance as to the reliability of, any information that others may give you. If anyone provides you with different or inconsistent information or representations, you should not rely on them. The distribution
of this prospectus and sale of these securities in certain jurisdictions may be restricted. Persons in possession of this prospectus are required to inform themselves about and observe any such restrictions. Cardinal Health is not making an offer to
sell or a solicitation of an offer to buy these securities in any jurisdiction where the offer, sale or solicitation is not permitted. The information appearing or incorporated by reference in this prospectus and any supplement to this prospectus is
accurate only as of the date of this prospectus or any supplement to this prospectus or the date of the document in which incorporated information appears. Our business, financial condition, results of operations and prospects may have changed since
those dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Wherever references are made in this prospectus to information that will be included in a prospectus supplement, to the
extent permitted by applicable law, rules or regulations, we may instead include such information or add, update or change the information contained in this prospectus by means of a post-effective amendment to the registration statement of which
this prospectus is a part, through filings we make with the SEC that are incorporated by reference into this prospectus or by any other method as may then be permitted under applicable law, rules or regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated or unless the context otherwise requires, all references in this prospectus to &#8220;we,&#8221; &#8220;us&#8221;
or &#8220;our&#8221; mean Cardinal Health, Inc. and its consolidated subsidiaries, and references to &#8220;Cardinal Health&#8221; or &#8220;the Company&#8221; refer to Cardinal Health, Inc., excluding its consolidated subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx42072_2"></A>WHERE YOU CAN FIND MORE INFORMATION AND INCORPORATION OF CERTAIN
DOCUMENTS BY REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may
access and read our SEC filings through the SEC&#8217;s website at www.sec.gov. This site contains reports, proxy and information statements and other information that we file electronically with the SEC. Documents may also be available on our
website at http://www.cardinalhealth.com under the heading &#8220;Investor Relations.&#8221; Other than the SEC filings we specifically incorporate by reference herein below, the information contained on or accessible through our website is neither
incorporated by reference into this registration statement or prospectus or any accompanying prospectus supplement nor intended to be used in connection with any offering hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the SEC, which
includes exhibits and other information not included in this prospectus or a prospectus supplement. The SEC allows us to &#8220;incorporate by reference&#8221; in this prospectus the information we file with it. This means that we are disclosing
important business and financial information to you by referring to other documents filed separately with the SEC that contain the omitted information. The information incorporated by reference is an important part of this prospectus, and
information that we file later with the SEC will automatically update and supersede this information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate by reference the
following documents filed with the SEC by us and any future filings we make with the SEC after the date of this prospectus under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;<U>Exchange
Act</U>&#8221;), until we complete our offering of the securities offered by this prospectus and any accompanying prospectus supplement. We are not incorporating by reference any information &#8220;furnished&#8221; rather than &#8220;filed&#8221;
under Item 2.02 or Item 7.01 of any Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> unless otherwise specified. Nothing in this prospectus shall be deemed to incorporate by reference herein information of the type described in
paragraph (d)(1), (d)(2), (d)(3) or (e)(5) of Item&nbsp;407 of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> contained in any of the documents or the future filings described below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="55%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>SEC Filings</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Period/Date</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/721371/000072137125000079/cah-20250630.htm">Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fiscal Year ended June&nbsp;30, 2025, filed with the SEC on August&nbsp;12, 2025.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Portions of the Company&#8217;s <A HREF="http://www.sec.gov/Archives/edgar/data/721371/000072137124000103/cah-20240913.htm">Proxy Statement</A> on&nbsp;Schedule&nbsp;14A&nbsp;for our 2024 Annual Meeting of Shareholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Incorporated by reference into the Company&#8217;s Annual Report <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;10-K&nbsp;for</FONT> the Fiscal Year ended June&nbsp;30, 2024, filed with the SEC on September&nbsp;16, 2024 (with
respect to the &#8220;Letter to Cardinal Health Shareholders,&#8221; &#8220;Notice of Annual Meeting of Shareholders,&#8221; &#8220;Proxy Summary,&#8221; &#8220;Corporate Governance,&#8221; &#8220;Executive Compensation,&#8221; &#8220;Audit
Committee Maters,&#8221; &#8220;Share Ownership Information,&#8221; and &#8220;Other Matters&#8221; only).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Description of common shares contained in <A HREF="http://www.sec.gov/Archives/edgar/data/721371/000072137119000090/a19q4_10-kx63019xexhibit44.htm">Exhibit 4.4</A> to the Company&#8217;s Annual Report on Form 10-K and any amendment
or report filed with the SEC for the purpose of updating the description</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fiscal Year ended June&nbsp;30, 2019, filed with the SEC on August&nbsp;20, 2019.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained or incorporated by reference in this prospectus shall be deemed to be modified or
superseded for purposes of this prospectus to the extent that a statement contained herein, or in any subsequently filed document which also is incorporated herein by reference, modifies or supersedes such earlier statement. Any statement so
modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. Any statement made in this prospectus concerning the contents of any contract,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement or other document is only a summary of the actual contract, agreement or other document. If we have filed or incorporated by reference any contract, agreement or other document as an
exhibit to the registration statement, you should read the exhibit for a more complete understanding of the document or matter involved. Each statement regarding a contract, agreement or other document is qualified by reference to the actual
document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will furnish without charge to each person (including any beneficial owner) to whom a prospectus is delivered, upon written
or oral request, a copy of any or all of the foregoing documents incorporated herein by reference (other than certain exhibits). Requests for such documents should be made to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cardinal Health, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7000
Cardinal Place </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dublin, Ohio 43017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(614) <FONT STYLE="white-space:nowrap">757-5000</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx42072_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in Cardinal Health&#8217;s securities involves significant risks. Before you invest in Cardinal Health&#8217;s securities, in
addition to the other information contained in this prospectus and in the accompanying prospectus supplement, you should carefully consider the risks and uncertainties identified in Cardinal Health&#8217;s reports filed with the SEC that are
incorporated by reference into this prospectus and the accompanying prospectus supplement herein and therein, including, in particular, the risk factors set forth in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year
ended June&nbsp;30, 2025, the risk factors described under the caption &#8220;Risk Factors&#8221; in any applicable prospectus supplement and any risk factors set forth in our other filings with the SEC, pursuant to Section&nbsp;13(a), 13(c), 14 or
15(d) of the Exchange Act. The occurrence of any of these risks might cause you to lose all or a part of your investment in the offered securities. Furthermore, additional risks and uncertainties not presently known to us or that we currently deem
immaterial may also impair our business operations. See &#8220;Where You Can Find More Information and Incorporation of Certain Documents by Reference&#8221; above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx42072_4"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cardinal Health&#8217;s filings with the SEC, including Cardinal Health&#8217;s Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended June&nbsp;30, 2025 (the &#8220;<U>2025 Form <FONT STYLE="white-space:nowrap">10-K</FONT></U>&#8221;), any subsequent Annual Report, any Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> or any Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> of Cardinal Health (along with any exhibits and amendments to such reports), as well as Cardinal Health&#8217;s news releases or any
other written or oral statements made by or on behalf of Cardinal Health, may include, directly or by incorporation by reference, forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the
Exchange Act intended to be covered by the safe harbor provided for under these sections that reflect Cardinal Health&#8217;s current view (as of the date the forward-looking statement is first made) about future events, prospects, projections or
financial performance. The matters discussed in these forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied in or by such
statements. These risks and uncertainties include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitive pressures in the markets in which we operate, including pricing pressures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties relating to the pricing of and demand for generic pharmaceuticals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties related to recently imposed or threatened tariffs on China, Mexico and Canada and other countries,
and any retaliatory actions taken by these countries, which will result in us incurring additional costs to procure products or materials that we source, manufacture and distribute, including the risk that we will not be successful at mitigating the
negative impact of such increased costs, the risk that we may not be able to establish alternate sources of supply and may experience supply disruptions or shortages; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties relating to the timing, frequency and profitability of generic pharmaceutical launches or other
components of our pharmaceutical generics program; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the timing or frequency of the introduction of branded pharmaceuticals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">material reductions in purchases, pricing changes, <FONT STYLE="white-space:nowrap">non-renewal,</FONT> early
termination, or delinquencies or defaults under contracts with key customers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs or claims resulting from quality issues, or other potential or alleged errors or defects in our
manufacturing or sourcing of medical devices or other products or in our compounding, repackaging, information systems or pharmacy management services that may injure persons or damage property or operations, including costs from recalls,
remediation efforts, and related product liability claims and lawsuits, including class action lawsuits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any compromise of our information systems or of those of a third-party service provider, including unauthorized
access to or use or disclosure of company or customer information, disruption of access and ancillary risks associated with our ability to effectively manage any issues arising from any such compromise or disruption; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continuing risks associated with the resolution and defense of the lawsuits and investigations in which we have
been or will be named relating to the distribution of prescription opioid pain medication, including the investigations by the U.S. Department of Justice which concerns our anti-diversion program, our anti-diversion policies and procedures and our
distribution of certain controlled substances; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with the national opioid settlement agreement, including the risk that the maintenance of the
required changes to distributors&#8217; controlled substance anti-diversion programs may result in unforeseen costs or operational challenges and the risk that if we fail to or are alleged to have failed to comply with the terms of the settlement
agreement, we could incur monetary or other penalties or result in additional lawsuits being filed against us; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties related to Cardinal Health Brand products, including our ability to manage cost and infrastructure,
retain margin, increase volume and improve performance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significantly increased costs for commodities and other materials used in the Global Medical Products and
Distribution segment manufacturing, including various components, compounds, raw materials or energy such as <FONT STYLE="white-space:nowrap">oil-based</FONT> resins, pulp, cotton, latex and other commodities and the possibility that we may not
successfully offset or mitigate these increases; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks arising from acquisitions, including possible liabilities relating to the operations or activities of such
businesses prior to their acquisition, and uncertainties relating to our ability to achieve the anticipated results from acquisitions, including as a result of entering new lines of business with risks and uncertainties that may be different from or
more significant than risks and uncertainties facing our legacy businesses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with the tax benefit from our self-insurance loss claims, including, certain state courts&#8217;
interpretation of laws and insurance policies in ways that may impact our self-insurance loss, which could negatively impact our financial position; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruption, damage or lack of access to, or failure of, our or our third-party service providers&#8217;
information systems, our critical facilities, including our national logistics center, or our distribution networks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with our Corporate Integrity Agreement with the Office of Inspector General of the Department of
Health and Human Services, including the risk that failure to comply with the requirements set forth therein could result in monetary or other penalties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our high sales concentration with certain key customers, including CVS Health Corporation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain the benefits of our generic pharmaceutical sourcing venture with CVS Health Corporation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement
Administration, certain agencies within the U.S. Department of Health and Human Services (including the U.S. Food and Drug Administration, Centers for Medicare and Medicaid Services, the Office of Inspector General and the Office for Civil Rights),
the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance authorities, state health departments, state insurance departments, state
Medicaid departments or comparable regulatory bodies or governmental authorities or foreign equivalents that, in each case, could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning
letters, recalls, seizures, injunctions or monetary sanctions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shortages in commodities, components, compounds, raw materials or energy used by our businesses, including supply
disruptions of radioisotopes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily
available; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties with respect to certain business process initiatives, including IT infrastructure activities and
outsourcing relationships, including the ability to achieve the expected benefits from such initiatives, the risk that we could incur unexpected charges, and the risk that we may fail to retain key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties or delays in the development, production, manufacturing, sourcing and marketing of new or existing
products and services, including difficulties or delays associated with obtaining or maintaining requisite regulatory consents, whether our own or third parties&#8217;, or approvals associated with those activities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing disruptions, whether due to regulatory action, including regulatory action to reduce ethylene oxide
(&#8220;<U>EtO</U>&#8221;) emissions, production quality deviations, safety issues or raw material shortages or defects, or because a key product is manufactured at a single manufacturing facility with limited alternate facilities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with industry reliance on EtO to sterilize certain medical products that we manufacture or
distribute, including the possibility that regulatory actions to reduce EtO emissions could become more widespread, which may result in increased costs or supply shortages; and risks that the lawsuits against us alleging personal injury resulting
from EtO exposure could become more widespread; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions,
including the possibility that the corporate tax rate in the U.S. could be increased; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks arising from possible violations of healthcare fraud and abuse laws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks arising from possible violations of the U.S. Foreign Corrupt Practices Act and other similar
anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks arising from our collecting, handling and maintaining patient-identifiable health information and other
sensitive personal and financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks arising from certain of our businesses being Medicare-certified suppliers or participating in other federal
and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program, which businesses are subject to accreditation and quality standards and other rules and regulations, including applicable reporting, billing,
payment and record-keeping requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks arising from pharmaceutical manufacturers&#8217; restriction of sales under the 340B drug pricing program
to contract pharmacies, which may adversely impact our customers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks arising from certain of our businesses manufacturing pharmaceutical and medical products or repackaging
pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs, which businesses are subject to federal and state laws that establish eligibility for reimbursement by such programs and
other applicable standards and regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in laws or changes in the interpretation or application of laws or regulations, as well as possible
failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier
relationships, or changes in customer mix; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and
payments to settle these challenges, which may adversely affect our effective tax rate or tax payments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties due to possible government healthcare reform, including proposals related to Medicare drug rebate
arrangements, possible repeal or replacement of major parts of the Patient Protection and Affordable Care Act, proposals related to prescription drug pricing transparency and the possible adoption of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Medicare-For-All;</FONT></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reductions or limitations on governmental funding at the state or federal level or efforts by healthcare
insurance companies to limit payments for products and services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in manufacturers&#8217; pricing, selling, inventory, distribution or supply policies or practices;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in legislation or regulations governing prescription drug pricing, healthcare services or mandated
benefits; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties arising as a result of the Supreme Court decision on Dobbs vs. Jackson, including uncertainties
associated with states&#8217; proposed and adopted laws which may impact our ability to distribute or store certain pharmaceutical products and the risk that we could incur unforeseen costs to comply with these new laws in various jurisdictions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in hospital buying groups or hospital buying practices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in distribution or sourcing models for pharmaceutical and medical and surgical products, including an
increase in direct and limited distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to the prescription drug reimbursement formula and related reporting requirements for generic
pharmaceuticals under Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continuing consolidation in the healthcare industry, which could give the resulting enterprises greater
bargaining power and may increase pressure on prices for our products and services or result in the loss of customers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks to our business and information and controls systems in the event that business process improvements,
infrastructure modernization or initiatives to use third-party service providers for key systems and processes are not effectively implemented; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that we may not effectively implement and maintain data governance structures across businesses to allow
us to access and interpret our data, which could put us at a competitive disadvantage relative to our peers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results, costs, effects or timing of any commercial disputes, government contract compliance matters, patent
infringement claims, qui tam actions, government investigations, shareholder lawsuits or other legal proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that our business performance or internal control over financial reporting may be adversely
impacted if we are not successful at attracting, retaining and developing talent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">losses relating to product liability lawsuits and claims regarding products for which we cannot obtain product
liability insurance or for which such insurance may not be adequate to cover our losses, including the product liability lawsuits we are currently defending relating to alleged personal injuries associated with the use of Cordis inferior vena cava
filter products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with the importation of products or source materials used in products that we manufacture or
distribute, including risks associated with our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-of-origin</FONT></FONT> determinations and the possibility that we could experience additional supply disruptions as a result
of the Uyghur Forced Labor Prevention Act or other similar regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain adequate intellectual property protections; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to manage and complete divestitures or other strategic business combination transactions, including
our ability to find buyers or other strategic exit opportunities and risks associated with the possibility that we could experience greater <FONT STYLE="white-space:nowrap">dis-synergies</FONT> than anticipated or otherwise fail to achieve our
strategic objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">bankruptcy, insolvency or other credit failure of a customer or supplier that owes us a substantial amount;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with global operations, including the effect of local economic environments, inflation,
recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their
impact on our ability to source products or materials that we need to conduct our business; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with our use of and reliance on the global capital and credit markets, including our ability to
access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to introduce and market new products and our ability to keep pace with advances in technology;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant charges to earnings if goodwill or intangible assets become impaired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties relating to general political, business, industry, regulatory and market conditions; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other factors described in the &#8220;Risk Factors&#8221; section of the 2025 Form
<FONT STYLE="white-space:nowrap">10-K.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This list of important factors is not intended to be exhaustive. The risk
factors set forth in the section titled &#8220;Risk Factors&#8221; and incorporated by reference in this prospectus and any accompanying prospectus supplement discuss certain of these matters more fully. We discuss certain of these matters more
fully, as well as certain other factors that may affect our business operations, financial condition, and results of operations, in our filings with the SEC, including our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly
Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
and when made, we believe that our forward-looking statements are reasonable. However,&nbsp;as a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or
implied by these forward-looking statements. You should not place undue reliance on these forward-looking statements. The words &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221;
&#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;likely,&#8221; and similar expressions generally identify &#8220;forward-looking statements,&#8221; which speak
only as of the date the statements were made, and also include statements reflecting future results or guidance, statements of outlook and expense accruals. We undertake no obligation to update or revise any forward-looking statements or to update
the reasons actual results could differ materially from those anticipated, to reflect circumstances or events that occur after the statements are made, except to the extent required by applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx42072_5"></A>THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cardinal Health, Inc., an Ohio corporation formed in 1979, is a global healthcare services and products company providing customized solutions
for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices&nbsp;and patients in the home. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain
efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional
information concerning our business and our financial results and condition, please refer to the documents incorporated by reference in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The mailing address of our executive offices is 7000 Cardinal Place, Dublin, Ohio 43017, and our telephone number is (614) <FONT
STYLE="white-space:nowrap">757-5000.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx42072_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as we may describe otherwise in a prospectus supplement or a free writing prospectus, we intend to use the net proceeds from the sale
of any offered securities for general corporate purposes, including, but not limited to, working capital, capital expenditures, repayment or refinancing of indebtedness, acquisitions, and the repurchase, redemption or retirement of Cardinal
Health&#8217;s securities. The net proceeds may be invested temporarily or applied to repay short-term, interest-bearing, investment-grade securities or similar assets until they are used for their stated purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx42072_7"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of Cardinal Health&#8217;s capital stock. The following summary of the terms of Cardinal Health&#8217;s capital
stock is not meant to be complete and is qualified by reference to Cardinal Health&#8217;s Amended and Restated Articles of Incorporation, as amended (the &#8220;<U>Articles</U>&#8221;), and Cardinal Health&#8217;s Restated Code of Regulations (the
&#8220;<U>Regulations</U>&#8221;), which are the documents that establish these rights. Copies of the Articles and Regulations are incorporated by reference in the registration statement of which this prospectus is a part. See &#8220;Where You Can
Find More Information and Incorporation of Certain Documents by Reference&#8221; on page 2 of this prospectus for information on how to obtain copies of documents incorporated by reference in the registration statement of which this prospectus is a
part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Articles authorize Cardinal Health to issue up to 750&nbsp;million common shares. As of June&nbsp;30, 2025, approximately
271&nbsp;million common shares were issued and approximately 32&nbsp;million were held in treasury. The Articles also authorize Cardinal Health to issue up to 5&nbsp;million Class&nbsp;B common shares, none of which are outstanding or reserved for
issuance, and 500,000 <FONT STYLE="white-space:nowrap">non-voting</FONT> preferred shares, none of which are outstanding or reserved for issuance. The principal stock exchange on which our common shares are listed is the New York Stock Exchange
under the symbol &#8220;CAH.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, Cardinal Health may issue additional authorized but unissued common shares for
share dividends, stock splits, employee benefit and compensation programs, financing and acquisition transactions, and other general purposes. Those common shares will be available for issuance without action by Cardinal Health&#8217;s shareholders,
unless action by the Cardinal Health shareholders is required by applicable law or the rules of the New York Stock Exchange or any other stock exchange on which common shares may be listed in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Common Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the
outstanding common shares are fully paid and nonassessable. Holders of common shares do not have preemptive rights and have no right to convert their common shares into any other security. All common shares are entitled to participate equally and
ratably in dividends, when and as declared by Cardinal Health&#8217;s board of directors. In the event of the liquidation of Cardinal Health, holders of common shares are entitled to share ratably in assets remaining after payment of all
liabilities, subject to prior distribution rights of any preferred shares then outstanding. Holders of common shares are entitled to one vote per share upon all matters on which shareholders are entitled to vote. Holders of Class&nbsp;B common
shares (if any are issued in the future) are entitled to <FONT STYLE="white-space:nowrap">one-fifth</FONT> of one vote per share upon all matters on which shareholders are entitled to vote. Except as otherwise expressly provided by law, the Articles
or the Regulations, all matters on which shareholders are entitled to vote will be decided by the majority of votes cast without regard to abstentions. Under certain circumstances, holders of Class&nbsp;B common shares have a right to a separate
class vote. Holders of common shares do not have any rights to cumulate votes in the election of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Preferred Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No shares of <FONT STYLE="white-space:nowrap">non-voting</FONT> preferred shares are currently outstanding. Under the Articles, Cardinal
Health&#8217;s board of directors, without further action by its shareholders, is authorized to issue up to 500,000 <FONT STYLE="white-space:nowrap">non-voting</FONT> preferred shares, without par value, in one or more series and to fix the
designations, preferences, limitations and relative or other rights thereof, including the designation and authorized number of shares constituting each series, dividend rights, liquidation price, redemption rights, sinking fund requirements,
conversion rights and restrictions on the issuance of such shares. The issuance of preferred shares could adversely affect the holders of common shares. The issuance of preferred shares could also have the effect, under certain circumstances, of
delaying, deferring or preventing a change of control of Cardinal Health. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cardinal Health&#8217;s board of directors currently consists of fifteen members. The Regulations provide that the number of directors is fixed
from time to time by the board of directors, but in no case may the number of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directors be decreased to fewer than nine nor increased to more than 16. The board of directors may fill any vacancy, including a vacancy created by an increase in the number of directors. Each
director serves until the next annual meeting of shareholders and until his or her successor is duly elected and qualified or until his or her earlier resignation, removal from office or death. In uncontested elections of directors, as defined in
the Articles, directors are elected by a majority of the votes cast; director elections other than uncontested elections are governed by a plurality voting standard. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Anti-takeover Protections </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some provisions of Ohio law, the Articles and the Regulations may have the effect of delaying, deferring or discouraging another party from
acquiring control of Cardinal Health. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Articles and Regulations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Articles and Regulations: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize the board of directors to issue, at any time, nonvoting preferred shares, the terms of which may be
determined by the board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">do not authorize cumulative voting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize the board of directors to amend, repeal, or adopt new regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that only the chairman of the board of directors, the chief executive officer or the president, or a
majority of the directors may call a special meeting of the shareholders, except that a special meeting must be called upon the request from at least 25% of the combined voting power of the outstanding shares entitled to vote at the meeting; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide an advanced written notice procedure with respect to shareholder proposals and shareholder nomination of
candidates for election as directors. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ohio Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes Chapter 1704 of the Ohio Revised Code which may have the effect of prohibiting, raising the costs of, or otherwise
impeding, a change of control of Cardinal Health, whether by merger, consolidation or sale of assets or stock (by tender offer or otherwise), or by other methods. Chapter 1704 provides generally that any person who has beneficial ownership of 10% or
more of a corporation&#8217;s voting stock (thereby being an &#8220;interested shareholder&#8221;) may not engage in a wide range of business combinations with the corporation for a period of three years following the date the person became an
interested shareholder, unless the directors of the corporation have approved the transaction or the interested shareholder&#8217;s acquisition of shares of the corporation, in either case, prior to the date the interested shareholder became an
interested shareholder of the corporation. After the three-year period, business combinations between the corporation and the interested shareholder are prohibited unless certain fair price provisions are complied with or the shareholders of the
corporation approve the transaction by the affirmative vote of <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the voting power of the corporation, including at least a majority of the disinterested shareholders. These restrictions on
interested shareholders do not apply under certain circumstances, including when a person becomes an &#8220;interested shareholder&#8221; only because a corporation has repurchased some of its voting stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Exclusive Forum Provision </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Regulations provide that, unless Cardinal Health consents in writing to the selection of an alternate forum, the United States District
Court for the Southern District of Ohio, Eastern Division, (or if that court determines that it lacks jurisdiction to hear the action, the Franklin County, Ohio Court of Common Pleas, which prior to the amendment to the Regulations adopted by
Cardinal Health&#8217;s board of directors on November&nbsp;6, 2019, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
was the court specified for such proceedings) will be the exclusive forum for derivative suits and certain other actions, including any action asserting a claim against Cardinal Health or any
director, officer or other employee arising under Ohio corporation law, the Articles or the Regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for the common shares is Computershare Trust Company, N.A., P.O. Box 505000, Louisville, KY
40233-5000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx42072_8"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description summarizes the general terms and provisions of the debt securities that Cardinal Health may offer pursuant to this
prospectus that are common to all series. The specific terms relating to any series of the debt securities that Cardinal Health may offer will be described in a prospectus supplement, which you should read. Because the terms of specific series of
debt securities offered may differ from the general information that Cardinal Health has provided below, you should rely on information in the applicable prospectus supplement that contradicts any information below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As required by federal law for all bonds and notes of companies that are publicly offered, the debt securities will be governed by a document
called an &#8220;indenture.&#8221; An indenture is a contract between a financial institution, acting on your behalf as trustee of the debt securities offered, and Cardinal Health. The debt securities will be issued pursuant to an indenture, dated
as of June&nbsp;2, 2008, between Cardinal Health and The Bank of New York Mellon Trust Company, N.A. (formerly The Bank of New York Trust Company, N.A.), as trustee, unless otherwise indicated in the applicable prospectus supplement. When Cardinal
Health refers to the &#8220;indenture&#8221; in this prospectus, Cardinal Health is referring to the indenture under which your debt securities are issued, as may be supplemented by any supplemental indenture applicable to your debt securities. The
trustee has two main roles. First, subject to some limitations on the extent to which the trustee can act on your behalf, the trustee can enforce your rights against Cardinal Health if Cardinal Health defaults on its obligations under the indenture.
Second, the trustee performs certain administrative duties for Cardinal Health with respect to the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise
provided in any applicable prospectus supplement, the following section is a summary of the principal terms and provisions that will be included in the indenture. This summary is not complete and is subject to, and qualified in its entirety by
reference to, the terms and provisions of the indenture, which will be in the form filed as an exhibit to or incorporated by reference in the registration statement of which this prospectus is a part. If this summary refers to particular provisions
in the indenture, such provisions, including the definition of terms, are incorporated by reference in this prospectus as part of this summary. Cardinal Health urges you to read the applicable indenture and any supplement thereto because these
documents, and not this section, define your rights as a holder of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this section, &#8220;<U>Cardinal Health</U>&#8221;
refers to Cardinal Health, Inc., excluding its subsidiaries, unless otherwise expressly stated or the context otherwise requires. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture
does not limit the amount of debt securities or any other debt Cardinal Health may incur. The indenture provides that the debt securities may be issued from time to time in one or more series. The debt securities may have the same or various
maturities. The debt securities may be issued at par, at a premium or with original issue discount. Cardinal Health may also reopen a previous issue of securities and issue additional securities of the series. The debt securities will be unsecured
obligations of Cardinal Health. Senior debt securities will rank equally in right of payment with all of Cardinal Health&#8217;s existing and future unsecured and unsubordinated indebtedness. Subordinated debt securities will be unsecured and
subordinated in right of payment to the prior payment in full of all of Cardinal Health&#8217;s unsecured and senior indebtedness. Unless otherwise specified in a prospectus supplement, a default in Cardinal Health&#8217;s obligations with respect
to any other indebtedness will not constitute a default or an event of default with respect to the debt securities. The indenture does not contain any covenants or provisions that afford holders of debt securities protection in the event of a highly
leveraged transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cardinal Health conducts nearly all of its operations through subsidiaries and it expects that it will continue to
do so. As a result, the right of Cardinal Health to participate as a shareholder in any distribution of assets of any subsidiary upon its liquidation or reorganization or otherwise and the ability of holders of the debt securities to benefit as
creditors of Cardinal Health from any distribution are subject to the prior claims of creditors of the subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to any series of debt securities will, among other
things, describe the following terms, where applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the debt securities and whether the debt securities will be senior or subordinated;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the total principal amount of the debt securities and any limit upon the aggregate principal amount of the debt
securities of the series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates on which the principal of the debt securities will be payable, or the method by which such date
or dates will be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate or rates at which the debt securities will bear interest, if any, or the method by which such rate will
be determined, the date or dates from which such interest will accrue, the interest payment dates on which such interest will be payable and the record dates for the determination of holders of debt securities to whom interest is payable, or the
method by which such date or dates will be determined, and the basis upon which interest will be calculated if other than on the basis of a <FONT STYLE="white-space:nowrap">360-day</FONT> year of twelve <FONT STYLE="white-space:nowrap">30-day</FONT>
months; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if in addition to or other than The City of New York, the place for payment, registration, transfer, exchange or
conversion of the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any optional redemption provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sinking fund or analogous provisions that would obligate us to redeem, repurchase or repay the debt
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than denominations of $1,000 and any integral multiple thereof in the case of debt securities in
registered form and denominations of $5,000 in the case of debt securities in bearer form, the denominations in which the debt securities will be issuable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the principal amount thereof, the portion of the principal amount of debt securities which will be
payable upon declaration of acceleration of the maturity thereof or provable in bankruptcy or the method by which such portion will be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than U.S. dollars, the currency or currencies in which the debt securities will be denominated or
payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the amount of payments of principal of or interest, if any, on the debt securities may be determined with
reference to an index, formula or other method (which may be based on one or more currencies, commodities, equity indices or other indices), and how such amounts will be determined; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the provisions of the indenture described under &#8220;Defeasance&#8221; are not applicable to the debt
securities and any provisions in modification of such provisions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions granting special rights to the holders of the debt securities upon the occurrence of specified
events; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities are to be issuable in registered form, in bearer form or both, any restrictions
applicable to the offer, sale or delivery of debt securities in bearer form, whether the debt securities are to be issuable initially in temporary global form or issuable in permanent global form, and, if so, whether beneficial owners may exchange
such interests for debt securities of like tenor of any authorized form and denomination and the circumstances under which any such exchanges may occur, and whether debt securities in registered form may be exchanged for debt securities in bearer
form and the circumstances under which any such exchanges may occur; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any modifications to the events of default or covenants of Cardinal Health with respect to the debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the debt securities are to be issuable in definitive form only upon receipt of certain certificates or other
documents or satisfaction of other conditions, the form and/or terms of such certificates, documents or conditions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the debt securities are to be issued upon the exercise of warrants, the time, manner and place for such debt
securities to be authenticated and delivered; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the debt securities are to be convertible into or exchangeable for any other securities, and the applicable
terms and conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities are subject to subordination and the terms of any such subordination;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other material terms of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any trustees, authenticating or paying agents, transfer agents or registrars or any other agents with respect to
the debt securities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities or any portion thereof will be issuable as global securities and any depositary for
such global securities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in a prospectus supplement, principal and premium, if any, will be
payable, and the debt securities will be transferable and exchangeable without service charge, at the office of the trustee under the indenture. Interest on any series of the debt securities will be payable on the interest payment dates to the
persons in whose names the debt securities are registered at the close of business on the related record dates, and, unless other arrangements are made, will be paid by checks mailed to such persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities may be issued as discounted debt securities (bearing no interest or interest at a rate which at the time of issuance is
below market rates) and sold at a discount which may be substantially below their stated principal amount (&#8220;<U>Original Issue Discount Securities</U>&#8221;). The applicable prospectus supplement may describe the federal income tax
consequences and other special considerations applicable to any Original Issue Discount Securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Definitions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The definitions set forth below are a description of the terms that are defined in the indenture and used in this prospectus. The complete
definitions are set forth in the indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Attributable Debt</U>&#8221; means, in connection with a sale and lease-back
transaction, the lesser of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fair value of the assets subject to the transaction; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate of present values (discounted at a rate per annum equal to the weighted average Yield to Maturity
of the debt securities of all series then outstanding and compounded semiannually) of Cardinal Health&#8217;s or any Consolidated Subsidiary&#8217;s obligations for net rental payments during the remaining term of all leases. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Consolidated Subsidiary</U>&#8221; means any Subsidiary substantially all the property of which is located, and substantially all
the operations of which are conducted, in the United States of America whose financial statements are consolidated with those of Cardinal Health in accordance with generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Exempted Debt</U>&#8221; means the sum of the following as of the date of determination: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our indebtedness incurred after the date of the indenture and secured by liens not permitted by the limitation on
liens provisions of the indenture; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Attributable Debt in respect of every sale and lease-back transaction entered into after the date of the
indenture, other than leases permitted by the limitation on sale and lease-back provisions of the indenture. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Financing Subsidiary</U>&#8221; means any Subsidiary, including its Subsidiaries,
engaged in one or more of the following activities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the business of making loans or advances, extending credit or providing financial accommodations (including
leasing new or used products) to others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the business of purchasing notes, accounts receivable (whether or not payable in installments), conditional sale
contracts or other obligations of others originating in sales at wholesale or retail; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other business as may be reasonably incidental to those described herein, including the ownership and use of
property in connection therewith. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Funded Indebtedness</U>&#8221; means all Indebtedness having a maturity of
more than 12 months from the date as of which the amount of Indebtedness is to be determined or having a maturity of less than 12 months but by its terms being renewable or extendible beyond 12 months from such date at the option of the borrower.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Indebtedness</U>&#8221; means all items classified as indebtedness on our most recently available balance sheet in accordance
with generally accepted accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Net Worth</U>&#8221; means, as of any date of determination, the total
shareholder&#8217;s equity of Cardinal Health and its Subsidiaries calculated on a consolidated basis in accordance with generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Original Issue Discount Security</U>&#8221; means any debt security that provides for an amount less than the principal amount
thereof to be due and payable upon a declaration of acceleration of the maturity thereof following an event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Rate
Hedging Obligations</U>&#8221; means any and all obligations of anyone arising under: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any and all agreements, devices or arrangements designed to protect at least one of the parties thereto from the
fluctuations of interest rates, exchange rates or forward rates applicable to such party&#8217;s assets, liabilities or exchange transactions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any and all cancellations, buybacks, reversals, terminations or assignments of the same. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Restricted Subsidiary</U>&#8221; means a &#8220;significant subsidiary&#8221; as defined in Article 1, Rule <FONT
STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X,</FONT> promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Senior Funded Indebtedness</U>&#8221; means any of Cardinal Health&#8217;s Funded Indebtedness that is not subordinated in right of
payment to any of Cardinal Health&#8217;s other Indebtedness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Subsidiary</U>&#8221; means any corporation, partnership, limited
liability company, business trust, trust or other legal entity of which at least a majority of the outstanding stock or other ownership interests having voting power to elect a majority of the board of directors, managers or trustees of that
corporation, partnership, limited liability company, business trust, trust or other legal entity (irrespective of whether or not at the time stock or other ownership interests of any other class or classes of such corporation, partnership, limited
liability company, business trust, trust or other legal entity shall have or might have voting power by reason of the happening of any contingency) is at the time owned by Cardinal Health or by Cardinal Health and one or more Subsidiaries or by one
or more Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Yield to Maturity</U>&#8221; means the yield to maturity on a series of debt securities, calculated at
the time of issuance of such series, or, if applicable, at the most recent redetermination of interest on such series, and calculated in accordance with accepted financial practice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Certain Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following is a summary of the material covenants contained in the indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>Limitations on Liens </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as any of the debt securities remain outstanding, Cardinal Health will not, and it will not permit any Consolidated Subsidiary to,
create or assume any Indebtedness for borrowed money that is secured by a mortgage, pledge, security interest or lien (the &#8220;<U>liens</U>&#8221;) of or upon any assets of Cardinal Health or any Consolidated Subsidiary, whether now owned or
hereafter acquired, without equally and ratably securing the debt securities by a lien ranking ratably with and equal to such secured Indebtedness. The foregoing restriction does not apply to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liens existing on the date of the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liens on assets of any corporation existing at the time it becomes a Consolidated Subsidiary;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liens on assets existing at the time Cardinal Health or a Consolidated Subsidiary acquires them, or to secure
the payment of the purchase price for them, or to secure Indebtedness incurred or guaranteed by Cardinal Health or a Consolidated Subsidiary for the purpose of financing the purchase price of assets, or, in the case of real property, construction or
improvements thereon, which Indebtedness is incurred or guaranteed prior to, at the time of, or within 360 days after the acquisition (or in the case of real property, completion of construction or improvements or commencement of full operation of
such asset, whichever is later) provided that the lien shall not apply to any assets theretofore owned by Cardinal Health or a Consolidated Subsidiary other than, in the case of any such construction or improvements, any real property on which the
construction or improvement is located; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liens securing Indebtedness owing by any Consolidated Subsidiary to Cardinal Health or another wholly owned
domestic Subsidiary; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liens on any assets of a corporation existing at the time the corporation is merged into or consolidated with
Cardinal Health or a Subsidiary or at the time of a purchase, lease or other acquisition of the assets of a corporation or firm as an entirety or substantially as an entirety by Cardinal Health or a Subsidiary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liens on any assets of Cardinal Health or a Consolidated Subsidiary in favor of the United States of America or
any State or political subdivision thereof, or in favor of any other country, or political subdivision thereof, to secure certain payments pursuant to any contract or statute or to secure any Indebtedness incurred or guaranteed for the purpose of
financing all or any part of the purchase price (or, in the case of real property, the cost of construction) of the assets subject to such liens (including, but not limited to, liens incurred in connection with pollution control, industrial revenue
or similar financings); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any extension, renewal or replacement (or successive extensions, renewals or replacements) in whole or in part,
of any lien referred to in the foregoing clauses (a)&nbsp;to (f), inclusive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">certain statutory liens or other similar liens arising in the ordinary course of business or certain liens
arising out of governmental contracts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">certain pledges, deposits or liens made or arising under workers&#8217; compensation or similar legislation or
in certain other circumstances; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liens created by or resulting from certain legal proceedings, including certain liens arising out of judgments
or awards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liens for certain taxes or assessments, landlord&#8217;s liens and liens and charges incidental to the conduct
of our business, or our ownership of our assets which were not incurred in connection with the borrowing of money and which do not, in Cardinal Health&#8217;s opinion, materially impair our use of such assets in our operations or the value of the
assets for its purposes; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">liens on any assets of a Financing Subsidiary. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing restrictions, we may create or assume any Indebtedness which is secured by a lien without securing the debt
securities, provided that at the time of such creation or assumption, and immediately after giving effect thereto, the Exempted Debt then outstanding at such time does not exceed 20% of Net Worth. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>Limitations on Subsidiary Indebtedness </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cardinal Health will not permit any Restricted Subsidiary directly or indirectly to incur any Indebtedness for borrowed money, except that the
foregoing limitations will not apply to the incurrence of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness outstanding on the date of the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness of a Restricted Subsidiary that represents its assumption of Indebtedness of another Subsidiary,
and Indebtedness owed by any Restricted Subsidiary to Cardinal Health or to another Subsidiary; provided that such Indebtedness will be held at all times by either Cardinal Health or a Subsidiary; and provided further that upon the transfer or
disposition of such Indebtedness to someone other than Cardinal Health or another Subsidiary, the incurrence of such Indebtedness will be deemed to be an incurrence that is not permitted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness arising from (i)&nbsp;the endorsement of negotiable instruments for deposit or collection or
similar transactions in the ordinary course of business or (ii)&nbsp;the honoring by a bank or other financial institution of a check, draft or similar instrument inadvertently (except in the case of daylight overdrafts) drawn against insufficient
funds in the ordinary course of business; provided that such overdraft is extinguished within five business days of incurrence; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness arising from guarantees of loans and advances by third parties to employees and officers of a
Restricted Subsidiary in the ordinary course of business for bona fide business purposes; provided that the aggregate amount of such guarantees by all Restricted Subsidiaries does not exceed $1,000,000; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness incurred by a foreign Restricted Subsidiary in the ordinary course of business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness of any corporation existing at the time such corporation becomes a Restricted Subsidiary or is
merged into a Restricted Subsidiary or at the time of a purchase, lease or other acquisition by a Restricted Subsidiary of all or substantially all of the assets of such corporation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness of a Restricted Subsidiary arising from agreements or guarantees providing for or creating any
obligations of Cardinal Health or any of its Subsidiaries incurred in connection with the disposition of any business, property or Subsidiary, excluding guarantees or similar credit support by a Restricted Subsidiary of indebtedness incurred by the
acquirer of such business, property or Subsidiary for the purpose of financing such acquisition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness of a Restricted Subsidiary with respect to bonds, bankers&#8217; acceptances or letters of credit
provided by such Subsidiary in the ordinary course of business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness secured by a lien permitted by the provisions regarding limitations on liens or arising in respect
of a sale and lease-back transaction permitted by the provisions regarding such transactions, or any Indebtedness incurred to finance the purchase price or cost of construction of improvements with respect to certain property or assets acquired
after the date of the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness that is issued, assumed or guaranteed in connection with compliance by a Restricted Subsidiary
with the requirements of any program, applicable to such Restricted Subsidiary, adopted by any governmental authority that provides for financial or tax benefits which are not available directly to Cardinal Health; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness arising from Rate Hedging Obligations incurred to limit risks of currency or interest rate
fluctuations to which a Subsidiary is otherwise subject by virtue of the operations of its business, and not for speculative purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness incurred by any Financing Subsidiary; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indebtedness incurred in connection with refinancing of any Indebtedness described in clauses (a), (b), (f),
(g), and (i)&nbsp;above (the &#8220;<U>Refinancing Indebtedness</U>&#8221;), provided that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the principal amount of the Refinancing Indebtedness does not exceed the principal amount of the Indebtedness
refinanced (plus the premiums paid and expenses incurred in connection therewith), </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Refinancing Indebtedness has a weighted average life to maturity equal to or greater than the weighted
average life to maturity of the Indebtedness being refinanced, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Refinancing Indebtedness ranks no more senior, and is at least as subordinated in right of payment, as the
Indebtedness being refinanced. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing restrictions, Restricted Subsidiaries may incur any
Indebtedness for borrowed money that would otherwise be subject to the foregoing restrictions in an aggregate principal amount which, together with the aggregate principal amount of other Indebtedness (not including the Indebtedness permitted
above), does not, at the time such Indebtedness is incurred, exceed 20% of Net Worth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>Limitation on Sale and Lease-Back
Transactions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sale and lease-back transactions (except those transactions involving leases for less than three years) by Cardinal
Health or any Consolidated Subsidiary of any assets are prohibited unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cardinal Health or the Consolidated Subsidiary would be entitled to incur Indebtedness secured by a lien on the
assets to be leased in an amount at least equal to the Attributable Debt with respect to such transaction without equally and ratably securing the notes; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proceeds of the sale of the assets to be leased are at least equal to their fair value as determined by
Cardinal Health&#8217;s board of directors and the proceeds are applied to the purchase or acquisition (or, in the case of real property, the construction) of assets or to the retirement of Senior Funded Indebtedness. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing limitation will not apply if at the time Cardinal Health or any Consolidated Subsidiary enters into such sale and lease-back
transaction, immediately after giving effect thereto, Exempted Debt does not exceed 20% of Net Worth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>Merger, Consolidation, Sale,
Lease or Conveyance </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cardinal Health will not merge or consolidate with any other corporation and will not sell, lease or convey
all or substantially all its assets to any person, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cardinal Health will be the continuing corporation; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a) the successor corporation or person that acquires all or substantially all of Cardinal Health&#8217;s assets
is a corporation, partnership, limited liability company, business trust, trust or other legal entity organized under the laws of the United States or a State thereof or the District of Columbia; and (b)&nbsp;the successor corporation or person
expressly assumes all of Cardinal Health&#8217;s obligations under the indenture and the debt securities; and (c)&nbsp;immediately after such merger, consolidation, sale, lease or conveyance, the successor corporation or person is not in default in
the performance of the covenants and conditions of the indenture to be performed or observed by Cardinal Health. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Modification of the Indenture </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cardinal Health and the trustee cannot modify the indenture or any supplemental indenture or the rights of the holders of the debt securities
without the consent of holders of at least a majority of the principal amount of the outstanding debt securities of each series affected by the modification. Cardinal Health and the trustee cannot modify the indenture without the consent of the
holder of each outstanding debt security of such series affected by such modification to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">extend the final maturity of any of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reduce the principal amount; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reduce the rate or extend the time of payment of interest; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reduce any amount payable on redemption; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reduce the amount of the principal of an Original Issue Discount Security that would be due and payable upon an
acceleration of the maturity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reduce the amount of an Original Issue Discount Security provable in bankruptcy; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">impair or affect the right of any holder of the debt securities to institute suit for payment.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the consent of all holders of the debt securities is required to reduce the percentage of consent required
to effect any modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cardinal Health and the trustee may modify the indenture or enter into supplemental indentures without the
consent of the holders of the debt securities, in certain cases, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to convey, transfer, assign, mortgage or pledge to the trustee as security for the debt securities any property
or assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to evidence the succession of another corporation, partnership, limited liability company, business trust,
trust or other legal entity to Cardinal Health and the assumption by the successor corporation, partnership, limited liability company, business trust, trust or other legal entity of the covenants, agreements and obligations of Cardinal Health;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to add to Cardinal Health&#8217;s covenants any further covenants, restrictions, conditions or provisions
considered to be for the protection of the holders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to cure any ambiguity or to correct or supplement any provision contained in the indenture which may be
defective or inconsistent with any other provision contained in the indenture or to make such other provisions in regard to matters or questions arising under the indenture that will not adversely affect the interests of the holders of the debt
securities in any material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to establish the form or terms of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to evidence or provide for the acceptance of appointment by a successor trustee and to add to or change any of
the provisions of the indenture that may be necessary to provide for or facilitate the administration of the trusts created thereunder by more than one trustee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to add to or change any of the provisions of the indenture to such extent as may be necessary to permit or
facilitate the issuance of debt securities in bearer form, registrable or not registrable as to principal, and with or without interest coupons, or to permit or facilitate the issuance of debt securities in uncertificated form;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to supplement any of the provisions of the indenture to such extent as is necessary to permit or facilitate the
defeasance and discharge of any series of debt securities, provided that any such action will not adversely affect the interests of any holder of an outstanding debt security of such series or any other outstanding debt security in any material
respect; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to amend or supplement any provision contained in the indenture or in any supplemental indenture, provided that
no such amendment or supplement will materially adversely affect the interests of the holders of any debt securities then outstanding. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following constitute events of default under the indenture with respect to each series of debt securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">failure to pay principal of and premium, if any, on any debt securities of such series when due;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">failure to pay interest on any debt securities of such series when due for 30 days; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">failure to perform any other covenant or agreement of Cardinal Health in respect of the debt securities of such
series for 90 days after written notice to Cardinal Health specifying that such notice is a &#8220;notice of default&#8221; under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">failure to pay any sinking fund installment when due on any debt securities of such series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">certain events of bankruptcy or insolvency of Cardinal Health; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other event of default provided in the supplemental indenture or resolutions of Cardinal Health&#8217;s
board of directors under which such debt securities are issued or in the form of debt security for such series. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an
event of default occurs and is continuing due to the default in the performance or breach of clauses (1), (2), (3), (4) or (6)&nbsp;above with respect to any series of debt securities but not with respect to all outstanding debt securities issued,
either the trustee or the holders of not less than 25% in principal amount of the outstanding debt securities of each affected series (each series voting as a separate class) may declare the principal amount and interest accrued of all such affected
series of the debt securities to be due and payable immediately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default occurs and is continuing due to a default in the
performance of any of the covenants or agreements in the indenture applicable to all outstanding debt securities issued and then outstanding or due to certain events of bankruptcy or insolvency of Cardinal Health, either the trustee or the holders
of not less than 25% in principal amount of all debt securities issued (treated as one class) may declare the principal amount and interest accrued of all such debt securities to be due and payable immediately. However, such declarations may be
annulled and any defaults may be waived upon the occurrence of certain conditions, including deposit by Cardinal Health with the trustee of a sum sufficient to pay all matured installments of interest and principal and certain expenses of the
trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A default by Cardinal Health with respect to any Indebtedness other than the debt securities will not constitute an event of
default with respect to the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trustee may withhold notice to the holders of any series of debt securities of any
default (except in payment of principal of, or interest on, or in the payment of any sinking or purchase fund installment) if the trustee considers it in the interest of such holders to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the provisions for indemnity and certain other limitations contained in the indenture, the holders of a majority in principal
amount of each series of the debt securities then outstanding will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No holder of the debt securities of a series may institute any action against Cardinal Health under the indenture unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that holder gives to the trustee advance written notice of default and its continuance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the holders of not less than 25% in aggregate principal amount of the debt securities of such series then
outstanding affected by that event of default request the trustee to institute such action; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that holder or holders has offered the trustee reasonable indemnity as it may require; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the trustee has not instituted such action within 60 days of such notice, request and offer of indemnity; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the trustee has not, during such <FONT STYLE="white-space:nowrap">60-day</FONT> period, received direction
inconsistent with such written request by the holders of a majority in aggregate principal amount of the debt securities of each affected series then outstanding. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time prior to the evidencing to the trustee of the taking of any action by the holders of the percentage in aggregate principal amount
of the debt securities of any or all series specified in the indenture in connection </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with such action, any holder of a debt security may, by filing written notice with the trustee, revoke such action concerning such security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cardinal Health is required to deliver to the trustee each year a certificate as to whether or not, to the knowledge of the officers signing
such certificate, Cardinal Health is in compliance with the conditions and covenants under the indenture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Satisfaction and Discharge
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture provides that Cardinal Health will be discharged from all obligations under the indenture and the indenture will cease
to be of further effect when: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cardinal Health has paid all sums payable by it under the indenture; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cardinal Health has delivered to the trustee for cancellation all authenticated debt securities; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all the debt securities not delivered to the trustee for cancellation have become due and payable or are by
their terms to become due and payable within one year or are to be called for redemption within one year under arrangements satisfactory to the trustee, and Cardinal Health has irrevocably deposited with the trustee as trust funds an amount in cash
sufficient to pay the principal and interest at maturity or upon redemption of such debt securities not previously delivered to the trustee for cancellation and paid all other sums payable with respect to such debt securities; and
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the trustee, on demand of and at the expense of Cardinal Health and upon compliance by Cardinal Health with certain conditions, will
execute proper instruments acknowledging satisfaction and discharge of the indenture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Defeasance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#8220;defeasance,&#8221; as used in the indenture, means discharge from some or all of our obligations under the indenture. If we
deposit with the trustee sufficient cash or government securities to pay the principal, any premium, interest and any other sums due at maturity or on a redemption date of the securities of a particular series, then at our option: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">we will be discharged from our obligations with respect to the securities of such series; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">we will no longer be under any obligation to comply with certain restrictive covenants under the indenture, and
certain events of default will no longer apply to us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this happens, the holders of the securities of the affected
series will not be entitled to the benefits of the indenture except for registration of transfer and exchange of debt securities and replacement of lost, stolen or mutilated securities. Such holders may look only to such deposited funds or
obligations for payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To exercise such option, we are required to deliver to the Trustee an opinion of counsel to the effect that the
deposit and related defeasance would not cause the holders of the securities to recognize income, gain or loss for federal income tax purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Form and Denomination of Debt Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>Denomination of Debt Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, the debt securities will be denominated in U.S. dollars, in minimum
denominations of $1,000 and integral multiples thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>Registered Form </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cardinal Health may issue the debt securities in registered form, in which case Cardinal Health may issue them either in book-entry form only
or in &#8220;certificated&#8221; form. Cardinal Health will issue registered debt securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in book-entry form only, unless it specifies otherwise in the applicable prospectus supplement. Debt securities issued in book-entry form will be represented by global securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Holders of Registered Debt Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>Book-Entry Holders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cardinal Health will issue registered debt securities in book-entry form only, unless Cardinal Health specifies otherwise in the applicable
prospectus supplement. Debt securities held in book-entry form will be represented by one or more global securities registered in the name of a depositary or its nominee. The depositary or its nominee will hold such global securities on behalf of
financial institutions that participate in such depositary&#8217;s book-entry system. These participating financial institutions, in turn, hold beneficial interests in the global securities either on their own behalf or on behalf of their customers.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the indenture, only the person in whose name a debt security is registered is recognized as the holder of that debt security.
Consequently, for debt securities issued in global form, Cardinal Health will recognize only the depositary or its nominee as the holder of the debt securities, and Cardinal Health will make all payments on the debt securities to the depositary or
its nominee. The depositary will then pass along the payments that it receives to its participants, which in turn will pass the payments along to their customers who are the beneficial owners of the debt securities. The depositary and its
participants do so under agreements they have made with one another or with their customers or by law; they are not obligated to do so under the terms of the debt securities or the terms of the indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, investors will not own debt securities directly. Instead, they will own beneficial interests in a global security, through a
bank, broker or other financial institution that participates in the depositary&#8217;s book-entry system, or that holds an interest through a participant in the depositary&#8217;s book-entry system. As long as the debt securities are issued in
global form, investors will be indirect holders, and not holders, of the debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>Street Name Holders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Cardinal Health issues debt securities in certificated form, or in the event that a global security is terminated, investors
may choose to hold their debt securities either in their own names or in &#8220;street name.&#8221; Debt securities held in street name are registered in the name of a bank, broker or other financial institution chosen by the investor, and the
investor would hold a beneficial interest in those debt securities through the account that he or she maintains at such bank, broker or other financial institution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For debt securities held in street name, Cardinal Health will recognize only the intermediary banks, brokers and other financial institutions
in whose names the debt securities are registered as the holders of those debt securities, and Cardinal Health will make all payments on those debt securities to them. These institutions will pass along the payments that they receive from Cardinal
Health to their customers who are the beneficial owners pursuant to agreements that they have entered into with such customers or by law; they are not obligated to do so under the terms of the debt securities or the terms of the indenture. Investors
who hold debt securities in street name will be indirect holders, and not holders, of the debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>Registered Holders
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cardinal Health&#8217;s obligations, as well as the obligations of the trustee and those of any third parties employed by the
trustee or Cardinal Health, run only to the registered holders of the debt securities. Cardinal Health does not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means and who
are, therefore, not the registered holders of the debt securities. This will be the case whether an investor chooses to be an indirect holder of a debt security, or has no choice in the matter because Cardinal Health is issuing the debt securities
only in global form. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, once Cardinal Health makes a payment or gives a notice to the registered holder
of the debt securities, Cardinal Health has no further responsibility with respect to such payment or notice even if that registered holder is required, under agreements with depositary participants or customers or by law, to pass it along to the
indirect holders but does not do so. Similarly, if Cardinal Health wants to obtain the approval of the holders for any purpose (for example, to amend an indenture or to relieve Cardinal Health of the consequences of a default or of our obligation to
comply with a particular provision of an indenture), Cardinal Health would seek the approval only from the registered holders, and not the indirect holders, of the debt securities. Whether and how the registered holders contact the indirect holders
is up to the registered holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, when Cardinal Health refers to &#8220;you&#8221; or &#8220;your&#8221; in
this prospectus, Cardinal Health is referring to investors who invest in the debt securities being offered by this prospectus, whether they are the registered holders or only indirect holders of the debt securities offered. When Cardinal Health
refers to &#8220;your debt securities&#8221; in this prospectus, Cardinal Health means the series of debt securities in which you hold a direct or indirect interest. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>Special Considerations for Indirect Holders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold debt securities through a bank, broker or other financial institution, either in book-entry form or in street name, Cardinal Health
urges you to check with that institution to find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it handles securities payments and notices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether it imposes fees or charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would handle a request for its consent, as a registered holder of the debt securities, if ever required;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if permitted for a particular series of debt securities, whether and how you can instruct it to send you debt
securities registered in your own name so you can be a registered holder of such debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would exercise rights under the debt securities if there were a default or other event triggering the need
for holders to act to protect their interests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the debt securities are in book-entry form, how the depositary&#8217;s rules and procedures will affect these
matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security represents one or any other number of individual debt securities. Generally, all debt securities represented by the same
global securities will have the same terms. Each debt security issued in book-entry form will be represented by a global security that Cardinal Health deposits with and registers in the name of a financial institution or its nominee that Cardinal
Health selects. The financial institution that Cardinal Health selects for this purpose is called the depositary. Unless Cardinal Health specifies otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, New York,
known as DTC, will be the depositary for all debt securities that Cardinal Health issues in book-entry form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security may not be
transferred to or registered in the name of anyone other than the depositary or its nominee, unless special termination situations arise. Cardinal Health describes those situations below under &#8220;&#8212; Special Situations When a Global Security
Will Be Terminated.&#8221; As a result of these arrangements, the depositary, or its nominee, will be the sole registered holder of all debt securities represented by a global security, and investors will be permitted to own only beneficial
interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account either with the depositary or with another institution that has an account with
the depositary. Thus, an investor whose security is represented by a global security will not be a registered holder of the debt security, but an indirect holder of a beneficial interest in the global security. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>Special Considerations for Global Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an indirect holder, an investor&#8217;s rights relating to a global security will be governed by the account rules of the investor&#8217;s
financial institution and of the depositary, as well as general laws relating to securities transfers. The depositary that holds the global security will be considered the registered holder of the debt securities represented by such global security.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If debt securities are issued only in the form of a global security, an investor should be aware of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An investor cannot cause the debt securities to be registered in his or her name, and cannot obtain <FONT
STYLE="white-space:nowrap">non-global</FONT> certificates for his or her interest in the debt securities, except in the special situations we describe below under &#8220;&#8212; Special Situations When a Global Security Will Be Terminated.&#8221;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An investor will be an indirect holder and must look to his or her own bank or broker for payments on the debt
securities and protection of his or her legal rights relating to the debt securities, as we describe under &#8220;&#8212; Holders of Registered Debt Securities&#8221; above. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An investor may not be able to sell his or her interest in the debt securities to some insurance companies and
other institutions that are required by law to own their securities in <FONT STYLE="white-space:nowrap">non-book-entry</FONT> form. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An investor may not be able to pledge his or her interest in the debt securities in circumstances where
certificates representing the debt securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary&#8217;s policies, which may change from time to time, will govern payments, transfers, exchanges
and other matters relating to an investor&#8217;s interest in the debt securities. Neither the trustee nor Cardinal Health have any responsibility for any aspect of the depositary&#8217;s actions or for the depositary&#8217;s records of ownership
interests in a global security. Additionally, neither the trustee nor Cardinal Health supervise the depositary in any way. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DTC requires that those who purchase and sell interests in a global security that is deposited in its book-entry
system use immediately available funds. Your broker or bank may also require you to use immediately available funds when purchasing or selling interests in a global security. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Financial institutions that participate in the depositary&#8217;s book-entry system, and through which an
investor holds its interest in a global security, may also have their own policies affecting payments, notices and other matters relating to the debt security. There may be more than one financial intermediary in the chain of ownership for an
investor. Cardinal Health does not monitor and is not responsible for the actions of any of such intermediaries. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>Special Situations When a Global Security Will Be Terminated </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a few special situations described below, a global security will be terminated and interests in the global security will be exchanged for
certificates in <FONT STYLE="white-space:nowrap">non-global</FONT> form, referred to as &#8220;certificated&#8221; debt securities. After such an exchange, it will be up to the investor as to whether to hold the certificated debt securities directly
or in street name. Cardinal Health has described the rights of direct holders and street name holders under &#8220;&#8212; Holders of Registered Debt Securities&#8221; above. Investors must consult their own banks or brokers to find out how to have
their interests in a global security exchanged on termination of a global security for certificated debt securities to be held directly in their own names. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The special situations for termination of a global security are as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the depositary notifies Cardinal Health that it is unwilling, unable or no longer qualified to continue as
depositary for that global security, and Cardinal Health does not appoint another institution to act as depositary within 90 days of such notification; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if Cardinal Health notifies the trustee that it wishes to terminate that global security; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an event of default has occurred with regard to the debt securities represented by that global security and
such event of default has not been cured or waived. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement may list situations for
terminating a global security that would apply only to the particular series of debt securities covered by such prospectus supplement. If a global security were terminated, only the depositary, and not Cardinal Health or the trustee, would be
responsible for deciding the names of the institutions in whose names the debt securities represented by the global security would be registered and, therefore, who would be the registered holders of those debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and Transfer of Registered Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cease to issue registered debt securities in global form, we will issue them: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">only in fully registered certificated form; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unless otherwise indicated in the applicable prospectus supplement, in denominations of $1,000 and amounts that
are multiples of $1,000. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders may exchange their certificated securities for debt securities of smaller
denominations or combined into fewer debt securities of larger denominations, as long as the total principal amount is not changed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders may exchange or transfer their certificated securities at the trustee&#8217;s office. Cardinal Health has appointed the trustee to act
as its agent for registering debt securities in the names of holders transferring debt securities. Cardinal Health may appoint another entity to perform these functions or perform them itself. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders will not be required to pay a service charge to transfer or exchange their certificated securities, but they may be required to pay
any tax or other governmental charge associated with the transfer or exchange. The transfer or exchange will be made only if Cardinal Health&#8217;s transfer agent is satisfied with the holders proof of legal ownership. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Cardinal Health has designated additional transfer agents for your debt security, they will be named in the applicable prospectus
supplement. Cardinal Health may appoint additional transfer agents or cancel the appointment of any particular transfer agent. Cardinal Health may also approve a change in the location of the office through which any transfer agent acts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any certificated securities of a particular series are redeemable and Cardinal Health redeems less than all the debt securities of that
series, Cardinal Health may block the transfer or exchange of those debt securities during the period beginning 15 days before the day Cardinal Health mails the notice of redemption and ending on the day of that mailing, in order to freeze the list
of holders to prepare the mailing. Cardinal Health may also refuse to register transfers or exchanges of any certificated securities selected for redemption, except that Cardinal Health will continue to permit transfers and exchanges of the
unredeemed portion of any debt security that will be partially redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a registered debt security is issued in global form, only the
depositary will be entitled to transfer and exchange the debt security as described in this subsection because it will be the sole holder of the debt security. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Payment and Paying Agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On each due date for interest payments on the debt securities, Cardinal Health will pay interest to each person shown on the trustee&#8217;s
records as owner of the debt securities at the close of business on a designated day that is in advance of the due date for interest. Cardinal Health will pay interest to each such person even if such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
person no longer owns the debt security on the interest due date. The designated day on which Cardinal Health will determine the owner of the debt security, as shown on the trustee&#8217;s
records, is also known as the &#8220;record date.&#8221; The record date will usually be about two weeks in advance of the interest due date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because Cardinal Health will pay interest on the debt securities to the holders of the debt securities based on ownership as of the applicable
record date with respect to any given interest period, and not to the holders of the debt securities on the interest due date (that is, the day that the interest is to be paid), it is up to the holders who are buying and selling the debt securities
to work out between themselves the appropriate purchase price for the debt securities. It is common for purchase prices of debt securities to be adjusted so as to prorate the interest on the debt securities fairly between the buyer and the seller
based on their respective ownership periods within the applicable interest period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>Payments on Global Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cardinal Health will make payments on a global security by wire transfer of immediately available funds directly to the depositary, or its
nominee, and not to any indirect holders who own beneficial interests in the global security. An indirect holder&#8217;s right to those payments will be governed by the rules and practices of the depositary and its participants, as described under
&#8220;&#8212; Global Securities&#8221; above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>Payments on Certificated Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cardinal Health will make interest payments on debt securities held in certificated form by mailing a check on each due date for interest
payments to the holder of the certificated securities, as shown on the trustee&#8217;s records, as of the close of business on the record date. Cardinal Health will make all payments of principal and premium, if any, on the certificated securities
by check at the office of the trustee in New York City, New York, and/or at other offices that may be specified in the applicable prospectus supplement or in a notice to holders, against surrender of the certificated security. All payments by check
will be made in <FONT STYLE="white-space:nowrap">next-day</FONT> funds (that is, funds that become available on the day after the check is cashed). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alternatively, if a certificated security has a face amount of at least $10,000,000, and the holder of such certificated security so requests,
Cardinal Health will pay any amount that becomes due on such certificated security by wire transfer of immediately available funds to an account specified by the holder at a bank in New York City, New York, on the applicable due date for payment. To
request payment by wire transfer, the holder must give appropriate transfer instructions to the trustee or other paying agent at least 15 business days before the requested wire payment is due. In the case of any interest payments, the instructions
must be given by the person who is shown on the trustee&#8217;s records as the holder of the certificated security on the applicable record date. Wire instructions, once properly given, will remain in effect unless and until new instructions are
given in the manner described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>Payment When Offices Are Closed </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If payment on a debt security is due on a day that is not a business day, Cardinal Health will make such payment on the next succeeding
business day. The indenture will provide that such payments will be treated as if they were made on the original due date for payment. A postponement of this kind will not result in a default under any debt security or indenture, and no interest
will accrue on the amount of any payment that is postponed in this manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Book-entry and other indirect holders should consult their
banks or brokers for information on how they will receive payments on their debt securities. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture is governed by New York law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>The Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trustee under the indenture is The Bank of New York Mellon Trust Company, N.A. The trustee serves as trustee for Cardinal Health&#8217;s
3.750% Notes due 2025, 4.700% Notes due 2026, 3.410% Notes due 2027, 5.125% Notes due 2029, 5.000% Notes due 2029, 5.450% Notes due 2034, 5.350% Notes due 2034, 4.600% Notes due 2043, 4.500% Notes due 2044, 4.900% Notes due 2045, 4.368% Notes due
2047 and 5.750% Notes due 2054. The trustee also serves as trustee for Allegiance Corporation&#8217;s 7.000% Debentures due 2026, which are guaranteed by Cardinal Health. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx42072_9"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of certain provisions of the units is not complete and is subject to, and qualified in its entirety by reference to, the
provisions of the unit agreement that will be filed with the SEC in connection with the offering of such units. You should refer to the provisions of the applicable unit agreement and applicable prospectus supplement for more specific information
about the units we offer. If any particular terms of the units described in the applicable prospectus supplement differ from any of the terms described herein, then the terms described herein will be deemed superseded by that prospectus supplement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units comprised of one or more common shares, preferred shares and debt securities in any combination. Each unit will be
issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued
may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement may describe: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of the units and of the securities comprising the units, including whether and under
what circumstances those securities may be held or transferred separately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions of the governing unit agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities
comprising the units; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the units offered thereunder. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx42072_10"></A>VALIDITY OF THE SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the offered securities will be passed upon for us by White&nbsp;&amp; Case LLP, New York, New York and Patrick Pope of
Cardinal Health. Mr.&nbsp;Pope is paid a salary by Cardinal Health and participates in various employee benefit plans offered to Cardinal Health&#8217;s employees generally. Mr.&nbsp;Pope holds equity incentive awards with respect to Cardinal
Health&#8217;s common shares valued at greater than $50,000. Certain legal matters with respect to the offered securities may be passed upon by counsel for any underwriters, dealers or agents, each of whom will be named in the related prospectus
supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx42072_11"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Cardinal Health, Inc. and subsidiaries appearing in Cardinal Health, Inc.&#8217;s Annual Report (Form
<FONT STYLE="white-space:nowrap">10-K)</FONT> for the year ended June&nbsp;30, 2025 (including the schedule appearing therein) and the effectiveness of Cardinal Health Inc. and subsidiaries&#8217; internal control over financial reporting as of
June&nbsp;30, 2025, have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their reports thereon, included therein, and incorporated herein by reference. Such consolidated financial statements
and Cardinal Health, Inc. management&#8217;s assessment of the effectiveness of internal control over financial reporting as of June&nbsp;30, 2025 are, and audited consolidated financial statements and Cardinal Health, Inc. management&#8217;s
assessment of internal control over financial reporting to be included in subsequently filed documents will be, incorporated herein in reliance upon the reports of Ernst&nbsp;&amp; Young LLP pertaining to such consolidated financial statements and
the effectiveness of our internal control over financial reporting as of the respective dates (to the extent covered by consents filed with the SEC) given on the authority of such firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx42072_12"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cardinal Health may sell the offered securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the solicitation of proposals of underwriters or dealers to purchase the offered securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through underwriters or dealers on a negotiated basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to institutional investors </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to a limited number of purchasers or to a single purchaser; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through agents; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a combination of any of these methods of sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The distribution of the securities may be made from time to time in one or more transactions, either: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to prevailing market prices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices determined by an auction process; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement with respect to any offered securities will set forth the terms of the offering, including the name or names of any
underwriters, dealers or agents, the purchase price of the offered securities and the proceeds to Cardinal Health from such sale, any underwriting discounts and commissions and other items constituting underwriters&#8217; compensation, any initial
public offering price and any discounts or concessions allowed or reallowed or paid to dealers, and any securities exchange on which such offered securities may be listed. Any initial public offering price, discounts or concessions allowed or
reallowed or paid to dealers may be changed from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be offered and sold through agents that we may
designate from time to time. Unless otherwise indicated in the applicable prospectus supplement, any such agent will be acting on a best efforts basis for the period of its appointment. Any such agent may be deemed to be an underwriter, as that term
is defined in the Securities Act, of any securities so offered and sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an underwriter or underwriters are utilized in the sale of
any offered securities, Cardinal Health will execute an underwriting agreement with such underwriter or underwriters, and the names of the underwriter or underwriters and the terms of the transactions, including commissions, discounts, and any other
compensation of the underwriters and dealers, if any, will be set forth in the prospectus supplement that will be used by the underwriters to make resales of the offered securities. Such underwriter or underwriters will acquire the offered
securities for their own account and may resell such offered securities from time to time in one or more transactions, including negotiated transactions, at fixed public offering prices or at varying prices determined at the time of sale. The
securities may be offered to the public either through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. If any underwriter or underwriters are utilized in the sale of any offered securities, unless
otherwise set forth in the applicable prospectus supplement, the underwriting agreement will provide that the obligations of the underwriters will be subject to certain conditions precedent and that the underwriters with respect to a sale of such
offered securities will be obligated to purchase all such offered securities if any are purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If so indicated in the prospectus
supplement or term sheet relating to a particular series or issue of offered securities, we will authorize underwriters, dealers or agents to solicit offers by certain institutions to purchase the offered securities from us under delayed delivery
contracts providing for payment and delivery at a future date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
These contracts will be subject only to those conditions set forth in the prospectus supplement or term sheet, and the prospectus supplement or term sheet will set forth the commission payable
for solicitation of these contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a dealer is utilized in the sale of any offered securities, Cardinal Health will sell such
offered securities to the dealer, as principal. The dealer may then resell such offered securities to the public at varying prices to be determined by such dealer at the time of resale. Any such dealer may be deemed to be an underwriter, as such
term is defined in the Securities Act, of the securities so offered and sold. The name of any such dealer and the terms of the transaction will be set forth in a prospectus supplement relating thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Offers to purchase securities may be solicited directly by Cardinal Health and sales thereof may be made by Cardinal Health directly to
institutional investors or others, who may be deemed to be underwriters, as such term is defined in the Securities Act, with respect to any resale of the offered securities. The terms of any such sales will be described in a prospectus supplement
relating thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cardinal Health may indemnify its agents, dealers and underwriters against certain civil liabilities, including
liabilities under the Securities Act, or contribute to payments which such agents, dealers or underwriters may be required to make in respect thereof. Agents, dealers and underwriters may be customers of, engage in transactions with, or perform
services for us in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, all securities
offered by this prospectus, other than Cardinal Health&#8217;s common shares, which are listed on the New York Stock Exchange, will be new issues with no established trading market. Cardinal Health may elect to list any series of securities on an
exchange, and in the case of Cardinal Health&#8217;s common shares, on any additional exchange, but, unless otherwise specified in the applicable prospectus supplement, Cardinal Health shall not be obligated to do so. In addition, underwriters will
not be obligated to make a market in any securities. No assurance can be given regarding the activity of trading in, or liquidity of, any securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in over-allotment, stabilizing transactions, short covering transactions and penalty bids in accordance with
Regulation M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which creates a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed
a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer
when the securities originally sold by the dealer are purchased in a covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may
discontinue any of those activities at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$&#8195;&#8195;&#8195;&#8195; </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g42072g04p81.jpg" ALT="LOGO" STYLE="width:2.51151in;height:0.983382in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Cardinal Health, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$&#8195;&#8195; &#8195;% Notes due 20&#8195; </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$&#8195;&#8195; &#8195;% Notes due 20&#8195; </B></P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Joint Book-Running Managers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Goldman Sachs&nbsp;&amp; Co. LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>BofA Securities </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Wells
Fargo Securities </B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement dated&nbsp;&#8195;&#8195;&#8195;&#8195;, 2025 </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g42072g01a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42072g01a10.jpg
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M47BW&"0R-#AA=79Y@;@9)3,W.E)467%SLW>8LK75_\0 '0$!  $% 0$!
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MR)G!1)T>\TBQ1RP$42 ZB7N]<:O#I;.R&QBK3*M\C=TV+G?C<@-NYFK@1NE
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M<RY8M\4=61O$ :&^\3TM'P16J)<X1.DA#'":,\T[N5JL&PKO5+J3GW3/%4B
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MZ5C^V_1>%$/Y#_X\EL!_&$ ']S+U 'T#U#=KH #_ #@ Y^;U#U_H'T#U_I]
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M\5QJR:?"0LO&VUG&3[A7/]%KK*.B)6PQ_P"=.X^#4<J.EC3+IVZ*MX)BW?\
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MV9UTBNET4!("RR+<3@LJDB*A 54(0Q$Q.0#B F#U(N0(@4!,80 H (B(B
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M7[8C]=1RJ03OJJG []MNO3O]P]/P]%#]2982ET\N&<RFE]4<VB:-K] HM.[
M2C2I0V']TB8C$YKKL=+W2/5L,>72FED=OK-F.O1\)=[8=6^U;29J(=K%(XK+
M8A'7H._7;T_#\1]RX]MM4!;;QD26J.NL/4?*U.G^-ZGF6)]I<P;3F?Q.L;!,
MZ-(;A%UNLOM*PRF3&FY-'1F>5J33>PLE9*:VO,J\:1D(UTN;:2A-N^VYZD=/
M3IL>Q[_QV4W9KUJQ=AJ%U::#%DU#*.G/63 NO583TV/C;-7BSE8KUTTV_7-[
M5E(\M1>6-3/;EE#6.>M(1(M7CSS<164HN+FW;$Y1N3T^>_3U/HHYQ_,\SF;5
MXP,ZV^F9Z]G:YT?O]M@*UHT+6I*2#1PC^O"<;3*.E9&[EW+IYE4Y+4!<0L65
M5Q 1+2"FEDD4FWSIE/KL3W[_ 'GJ?GVV^]<.LVW-UX[#D.R-HKE.Z^[TIVY[
M82;?19=G7:AK]AN.XPD_@N;6U:77:QEN8UK$M$&5+E<B1T-Y<5FL3*4+),Z#
M+M0)Z[#MMZ]/4@?7S\OD5R\,AH*WGRAQ4\V_@RK&\^1';=GGLY)4D*2K!T'J
M;0K=C5$EY:J-63 E9E'V@X3@%GD(.08M91A(SRS>410FV[DI2'Z]FC;[]CM\
M]MS_ **S78BI8_HG<GI]2]=J^;6!JVSWLY?J>AH,'5Y5:;OE>'%Z?$5>NI61
MJN:5=_I+1]!MCN&BOJ'*!:NUFUF8)QR;UH4#?8D;^7;TZGK]X'WJG$>ID.GX
MO Q#5*H6CR0WW4ZM+VU,J$7)=@\/V&+U1E)6B9GEA*I=LYQ_KQ!-Y./@59%6
M'IL[E</!5&NGL:FF0<9;BJZ@_P!7]1'EVV!)]>_GY=+J=M+'GB&J=?:9V$L%
M:JO62P0^PV6[.] E8^OY?<M7IZN7L\BRS196=7;5F3@YZ!MNLWYA2;$O^76B
MQ9;#N3MWPP/T#DJ1Y[=^FVWSW_Y#[_HH5M5EZBLMB2J5V4Q^/ZW0N(4'7L'R
MVNQM97SSL/J&G7?4XVXV*FYU7&J\5V NE,BZ'FR%(KU7B+1*Q,WJ9)P(9S.6
M2@2K4IZ[=-]]]C\@.WT'4]^G3Y*+\%QNE[/$=(*3=LTCH[.9*$[7]\[)D;B+
MB3U"(MFO::T<Y?G]O@(]-2M3,1!0/8_1$XR+.#V)5>9PR,"3IFU3$Q-^Y'HT
M;_3;MZ=6C;Y+Y]<*34-POE9E]2VCKPGV A=NGM2MN90M$8QO;RF3N8WB=<UW
M)75RL&J3MCJ>2T"$;1M+-$U7*JS$WC, .NE+C&Z78I:T$.X'8[;#SZ=NO\>1
>Z_(;K?0/O]@^_P#+]@^_W]?O_O$1_P#4?7A4K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g42072g04p81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42072g04p81.jpg
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M\@,!(@ "$0$#$0'_Q  =  $  P$!  ,!            !@<(!00" PD!_\0
M61   0,# 00%!P8)!0X%! ,  0 " P0%!A$'$B$Q"!-!46$4(C=Q@9&A,D)R
M=;&S%2-28G-TDK+!-#:"HM(6%Q@E,S5#1%-55I31X9.TPL/P5&.5TR1D\?_$
M !H! 0$  P$!               ! @,$!0;_Q  [$0$  0(#!00) P$( P
M     0(#! 41$B$Q05$389&A!B(R<8&QP='P,U+A%",D-$)B<I*R@N+Q_]H
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M';<X-&KB .\K^@AP!!!!X@A<V*PVF(ZMMU*YWY3XP]WO.I71:UK&AK &M T
M T 5C7FTU11'LS^>,OZB(JP$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M(\=ZNE+G >#.8]1T4]Q_8Y8+?NON3Y[E,.8>>KC_ &6\?>2I%R[7[-.GO6K
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MLQNQ3'2/O]M4LR3;5<*G?BL%''1Q\A--I))ZP/DCXJ'TENRO.ZOK *VX<?\
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M;3<UAQ&T_BMV2Z5 (IXCV=[W> ^)]JS9!#<<CO89&):RXU<FI[7.<>9/</@
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M[R>Y:KUSLZ-IZ64X"<?B:;7+C/N_-R!7>X7/,LF=.YCYZVKD#(H6<=T=C1X
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MJBI\QHX:RD<0'55,SJY6>);\EWJ&BTY:+E1WBVTUPME0RIHZA@DBE8>#@?\
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M*"65VC:M@X-XGYXY$=O,:\5>2,1$7GEKJ6*L@I):F%E5."8H7/ >\ :D@<R
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M6C$12_2S>UFS&G:[F^Y1!OKW)#_!8^6D>E_D44DEEQV"0.EB+JRH:#\G4;K
M?'3?/M'>LW(RAO38IZ*<8_4V_P 5P.DYZ(;I^F@^]:N_L4]%.,?J;?XK@=)S
MT0W3]-!]ZU&+%2W'T=?0WCGT9OOY%AQ;CZ.OH;QSZ,WW\B++[.D%Z'\D_11_
M?,6&%N?I!>A_)/T4?WS%AA"&T>B]Z)*']8G_ 'RK853]%[T24/ZQ/^^5;"(P
M_P!(STQ9!ZX?N6+Z.C[Z8,;_ $LGW3U]_2,],60>N'[EB^CH^^F#&_TLGW3T
M9<FX:RIAHJ2>JJI&Q4\#'22/=R:UHU)/L"P]M;VGW7/+M,WKI:>QQO(IJ-IT
M! /![_RG'GX<AXZHV]U,M)LBR22 D.= V,D?DOD:UWP)6%42$ZV8[,;YM J)
M3;1'36^!P;-63Z[C3^2T#BYVG'0>TC4*[*'HQ6AD0%?D-?+)VF&%D8]QWE/.
MCM'2Q[(;":/=\]LCI2.9DZQV]KX\-/4 K'0U8;VX8'0[/\EHK;;:JIJHIZ05
M#G5&[O E[VZ#0#AYH7@V)>E;&/UQOV%2?I17J"[;3Y(*9X>VW4L=(\@ZC?U<
M]P]F_IZPHQL2]*V,?KC?L**WFL8]*3TLU7ZK!^Z5LY8QZ4GI9JOU6#]THD(E
MLB])^*_6,/[X6^U@39%Z3\5^L8?WPM]H2S/TROY1B?T:K[8E9/1I]#ME^G4?
M?/5;=,K^48G]&J^V)63T:?0[9?IU'WST.2ST1$11O2]]'MJ^M&?=2KX=$#^8
M5W^LW?=1KY]+WT>VKZT9]U*OAT0/YA7?ZS=]U&B\DNZ1+'/V.Y$&\PV%Q]0F
M9JLH[+, JMH5XJ[?0UU/1R4\'E!=,TD.&\&Z#3Z06U=H-G=?\'OMKC&LM51R
M,C'Y^Z2W^L LE]&F]LL>U6DBJG=7'<(GT)+N&CG$.:/:YC1[4(2O_!CO?_$%
MM_\ ">G^#'>_^(+;_P"$]:I1#5E;_!CO?_$%M_\ ">M#;.<?GQ7"K59*J>.H
MFHXRQTL8(:[SB>&O@5(T1%"=(S:Q68W,W&\:FZFXR1B2JJF_*A:?DL;W.(XZ
M]@(TXG45ILVV*7W.Z=M[O5<ZWV^I.^V:8&6>H_. )Y'\HGCW$*+[5'&X[9+\
MVM>6M?<S YQ[&!P8/ZH"W53014M-%3T[&QPQ,#&,:- UH&@ ]B+P4U0='##8
M(P*FHN]4_M+IVM'L#6C[5"-NNR7&,-P8W6R1U;:ORF.+66<O&Z[>UX:>"U J
M,Z7-RCI\#MMOWAU]77!X;VEC&.WC[W,]Z$/%T//YL9!^N,_<6@%G_H>?S8R#
M]<9^XM (2P_@OI_H?KM_WCEN!8?P7T_T/UV_[QRW A*M^D9Z&LB]4'_F(U57
M0W_SAE/Z*G^V16KTC/0UD7J@_P#,1JJNAO\ YPRG]%3_ &R(<FG5#ML?HMRG
M]0E^Q3%0[;'Z+<I_4)?L1% =#_\ GM>OJ[_W6+6"R?T/_P">UZ^KO_=8M8(L
MBP[M>].-X^L(_L:MQ+#NU[TXWCZPC^QJ$-Q(B(@B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B#QWBV4EXM=5;KE RHHZF,QRQNY.!_^<^Q8MVN[)KK@
ME=+4P,DK; ]VL56UNIC!/!LFG(^/(_ ;>7QEC9-$^*9C9(W@M<QPU#@>PA!^
M;'+DIG8MJ.:6*!L%MR*M;"T:-9,6S-:.X!X=H%J#*]@V&7Z5\]/33VFH=J2Z
MA>&L)^@06CV:*!5?1?:7DT>5$,[!+1:D>T/1=555VV;/ZV,LFR2H8T_[&**(
M^]C05U^CU=*NLVU6BHN%5/55$[)V.EGD+W._$O/$DZ]BGU+T7AO#RK*B6]HC
MH=#[R]6%L_V)8UAMVI[K!+75MS@U,<L\@#6$@M)#6@=A//5![=O6)3YAL[K*
M2@C,E?2O;64[!S>YH(+1XEKG >.BPV]KF.<U[2US3H01H05^E"K/:!L6Q?,:
MJ2NDCEMURDXOJ*0@=8>][2""?$:$]Z$2H#9QMVOF(6B&U5=)#=K? -V 2/,<
MD3?R0X ZM'8".'+71?/:!MYR'*[;+:Z"EAM-'.-R40O,DLC3S;OG30'P /BI
MR.B]!UVIRJ7JM>7D(WM/7O\ \%8N [&,5P^ICK(H);C<F'5E36$.ZL][&@!H
M/CQ/BAN8NO-IKK+7&CNM-)2U08R1T4@T<T/:'-U'8="."MOHER!FTVI:>;[;
M*!^W&?X*[=H.Q.Q9MDDMZKZ^XTU3+&QCVTY9NG=&@/%I.NFGN39]L5LN$9)%
M>;;<[E-.R-\?5SEFXX.&G'1H/BAJM-?G]M3])65?6=1]XY?H"J9R'H]X]?+]
M<;K4W6[1S5M0^H>R-T>ZUSG$D#5FNG%"%1=$[TH2_5TO[T:V&JQV<;&K-@>0
M.N]MN%QJ)W0.@W*@L+='$'7@T'7S0K.1!8YZ2> S8YEDU\HH2;/=)#)O-'"*
M<\7-/=J=7#UD=BV,O+=;=1W:WST-SIHJJCF;NR12MWFN'J0A^>F-7^Y8U>(+
MI9*I]+6PGS7MX@@\P0>!![BK:GZ26724!ACHK1%4$:>4-B>2/$-+R-?AX*PL
MBZ--AK*E\MDNU9;&N.O4R,$[&^ U(=IZR5YK/T9+3#.U]WO]95Q ZF."!L.O
M@22Y%W,[24U[RD7S(*ITM7Y*UL];52GM<\,:->\D\!W ]RX*WU5[.["_!*O$
MZ"F_!]LJ6@/-/IODAP.\7.UU=JT<3JJW_P &;&?]\7G]J+^PAJL#8BX.V48P
M1_\ 1M'N)7"Z3GHANGZ:#[UJG>&8]!BN,T%DHYIIZ>C:6,DFTWR"XNXZ #MT
M7GS[%*3-,9J+)<)YX*>9S'N? 1O#=<'#34$=B(_/=;CZ.OH;QSZ,WW\BAW^#
M-C/^^+S^U%_85MX1C=-B.+T-CH9IIJ:D#PR2;3?.\]SSKH .;CV(LRC/2"]#
M^2?HH_OF+#"_0_-,=ILLQBNLE=+-#3U;6M>^'3?&C@[AJ".851?X,V,_[XO/
M[47]A")=_HO>B2A_6)_WRK84<V?XE283C4-EMT\\]/&]\@?.1O$N.IY !2-$
M8?Z1GIBR#UP_<L7T='WTP8W^ED^Z>M'9QL,L67Y/6WRON5SAJ:K<WF0F/<&Z
MT-&FK2>0[U\,+V$6'$\FH;W0W.Z35%(YSF,F,>X=6EO'1H/(]Z+JL+-+&S)<
M3NUFD<&"MIWQ->>37$>:[V'0^Q?G[>;966:Z55NN<#Z>LIGF.6-PX@C^':#V
MA?HXH7M!V9XWG3&OO-*Z.M8W=964[MR5H[B="'#P(/@A$LG;+=K-[V?LEIJ1
MD5;;)7;[J2<D!KNUS'#Y).@UYCP4SR?I)7VXT$E-9;736J21NZ:@R&9[?%NH
M !]8*DM1T7Z8S$TV4S,BUX-DH@YP]H>/L4KP[H^XI8JF.JN3JB]5##JUM3HV
M$'OW!S]1)'@AN9*NMLN=-34ERN<,S([EORPRS?*F /G/X\2-3S[5(MBSQ'M4
MQ=SN1K6-]_#^*UOM-V6V?:!^#/PC45=&:!KV1^2[HU:[=X$%IX#=&FG>HK8.
MCUC]DOEONE+=[NZ>BJ(ZAC7NCW2YC@X ^9RX(:KH6,>E)Z6:K]5@_=*V<JMV
MA;%;)F^1R7FXW&XT]0^-D99 6;NC1H.;24(96V1>D_%?K&']\+?:IO&NC]CV
M/Y!;KO2W2ZR3T4[)V,D='NN+3J =&:Z*Y$)9GZ97\HQ/Z-5]L2LGHT^AVR_3
MJ/OGKI;4=F%KVB/MKKK65M,:$2!GDQ:-[?W===YI_)"[V!XM2X9C%+8[?-//
M34Y>6R3Z;YWG%QUT ',H.^B(B*-Z7OH]M7UHS[J5?#H@?S"N_P!9N^ZC5C[3
M,$H-H%EI[9=*FJIH8*@5+74Y:'%P:YNAW@>&CBOYLSP.@V?V:IMUKJJJIBGG
M-0YU06EP<6M;H-T#AYH14O6/>D-L\J\3RF3(K1'(+16S=<)(M1Y+.3J02.0)
MXM/CIV+82^FLI8*VEEIJR&.>GE:6212-#FO!["#P(1(45LQZ0=IK;?!19J]U
M#<8VAAK PNBF_..[Q:[OX:>(Y*QJK:K@U-3&>3)[:Y@&ND<G6._9;J?@H7DW
M1UQ2Z3OGM<];:'N.O5Q.$D0]37<1^UHH]#T8*$2 S9/4N9VAM(UI]^\?L1=R
M367;G;LDVA6C'L=HY'T=3(]LU94#<) C<X!C.?,#B[W=JN15S@6QS%<,K8J^
MCAJ*RY1:[E55R;Q82-#NM #1[M?%6,B,==)[$:FRYW+>XHG&VW;202 <&3 :
M.:?$Z;WCJ>XJS=E6WJR5=DI:#,*EU!=(&",U+V%T50!P#M1KNN[]>'CV"Z;Y
M9[??;9-;KQ215=%,-'Q2C4'Q'<>XCB%2E[Z-%@JJATEHO%?0,<=>JD8V=K?
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M9O;N]IJ3QUU71K;Y<9MLUML-'4EENI[5)7UD0:TB1SG[C 21J-#QX$*=@
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4G5.(XMWAP.G>B(KUHB(@B(@__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g42072g68d84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42072g68d84.jpg
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M@0,!(@ "$0$#$0'_Q  =  $  @(# 0$             !P@%!@,$"0(!_\0
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M'S\6W(N[3O/>D1>N<9V835=RG [K5,WJNN=U/[^$]Z&*31]C/%;VS8HN<E+
M3GJ3OXQP[(P=4>4+?,/:*\-6C5?-3.N%0/AU1UFY]3!R?+FM[6 Q!C&PV .%
MSN4+)A^A8=>3[HVCO5HLV[?K5>;EN9MC\9/0V=T?TT1I\-[.0Q1P1-CAC9'&
MT9-:P9 #J 7VH6O^F]HUH[!;"3S35;O]#3^]:M'7Z0,=.+:9]:ZE<<B8O:(
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M)H/5F1FLROB:*.>)\4S&R1/!:YCAF' \Q"B=9C<TM54TUQ-<:QKOCKA 6C3
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M;6G+PEX_2.ZOBCHV[RIPX3F+GX=P'['4DA96WAQIP0=K80,Y#WYAOZQ5-43
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M,PVD <P<-H'2'<V2A9$I^X'GOKOWU)OK K5JJG \]]=^^I-]8%:M$2J=PO\
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MS92[CVM&KJ:N667SD-R+%?30H2=%.&,_^29^]4+5]-"?BIPQ]3;Z2A+:KO\
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MSF=BD1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$6+OU1=J:!C[+0T58_:9&U54Z
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M93R37.4?,&;#Y6.\JEPG(9G<@Z-ZNUOLENEK[O604='%[J69X:T=76>H;2M
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MU1JZP<1'LU1F"><N1"3U$M)_OGA*5LAVQ6&S-B'5+*0[\+SY%+2C#1!;:O\
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M%P:Y);K:<48DJV:E5=[O(]S>AK0"&]Q>X=RY=*_^]]*6C>PMY3654ERF;U1
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2MS<[5V#FR':MJ1 B(@(B(/_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
